Search Images Maps Play YouTube News Gmail Drive More »
Sign in
Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader.

Patents

  1. Advanced Patent Search
Publication numberUSRE40183 E1
Publication typeGrant
Application numberUS 11/145,508
Publication dateMar 25, 2008
Filing dateJun 3, 2005
Priority dateOct 4, 1991
Publication number11145508, 145508, US RE40183 E1, US RE40183E1, US-E1-RE40183, USRE40183 E1, USRE40183E1
InventorsJoseph J. Hlavka, Phaik-Eng Sum, Yakov Gluzman, Ving J. Lee, Adma A. Ross
Original AssigneeWyeth Holdings Corporation
Export CitationBiBTeX, EndNote, RefMan
External Links: USPTO, USPTO Assignment, Espacenet
7-Substituted-9-substituted amino-6-demethyl-6-deoxytetracyclines
US RE40183 E1
Abstract
The invention is drawn to 7-substituted-9-(substituted amino)-6-demethyl-6-deoxytetracycline compounds of the formula
wherein R, X, R5 and R6 are defined in the specification. The compounds of the invention are useful as broad spectrum antibiotics.
Images(81)
Previous page
Next page
Claims(103)
1. A compound of the formula
wherein:
X is selected from amino, NR1 R2, or halogen; the halogen is selected from bromine, chlorine, fluorine or iodine; R1 is selected from hydrogen, methyl, ethyl, n-propyl, 1-methylethyl, n-butyl and 1-methylpropyl; R2 is selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl, and 1,1-dimethylethyl such that when X=NR1 R2 and R1=hydrogen,
R2=methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl or 1,1-dimethylethyl; and when R1=methyl or ethyl;
R2=methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl or 2-methylpropyl; and when R1=n-propyl,
R2=n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl or 2-methylpropyl;
and when R1=1-methylethyl,
R2=n-butyl, 1-methylpropyl or 2-methylpropyl;
and when R1=n-butyl,
R2=n-butyl, 1-methylpropyl or 2-methylpropyl;
and when R1=1-methylpropyl,
R2=2-methylpropyl;
R is selected from R4 (CH2)n CO or R4′ (CH2)n SO2; and n=0-4;
and when R=R4(CH2)n CO and n−0n=0,
R4 is selected from amino; monosubstituted amino selected from straight or branched (C1-C6)alkylamino, cyclopropylamino, cyclobutylamino, benzylamino or phenylamino; disubstituted amino selected from dimethylamino, diethylamino, ethyl(1-methylethyl)amino, monomethylbenzylamino, piperidinyl, morpholinyl, 1-imidazolyl, 1-pyrrolyl, 1-(1,2,3-triazolyl) or 4-(1,2,4-triazolyl); a substituted (C3-C6)cycloalkyl group with substitution selected from cyano, amino or (C1-C3)acyl; a substituted (C6-C10)aryl group with substitution selected from halo, (C1-C4)alkoxy, trihalo (C1-C3)-alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl (C1-C3)alkylamino or carboxy; α-amino-(C1-C4)alkyl selected from aminomethyl, α-aminoethyl, α-aminopropyl or α-amino-butyl; carboxy (C2-C4)-alkylamino selected from aminoacetic acid, α-aminobutyric acid or α-aminopropionic acid and the optical isomers thereof; (C7-C9)aralkylamino; (C1-C4)alkoxycarbonylamino substituted (C1-C4) alkyl group;
α-hydroxy(C1-C3)alkyl selected from hydroxymethyl, α-hydroxyethyl or α-hydroxy-1-methylethyl or α-hydroxypropyl; α-mercapto (C1-C3)alkyl selected from mercaptomethyl, α-mercaptoethyl, α-mercapto-1-methylethyl or α-mercaptopropyl; halo-(C1-C3)alkyl group; a heterocycle selected from the group consisting of a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto, a five membered aromatic ring with two N, O, S, or Se heteroatoms optionally having a benzo or pyrido ring fused thereto, a six membered aromatic ring with one to three N, O, S or Se heteroatoms, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom; acyl or haloacyl group selected from acetyl, propionyl, chloroacetyl, trifluoroacetyl; (C3-C6)cycloalcylcarbonyl, (C6-C10)aroyl selected from benzoyl or naphthoyl; halo substituted (C6-C10)aroyl; (C1-C4) alkylbenzoyl, or (heterocycle)-carbonyl, the heterocycle as defined hereinabove;
(C1-C4)alkoxycarbonyl selected from methoxycarbonyl, ethoxycarbonyl, straight or branched propoxylcarbonyl, straight or branched butoxycarbonyl or allyloxycarbonyl; a substituted vinyl group with substitution selected from halogen, halo(C1-C3)alkyl, or a substituted (C6-C10)aryl group with substitution selected from halo, (C1-C4)-alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy;
(C1-C4)alkoxy group; C6-aryloxy selected from phenoxy or substituted phenoxy with substitution selected from halo, (C1-C4) alkyl, nitro, cyano, thiol, amino, carboxy, di(C1-C3)alkylamino; (C7-C10)aralkyloxy; vinyloxy or a substituted vinyloxy group with substitution selected from (C1-C4)alkyl, cyano, carboxy, or (C6-C10)aryl selected from phenyl, α-naphthyl, or β-naphthyl; RaRb amino(C1-C4)alkoxy group, wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or RaRb is (CH2)m, m=2-6, or (CH2)2W(CH2)2 (CH2)2 W(CH 2)2 wherein W is selected from N(C1-C3)alkyl, O, S, NH, NOB and B is selected from hydrogen or (C1-C3)alkyl; or RaRb aminoxy group, wherein RaRb is straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl, or 1,1-dimethylethyl or RaRb is (CH2)m, m=2-6, or (CH2)2W(CH2)2 wherein W is selected from N(C1-C3)alkyl, O, S, NH, NOB and B is selected from hydrogen or (C1-C3)alkyl;
and when R=R4 (CH2)nCO and n=1-4, R4 is selected from amino;
a substituted (C3-C6)cycloalkyl group with substitution selected from cyano, amino or (C1-C3)acyl; a substituted(C6-C10)-aryl group with substitution selected from halo, (C1-C4)-alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy; acyloxy or haloacyloxy group selected from acetyl, propionyl, chloroacetyl, trichlorocetyl, (C3-C6)cycloalkylcarbonyl, (C6-C10)aroyl selected from benzoyl or naphthoyl, halo substituted (C6-C10)aroyl, (C1-C4)alkylbenzoyl, or (heterocycle)-carbonyl, the heterocycle as defined hereinabove;
(C1-C4)alkoxy; C6-aryloxy selected from phenoxy or substituted phenoxy with substitution selected from halo, (C1-C4)-alkyl, nitro, cyano, thiol, amino, carboxy, di(C1-C3)-alkylamino; (C7-C10)aralkyloxy; (C1-C3)alkylthio group selected from methylthio, ethylthio, propylthio or allythio; C6-arylthio group selected from phenylthio or substituted phenylthio with substitution selected from halo, (C1-C4)alkyl, nitro, cyano, thiol, amino, carboxy, di(C1-C3)alkylamino; C6-arylsulfonyl group selected from phenylsulfonyl or substituted phenylsulfonyl with substitution selected from halo, (C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy; (C7-C8)aralkylthio group; a heterocycle as defined hereinabove; hydroxy; mercapto; mono- or di-straight or branched chain (C1-C6)-alkylamino with the alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl, 1,1-dimethylethyl, 2-methylbutyl, 1,1-dimethylpropyl, 2,2-dimethylpropyl, 3-methylbutyl, n-hexyl, 1-methylpentyl, 1,1-methylbutyl, 2,2-dimethylbutyl, 2-methylpentyl, 1,2-dimethylbutyl, 1,3-dimethylbutyl or 1-methyl-1-ethylpropyl; (C2-C5)azacycloalkyl group; a carboxy(C2-C4) alkylamino group with the carboxy alkyl selected from aminoacetic acid, α-aminopropionic acid, α-aminobutyric acid and the optical isomers thereof; α-hydroxy(C1-C3)alkyl selected from hydroxymethyl, α-hydroethyl or α-hydroxy-1-methylethyl or α-hydropropyl; halo(C1-C3)alkyl group; acyl or haloacyl selected from acetyl, propionyl, chloroacetyl, trifluoroacetyl; (C3-C6)cycloalkylcarbonyl; (C6-C10)aroyl selected from benzoyl or naphthoyl; halo substituted (C6-C10)aroyl; (C1-C4)alkylbenzoyl, or (heterocycle)carbonyl, the heterocycle as defined hereinabove;
(C1-C4)alkoxycarbonylamino, group selected from tert-butoxycarbonylamino, allyloxycarbonylamino, methoxycarbonylamino, ethoxycarbonylamino or propoxycarbonylamino; (C1-C4)alkoxycarbonyl group selected from methoxycarbonyl, ethoxycarbonyl, straight or branched propoxycarbonyl, allyloxycarbonyl or straight or branched butoxycarbonyl; RaRb-amino(C1-C4)alkoxy group wherein RaRb is straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or RaRb is (CH)m (CH2)m m=2-6 or (CH2)2W(CH2)2 wherein W is selected from N(C1-C3)-alkyl, O, S, NH, NOB, and B is selected from hydrogen or (C1-C3)alkyl; or RaRb aminoxy group, wherein RaRb is straight or branched (C1-C4)-alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl or RaRb is (CH2)m, m=2-6, or (CH2)2W(CH2)2 wherein W is selected from N(C1-C3)-alkyl, O, S, NH, NOB and B is selected from hydrogen or (C1-C3)alkyl, and when R═R4′ (CH2)SO2R═R4′ (CH 2)n SO 2 and n=0
R4′ is selected from amino; monosubstituted amino selected from straight or branched (C1-C6)alkylamino, cyclopropylamino, cyclobutylamino, benzylamino or phenylamino; disubstituted amino selected from dimethylamino, diethylamino, ethyl(1-methylethyl)amino, monomethylbenzlamino, piperidinyl, morpholinyl, 1-imidazoyl, 1-pyrrolyl, 1-(1,2,3-triazolyl) or 4-(1,2,4-triazolyl); a substituted (C3-C6)cycloalkyl group with substitution selected from cyano, amino or (C1-C3)acyl; halo(C1-C3)alkyl group; a heterocycle as defined hereinabove;
RaRb amino (C1-C4)alkoxy group, wherein RaRb is a straight or branched (C1-C4)-alkyl selected from methyl, ethyl, n-propyl, 1-methyl-ethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or RaRb is (CH2)m, m=2-6, or (CH2)2W(CH2)2 wherein W is selected from N(C1-C3) alkyl, O, S, NH, NOB and B is selected from hydrogen or (C1-C3)-alkyl; or RaRb aminoxy group, wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methyl-propyl, or 2-methyl-propyl or RaRb is (CH2)m, m=2-6, or (CH2)2W(CH2)2 wherein W is selected from N(C1-C3)alkyl, O, S, NYNH, NOB and B is selected from hydrogen or (C1-C3) alkyl; and when R═R4′ (CH2)nSO2 and n=1-4,
R4′ is selected from (C1-C4)carboxyalkyl; a substituted (C3-C6)cyclalkyl group with substitution selected from cyano, amino or (C1-C3)-acyl; (C1-C4)alkoxy; C6-aryloxy selected from phenoxy or substituted phenoxy with substitution selected from halo, (C1-C3)alkyl, nitro, cyano, thiol, amino, carboxy, di(C1-C3) alkylamino; (C7-C10)aralkyoxy; RaRb amino (C1-C4) alkoxy, wherein RaRb is a straight or branched (C1-C4)-alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or RaRb is (CH2)m, m=2-6, or (CH2)2W(CH2)2 wherein W is selected from N(C1-C3)alkyl, O, S, NYNH or NOB and B is selected from hydrogen or (C1-C3)alkyl; or RaRb aminoxy group, wherein RaRb is straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or RaRb is (CH2)m, m=2-6, or (CH2)2W(CH2)2 wherein W is selected from N(C1-C3)alkyl, O, S, NH, NOB and B is selected from hydrogen or (C1-C3)alkyl; (C1-C3) alkylthio selected from methylthio, ethylthio or n-propylthio; C6-arylthio selected from phenylthio or substituted phenylthio with substitution selected from halo, (C1-C3)alkyl, nitro, cyano, thiol, amino, carboxy, di(C1-C3)alkylamino; (C7-C8) aralkylthio; a heterocycle as defined hereinabove; hydroxy; mercapto; mono- or di-straight or branched (C1-C6)alkyl- amino group the alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl, 1,1-dimethylethyl, 2-methylbutyl, 1,1-dimethylpropyl, 2,2-dimethylpropyl, 3-methylbutyl, n-hexyl, 1-methylpentyl, 1,1-dimethylbutyl, 2,2-dimethylbutyl, 2-methylpentyl, 1,2-dimethylbutyl, 1,3-dimethylbutyl or 1-methyl-1-ethylpropyl; halo (C1-C3) alkyl; acyl or haloacyl selected from acetyl, propionyl, chloro-acetyl, trifluoroacetyl; (C3-C6) cycloalkylcarbonyl; (C6-C10) aroyl selected from benzoyl or naphthoyl; halo substituted (C6-C10)aroyl, (C1-C4) alkylbenzoyl, or (heterocycle) carbonyl, the heterocycle as defined hereinabove; (C1-C4)alkoxycarbonyl selected from methoxycarbonyl, ethoxycarbonyl, straight or branched propoxycarbonyl, allyloxycarbonyl or straight or branched butoxycarbonyl; R5 is selected from hydrogen; straight or branched (C1-C3) alkyl selected from methyl, ethyl n-propyl or 1-methylethyl; (C6-C10)aryl selected from phenyl, α-naphthyl or β-naphthyl; (C7-C9) aralkyl group; a heterocycle as defined hereinabove; or (CH2)nCOOR7 where n=0-4 and R7 is selected from hydrogen; straight or branched (C1-C3)alkyl group selected from methyl, ethyl, n-propyl or 1-methylethyl; or (C6-C10)aryl group selected from phenyl, α-naphthyl or β-naphthyl;
R6 is selected from hydrogen, straight or branched (C1-C3)alkyl group selected form methyl, ethyl, n-propyl or 1-methylethyl; (C6-C10)aryl group selected from phenyl, α-naphthyl or β-naphthyl; (C7-C9)-aralkyl group; a heterocycle as defined hereinabove; or CH2)n(COOR7′(CH 2)n COOR 7′ where n=0-4 and R7′ is selected from hydrogen; straight or branched (C1-C3)alkyl selected from methyl, ethyl, n-propyl or 1-methylethyl; or (C6-C10)aryl selected from phenyl, α-naphthyl or β-naphthyl; with the proviso that R5 and R6 cannot both be hydrogen ; or R5 and R6 taken together are (CH2)2W(CH2)2, wherein W is selected from (CH2)q and q=0-1, NH, N(C1-C3)-alkyl, N(C1-C4) alkoxy, oxygen, sulfur or substituted congeners selected from (L or D) proline, ethyl (L or D) prolinate, morpholine, pyrrolidine or piperidine; and the pharmacologically acceptable organic and inorganic salts or metal complexes.
2. The compound according to claim 1, wherein:
X is selected formfrom amino, NR1 R2, or halogen;
the halogen is selected from bromine, chlorine, fluorine or iodine;
and when X=NR1 R2 and R1=methyl or ethyl,
R2=methyl or ethyl
R is selected from R4 (CH2)nCO or R4′ (CH2)nSO2;
and when R=R4 (CH2)nCO and n=0,
R4 is selected from substituted (C6-C10)aryl group with substitution selected from halo, (C1-C4)alkoxy, nitro, amino, or (C1-C2)alkoxycarbonyl; (C1-C4)alkoxycarbonyl group selected from methoxycarbonyl, ethoxycarbonyl, straight or branched propoxyl-carbonyl, straight or branched butoxycarbonyl or allyl-oxycarbonyl; a substituted (C6-C10)aryl group with substitution selected from halo, (C1-C4)alkoxy, nitro, amino, (C1-C4) alkoxycarbonyl, trihalo-(C1-C3)alkyl group; (C1-C4)alkoxy group; C6-aryloxy group selected from phenoxy or substituted phenoxy with substitution selected from halo, (C1-C4)alkyl; (C7-C10)aralkyloxy group; vinyloxy or substituted vinyloxy group with substitution selected from (C1-C2)-alkyl; RaRb amino(C1-C4)alkoxy group, wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl; or RaRb aminoxy group, wherein RaRb is a straight or branched (C1-C4)-alkyl selected from methyl, ethyl, n-propyl, 1-methyl-ethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl;
and when R=R4 (CH2)nCO and n=1-4,
R4 is selected from amino; monosubstituted amino selected from straight or branched (C1-C6)alkyl-amino, cyclopropylamino, cyclobutylamino, benzylamino or phenylamino, said (C 1 -C 6)-alkyl selected from methyl, ethyl, n-propyl, 1 -methylethyl, n-butyl, 1 -methylpropyl, 2 -methylpropyl, 1,1 -dimethylethyl, 2 -methylbutyl, 1,1 -dimethylpropyl, 2,2 -dimethylpropyl, 3 -methylbutyl, n-hexyl, 1 -methylpentyl, 1,1 -dimethylbutyl, 2,2 -dimethylbutyl, 2 -methylpentyl, 1,2 -dimethylbutyl, 1,3 -dimethylbutyl or 1 -methyl- 1 -ethylpropyl; disubstituted amino selected from dimethylamino, diethylamino, ethyl(1-methylethyl)amino, monomethylbenzylamino, piperidinyl, morpholinyl , 1-imidazolyl, or 1-pyrrolyl or 1-(1,2,3-triazolyl) ; a substituted (C6-C10)aryl group with substitution selected from halo, (C1-C4)alkoxy, nitro, amino, (C1-C4)alkoxycarbonyl; acyloxy or haloacyloxy group selected from acetyl, propionyl or chloroacetyl; (C1-C4)alkoxy group; RaRb amino(C1-C4)alkoxy group, wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or RaRb is (CH2)m, m=2-6, or (CH2)2W(CH2)2 wherein W is selected from N(C1-C3)alkyl, O, S, NH, NOB and B is selected from hydrogen or (C1-C3)alkyl; or RaRb aminoxy group, wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or RaRb is (CH2)m, m=2-6, or (CH2)2W(CH2)2 wherein W is selected from N(C1-C3)-alkyl, O, S, NYNH, NOB and B is selected from hydrogen or (C1-C3)-alkyl; halo (C1-C3)-alkyl group; (C1-C4)alkoxycarbonylamino selected from tert-butoxycarbonylamino, allyloxycarbonylamino, methoxycarbonylamino, ethoxycarbonylamino or propoxycarbonylamino;
and when R═R4′ (CH2)nSO2 and n=0,
R4′ is selected from a substituted (C6-C10)aryl group with substitution selected from halo, (C1-C4)alkoxy, nitro, (C1-C4) alkoxycarbonyl;
R5 is selected from hydrogen; straight or branched (C1-C3)alkyl selected from methyl, ethyl, n-propyl or 1-methylethyl;
R6 is selected from hydrogen; straight or branched (C1-C3)alkyl selected from methyl, ethyl, n-propyl or 1-methylethyl; with the proviso that R5 and R6 cannot both be hydrogen; or R5 or R6 taken together are (CH2)2W(CH2)2, wherein W is selected from (CH2)q and q=0-1, NH, N(C1-C3)-alkyl, N(C1-C4)alkoxy, oxygen, sulfur or substituted congeners selected from (L or D)proline, ethyl(L or D)prolinate, morpholine, pyrrolidine or piperidine; and the pharmacologically acceptable organic and inorganic salts or metal complexes.
3. The compound according to claim 1 wherein said inorganic salts comprise hydrochloric, hydrobromic, hydroiodic, phosphoric, nitric or sulfate.
4. The compound according to claim 1 wherein said organic salts comprise acetate, benzoate, citrate, cysteine or other amino acids, fumarate, glycolate, maleate, succinate, tartrate, alkylsulfonate or arylsulfonate.
5. The compound according to claim 1 wherein said metal complexes comprise aluminium, calcium, iron, magnesium, manganese and complex salts.
6. A compound according to claim 1 [4S-(4α,12aα)]-4, 7-Bis(dimethylamino)-1,4,4a,5,5a,6,11, 12a-octahydro-3, 10,12,12a-tetrahydroxy-1,11-dioxo- 9-[(trifluoroacetyl)amino]-2-naphthacenecarboxamide sulfate.
7. A compound according to claim 1, [4S-(4α,12aα)]-4, 7-Bis(dimethylamino)-1,4,4a,5,5a,6, 11,12a-octahydro-3, 10,12,12a-tetrahydroxy-9-[(methoxyacetyl)amino]-1,11-dioxo-2-naphthacenecarboxamide.
8. A compound according to claim 1, [4S-(4α,12aα)]-9-[(4-Bromo-1-oxobutyl)amino]-4,7-bis(dimethylamino)-1,4, 4a,5,5a,6,11,12a-octahydro- 3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide.
9. A compound according to claim 1, [4S-(4α,12aα)]-4, 7-Bis(dimethylamino)-1,4,4a,5,5a,6, 11,12a-octahydro-3, 10,12,12a-tetrahydroxy-1,11-dioxo- 9-[(1-oxo-2-propenyl)amino]-2-naphthacenecarboxamide.
10. A compound according to claim 1, [4S-(4α,12aα)]-9-[[(Acetyloxy)acetyl]amino]-4,7-bis (dimethylamino)-1,4, 4a,5,5a,6,11,12a-octahydro-3,10, 12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide sulfide.
11. A compound according to claim 1, [4S-(4α,12aα)]-9-(Benzoylamino)-4,7-bis(dimethylamino)- 1,4,4a,5,5a,6,11, 12a-octahydro-3,10,12,12a-tetrahydroxy- 1,11-dioxo-2-naphthacenecarboxamide.
12. A compound according to claim 1, [4S-(4alpha,12aalpha)]-4,7-Bis(dimethylamino)-1,4,4a,5 5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-9-[(4-methyoxybenzoyl)amino]-1,11-dioxo-2-naphthacenecarboxamide.
13. A compound according to claim 1, [4S-(4alpha,12aalpha)]-4,7-Bis(dimethylamino)-1,4,4a,5 5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-9-[(2-methylbenzoyl)amino]-1,11-dioxo-2-naphthacenecarboxamide.
14. A compound according to claim 1, [4S-(4alpha,12aalpha)]-4,7-Bis(dimethylamino)-9-[(2-fluorobenzoyl)amino]-1,4,4a,5,5a,6,11,12a-octahydro-3, 10,12,12a-tetrahydroxy-1,11-dioxo-2-naphathacenecarboxamide.
15. A compound according to claim 1, [4S-(4alpha,12aalpha)]-4,7-Bis(dimethylamino)-1,4,4a, 5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-9-[(pentafluorobenzoyl)amino]-1,11 -dioxo-2-naphthacenecarboxamide hydrochloride.
16. A compound according to claim 1, [4S-(4alpha,12aalpha)]-4,7-Bis(dimethylamino)-1,4,4a,5 , 5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo- 9-[[3-(trifluoromethyl)benzoyl]amino]-2-naphthacenecarboxamide.
17. A compound according to claim 1, [4S-(4alpha,12aalpha)]-4,7-Bis(dimethylamino)-9-[(2-furanylcarbonyl)amino]- 1,4,4a,5,5a,6,11,12a-octahydro- 3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide.
18. A compound according to claim 1, [4S-(4alpha,12aalpha)]-4,7-Bis(dimethylamino)-1,4,4a, 5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy- 1,11-dioxo-9-[(2-thienylcarbonyl)amino]-2-naphthacenecarboxamide.
19. A compound according to claim 1, [4S-(4alpha,12aalpha)]-4,7-Bis(dimethylamino)-1,4,4a, 5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-9-[ (4-nitrobenzonyl)amino]-1, 11-dioxo-2-naphthacenecarboxamide.
20. A compound according to claim 1, [4S-(4α,12aα)]-9-[(4-Aminobenzoyl)amino]-4,7-bis-dimethylamino)- 1,4, 4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy- 1,11-dioxo-2-naphthacenecarboxamidesulfate.
21. A compound according to claim 1, [4S-(4α,12aα)]-4, 7-Bis(dimethylamino)-9-[[(4-dimethylamino)benzoyl]amino]-1,4,4a,5,5a,6,11,12a-octahydro- 3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide.
22. A compound according to claim 1, [7S-(7α,10aα)]-[2-[[(Aminocarbonyl)-4,7-bis(dimethylamino)- 5,5a,6,6a, 7,10,10a,12-octahydro-1,8,10a, 11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]amino]- 2-oxoethyl]carbamic acid 1,1-dimethylethyl ester.
23. A compound according to claim 1, [4S-(4α,12aα)]-9-[(Aminoacetyl)amino]-4,7-bis(dimethylamino)- 1,4,4a,5, 5a,6,11,12a-octahydro-3,10,12, 12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide mono(trifluoroacetate).
24. A compound according to claim 1, [4S-(4α,12aα)]-4, 7-Bis(dimethylamino)-1,4,4a,5,5a,6, 11,12a-octahydro-3, 10,12,12a-tetrahydroxy-1,11-dioxo- 9-[(phenylsulfonyl)amino]-2-naphthacenecarboxamide.
25. A compound according to claim 1, [4S-(4α,12aα)]-9-[[(4-Chlorophenyl)sulfonyl]amino]- 4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-tetrahydroxy- 1,11-dioxo-2-naphthacenecarboxamide.
26. A compound according to claim 1, [4S-(4α,12aα)]-4,7-Bis(dimethylamino)-1,4,4a,5, 5a,6,11,12a-octahydro-3, 10,12,12a-tetrahydroxy-9-[(3-nitrophenyl)sulfonyl]amino-1,11-dioxo-2-naphthacenecarboxamide.
27. A compound according to claim 1, [4S-(4α,12aα)]-4, 7-Bis(dimethylamino)-1,4,4a,- 5a,6,11,12a-octahydro-3,10, 12,12a-tetrahydroxy-9-[ [(4-nitrophenyl)sulfonyl]amino]-1, 11-dioxo-2-naphthacenecarboxamide.
28. A compound according to claim 1, [4S-(4α,12aα)]-4, 7-Bis(dimethylamino)-1,4,4a,5, 5a,6,11,12a-octahydro-3, 10,12,12a-tetrahydroxy-1,11-dioxo- 9-[(2-thienylsulfonyl)amino]-2-naphthacenecarboxamide.
29. A compound according to claim 1, [4S-(4α,12aα)]-9-[[(2-(Acetylamino)-4-methyl- 5-thiazolylsulfonyl]amino]-4,7-bis(dimethylamino)-1,4, 4a,5,5a,6,11,12a-octahydro-3, 10,12,12a-tetrahydroxy- 1,11-dioxo-2-naphthacenecarboxamide.
30. A compound according to claim 1, [4S-(4alpha,12aalpha)]-4,7-Bis(dimethylamino)-9-[ (ethylsulfonyl)amino]-1, 4,4a,5,5a,6,11,12a-octahydro- 3,10,12,12a-tetrahydroxy-1, 11-dioxo-2-naphthacenecarboxamide.
31. A compound according to claim 1, [4S-(4α,12aα)]-4, 7-Bis(dimethylamino)-9-(formylamino)- 1,4,4a,5a,6,11, 12a-octahydro-3,10,12,12a-tetrahydroxy- 1,11-dioxo-N-(1-pyrrolidinylmethyl)-2-naphthacenecarboxamide.
32. A compound according to claim 1, [4S-(4α,12aα)]-4, 7-Bis(dimethylamino)-1,4,4a,5,5a,6, 11,12a-octahydro-3, 10,12,12a-tetrahydroxy-9-[ (methanesulfonyl)amino]-1,11-dioxo-2-naphthacenecarboxamide.
33. A compound according to claim 1, [4S-(4α,12aα)]-4, 7-Bis(dimethylamino)-1,4,4a,5,5a,6, 11,12a-octahydro-3, 10,12,12a-tetrahydroxy-1,11-dioxo- 9-[[(phenylmethoxy-)acetyl]amino]-2-naphthacenecarboxamide.
34. A compound according to claim 1, [7S-(7α,10aα)]-[[9-(Aminocarbonyl)-4,7-bis(dimethylamino)- 5,5a,6,6a,7, 10,10a,12-octahydro-1,8,10a,11-tetrahydroxy- 10,12-dioxo-2-naphathacenyl]amino] oxoacetic acid ethyl ester.
35. A compound according to claim 1, [4S-(4α,12aα)]-4, 7-Bis(dimethylamino)-1,4,4a,5,5a, 6,11,12a-octahydro-3, 10,12,12a-tetrahydroxy-9-[ (hydroxyacetyl)amino]-1,11-dioxo-2-naphthacenecarboxamide.
36. A compound according to claim 1, [4S-(4α,12aα)]-4, 7-Bis(dimethylamino)-9-[[(methylamino)acetyl] amino]-1, 4,4a,5,5a,6,11,12a-octahydro- 3,10,12,12a-tetrahydroxy-1, 11-dioxo-2-napthacenecarboxamide hydrochloride.
37. A compound according to claim 1, [7S-(7α,10aα)]-[9-(Aminocarbonyl)-4,7-bis(dimethylamino)- 5,5a,6,6a,7, 10,10a,12-octahydro-1,8,10a,11-tetrahydroxy- 10,12-dioxo-2-naphthacenyl]carbamic acid methyl ester.
38. A compound according to claim 1, [7S-(7α,10aα)]-[9-(Aminocarbonyl)-4,7-bis(dimethylamino)- 5,5a,6,6a,7, 10,10a,12-octahydro-1,8,10a,11-tetrahydroxy- 10,12-dioxo-2-naphthacenyl]carbamic acid ethenyl ester.
39. A compound according to claim 1, [7S-(7α,10aα)]-[9-(Aminocarbonyl)-4,7-bis(dimethyl-amino)- 5,5a,6,6a,7, 10,10a,12-octahydro-1,8,10a,11-tetrahydroxy- 10,12-dioxo-2-naphthacenyl]carbamic acid ethenyl ester.
40. A compound according to claim 1, [7S-(7α,10aα)]-[9-(Aminocarbonyl)-4,7-bis(dimethyl-amino)- 5,5a,6,6a,7, 10,10a,12-octahydro-1,8,10a,11-tetrahydroxy- 10,12-dioxo-2-naphthacenyl]carbamic acid 2-propenyl ester.
41. A compound according to claim 1, [4S-(4α,12aα)]-4, 7-Bis(dimethylamino)-9-[[(dimethylamino)acetyl] amino]-1,4,4a,5,5a,6,11,12a-octahydro- 3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide sulfate.
42. A compound according to claim 1, [4S-(4α,12aα)]-4, 7-Bis(dimethylamino)-1,4,4a,5,5a,6, 11,12a-octahydro-3, 10,12,12a-tetrahydroxy-9-[ (methoxyacetyl)amino]-1,11-dioxo-2-naphthacenecarboxamide hydrochloride.
43. A compound according to claim 1, [4S-(4α,12aα)]-9-[[(4-Bromo-1-oxobutyl)amino]-4,7bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydroxy- 3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide sulfate.
44. A compound according to claim 1 [4S-(4α,12aα)]-9-[[(Acetyloxy)acetyl]amino]-4,7-bis (dimethylamino)-1,4, 4a,5,5a,6,11,12a-octahydro-3,10, 12,12a-tetrahydroxy-1,11-dioxo-2-napthacenecarboxamide.
45. A compound according to claim 1, [4S-(4α,12aα)]-9-(Benzolyamino)-4,7-bis(dimethylamino)- 1,4,4a,5,5a,6, 11,12a-octahydro-3,10,12,12a-tetra-hydroxy- 1,11 -dioxo-2-naphthacenecarboxamide sulfate.
46. A compound according to claim 1, [4S-(4alpha,12aalpha)]-4,7-Bis(dimethylamino)-1,4,4a,5, 5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11 -dioxo- 9-[[3-(trifluoromethyl)benzoyl]amino]-2-naphthacenecarboxamide hydrochloride.
47. A compound according to claim 1, [4S-(4α,12aα)]-9-[(4-Aminobenzoyl)amino]-4,7-bis(dimethylamino)- 1,4, 4a,5,5a,6,11,12a-octahydro-3,10,12, 12a-tetrahydroxy-1,11-dioxo-2-napthacenecarboxamide.
48. A compound according to claim 1, [4S-(4α,12aα)]-4, 7-Bis(dimethylamino)-9-[[(4-dimethylamino)benzoyl]amino]-1,4,4a,5,5a,6,11,12a-octahydro- 3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide hydrochloride.
49. A compound according to claim 1, [7S-(7α,10aα)]-[2-[[9-(Aminocarbonyl)-4,7-bis(dimethylamino)- 5,5a,6,6a, 7,10,10a,12-octahydro-1,8,10a, 11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]amino]- 2-oxoethyl]carbamic acid 1,1-dimethylethyl ester hydrochloride.
50. A compound according to claim 1, [4S-(4α,12aα)]-9-[(Aminocarbonyl)-amino]-4,7-bis(dimethylamino)- 1,4,4a,5, 5a,6,11,12a-octahydro-3,10,12, 12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide.
51. A compound according to claim 1, [4S-(4alpha,12aalpha)]-4,7-Bis(dimethylamino)-9-[ (ethylsulfonyl)amino]-1, 4,4a,5,5a,6,11,12a-octahydro- 3,10,12,12a-tetrahydroxy-1, 11-dioxo-2-naphthacenecarboxamide hydrochloride.
52. A compound according to claim 1, [4S-(4α,12aα)]-4, 7-Bis(dimethylamino)-1,4,4a,5,5a,6, 11,12a-octahydro-3, 10,12,12a-tetrahydroxy-9-[ (methansulfonyl)amino]-1,11-dioxo-2-naphthacenecarboxamide sulfate.
53. A compound according to claim 1, [4S-(4α,12aα)]-4, 7-Bis(dimethylamino)-1,4,4a,5,5a,6, 11,12a-octahydro-3, 10,12,12a-tetrahydroxy-1,11-dioxo- 9-[[(phenylmethoxy-)acetyl]amino]-2-naphthacenecarboxamide hydrochloride.
54. A compound according to claim 1, [4S-(4α,12aα)]-4, 7-Bis(dimethylamino)-1,4,4a,5,5a, 6 11,12a-octahydro-3, 10,12,12a-tetrahydroxy-9-[ (hydroxyacetyl)amino]-1,11-dioxo-2-naphthacenecarboxamide sulfate.
55. A compound according to claim 1, [4S-(4α,12aα)]-4, 7-Bis(dimethylamino)-9-[[(dimethylamino)acetyl] amino]-1,4,4a,5,5a,6,11,12a-octahydro- 3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide.
56. A compound according to claim 1, [7S-(7α,10aα)]-[9-(Aminocarbonyl)-4,7-bis(dimethylamino)- 5,5a,6,6a,7, 10,10a,12-octahydro-1,8,10a,11-tetrahydroxy- 10,12-dioxo-2-naphthacenyl]carbamic acid methyl ester sulfate.
57. A compound according to claim 1, [7S-(7α,10aα)]-[9-(Aminocarbonyl)-4,7-bis(dimethylamino)- 5,5a,6,6a,7, 10,10a,12-octahydro-1,8,10a,11-tetrahydroxy- 10,12-dioxo-2-naphthacenyl]carbamic acid (2-diethylamino)ethyl ester hydrochloride.
58. A compound according to claim 1, [7S-(7α,10aα)]-[9-(Aminocarbonyl)-4,7-bis(dimethylamino)- 5,5a,6,6a,7, 10,10a,12-octahydro-1,8,10a,11-tetrahydroxy- 10,12-dioxo-2-naphthacenyl]carbamic acid ethenyl ester sulfate.
59. A compound according to claim 1, [7S-(7α,10aα)]-[9-(Aminocarbonyl)-4,7-bis(dimethylamino)- 5,5a,6,6a,7, 10,10a,12-octahydro-1,8,10a,11-tetrahydroxy- 10,12-dioxo-2-naphthacenyl]carbamic acid 2-propenyl ester hydrochloride.
60. A compound according to claim 1, [4S-(4α,12aα)]-4, 7-Bis(dimethylamino)-9-[[(diethylamino) acetyl]amino]-1, 4,4a,5,5a,6,11,12a-octahydro-3,10,12, 12a-tetrahydroxy-1, 11-dioxo-2-naphthacenecarboxamide sulfate.
61. A compound according to claim 1, [4S-(4α,12aα)]-4, 7-Bis(dimethylamino)-9-[[(diethylamino) acetyl]amino]-1, 4,4a,5,5a,6,11,12a-octahydro-3,10,12, 12a-tetrahydroxy-1, 11-dioxo-2-naphthacenecarboxamide hydrochloride.
62. A compound according to claim 1, [4S-(4α,12aα)]-4, 7-Bis(dimethylamino)-9-[[(diethylamino) acetyl]amino]-1, 11-dioxo-2-naphthacenecarboxamide.
63. A compound according to claim 1, [4S-(4alpha,12aalpha)]-4,7-Bis(dimethylamino)-9-[[(dimethylamino)acetyl] amino]-1,4,4a,5,5a,6,11,12a-octahydro- 3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide dihydrochloride.
64. A compound according to claim 1, [4S-(4α,12aα)]-4, 7-Bis(dimethylamino)-9-(chloroacetylamino)- 1,4,4a,5,5a, 6,11,12a-octahydro-3,10,12,12a-tetrahydroxy- 1,11-dioxo-2-naphthacenecarboxamide.
65. A compound according to claim 1, [4S-(4alpha,12aalpha)]-9-[(Chloroacetyl)amino]-4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro- 3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide dihydrochloride.
66. A compound according to claim 1, [4S-(4alpha,12aalpha)]-9-[(Bromoacetyl)amino]-4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro- 3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide dihydrochloride.
67. A compound according to claim 1, [4S-(4alpha,12aalpha)]-9-[(Bromoacetyl)amino]-4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro- 3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide (free base).
68. A compound according to claim 1, [4S-(4alpha,12aalpha)]-9-[(Bromoacetyl)amino]-4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro- 3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide monohydrobromide.
69. A compound according to claim 1, [4S-(4alpha,12aalpha)]-9-[(2-Bromo-1-oxopropyl)amino]- 4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro- 3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide hydrobromide.
70. A compound according to claim 1, [4S-(4alpha,12aalpha)]-9-[(2-Bromo-1-oxopropyl)amino]- 4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro- 3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide hydrobromide.
71. A compound according to claim 1, [4S-(4alpha,12aalpha)]-4,7-Bis(dimethylamino)- 1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy- 9-[[(methylamino)acetyl]amino]-1,11-dioxo-2-naphthacenecarboxamide dihydrochloride.
72. A compound according to claim 1, [7S-(7alpha,10aalpha)]-N-[9-(Aminocarbonyl)-4,7-bis(dimethylamino)- 5,5a, 6,6a,7,10,10a,12-octahydro- 1,8,10a,11-tetrahydroxy-10, 12-dioxo-2-naphthacenyl]-4-morpholineacetamide dihydrochloride.
73. A compound according to claim 1, [4S-(4alpha,12aalpha)]-4,7-Bis(dimethylamino)-9-[ [(ethyamino)acetyl]amino]-1,4,4a,5,5a,6,11,12a,-octahydro- 3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide dihydrochloride.
74. A compound according to claim 1, [4S-(4alpha,12aalpha)]-9-[[(Cyclopropylamino)acetyl]amino]- 4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a,-octahydro- 3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide dihydrochloride.
75. A compound according to claim 1, [4S-(4alpha,12aalpha)]-4,7-Bis(dimethylamino)-9-[ [(butylamino)acetyl]amino]-1,4,4a,5,5a,6,11,12a-octahydro- 3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide dihydrochloride.
76. A compound according to claim 1, [4S-(4alpha,12aalpha)]-9-[[(Diethylamino)acetyl]amino]- 4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro- 3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide dihydrochloride.
77. A compound according to claim 1, [7S-(7alpha,10aalpha)]-N-[9-(Aminocarbonyl)-4,7-bis(dimethylamino)- 5,5a, 6,6a,7,10,10a,12-octahydro- 1,8,10a,11-tetrahydroxy-10, 12-dioxo-2-naphthacenyl]-1-pyrrolidineacetamide dihydrochloride.
78. A compound according to claim 1, [4S-(4alpha,12aalpha)]-4,7-Bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-9-[ [[(2-methylpropyl)amino]acetyl]amino]-1,11-dioxo-2-naphthacenecarboxamide dihydrochloride.
79. A compound according to claim 1, [7S-(7alpha,10aalpha)]-N-[9-(Aminocarbonyl)-4,7-bis(dimethylamino)- 5,5a, 6,6a,7,10,10a,12-octahydro-1,8,10a, 11-tetrahydroxy-10, 12-dioxo-2-naphthacenyl]-1-piperidineacetamide dihydrochloride.
80. A compound according to claim 1, [7S-(7alpha,10aalpha)]-N-[9-(Aminocarbonyl)-4,7-bis(dimethylamino)- 5,5a, 12-dioxo-2-naphthacenyl]-1H-imidazole- 1-acetamide dihydrochloride.
81. A compound according to claim 1, [4S-(4alpha,12aalpha)]-4,7-Bis(dimethylamino)-1,4,4a, 5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo- 9-[[(propylamino)acetyl]amino]-2-naphthacenecarboxamide dihydrochloride.
82. A compound according to claim 1, [4S-(4alpha,12aalpha)]-4,7-Bis(dimethylamino)-9-[[(dimethylamino)acetyl]amino]-1,4,4a,5,5a,6,11,12a-octahydro- 3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide.
83. A compound according to claim 1, [4S-(4alpha,12aalpha)]-4,7-Bis(dimethylamino)-9-[ [(hexylamino)acetyl]amino]-1,4,4a,5,5a,6,11,12a-octahydro- 3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide dihydrochloride.
84. A compound according to claim 1, [4S-(4alpha,12aalpha)]-4,7-Bis(dimethylamino)-9-[[2-(dimethylamino)-1-oxopropyl]amino]-1,4,4a,5,5a,6,11, 12a-octahydro-3,10, 12,12a-tetrahydroxy-1,11-dioxo-2-napthacenecarboxamide dihydrochloride.
85. A compound according to claim 1, [4S-(4alpha,12aalpha)]-4,7-Bis(dimethylamino)-1,4,4a, 5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-9-[[2-(methylamino)- 1-oxo-propyl]amino]-1,11-dioxo-2-naphthacenecarboxamide dihydrochloride.
86. A compound according to claim 1, [7S-(7alpha,10aalpha)]-N-[9-(Aminocarbonyl)-4,7-bis(dimethylamino)- 5,5a, 6,6a,7,10,10a,12-octahydro-1,8,10a, 11-tetrahydroxy-10, 12-dioxo-2-naphthacencyl]-alphamethyl-1-pyrrolidineacetamide dihydrochloride.
87. A compound according to claim 1 [4S-(4alpha,12aalpha)]-4,7-Bis(dimethylamino)-9-[[4-(dimethylamino)-1-oxobutyl]amino]-1,4,4a,5,5a,6,11,12a-octahydro- 3,10, 12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide dihydrochloride.
88. A compound according to claim 1, [4S-(4alpha,12aalpha)]-9-[[(Butylmethylamino)acetyl]amino]- 4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro- 3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecenecarboxamide dihydrochloride.
89. A compound according to claim 1, [4S-(4alpha,12aalpha)]-4,7-Bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo- 9-[[(pentylamino)acetyl]amino]-2-naphthacenecarboxamide dihydrochloride.
90. A compound according to claim 1, [4S-(4alpha,12aalpha)]-4,7-Bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo- 9-[[(phenylmethyl)amino]acetyl]amino]-2-naphthacenecarboxamide dihydrochloride.
91. A compound according to claim 1, [7S-(7alpha,10aalpha) ]-N-[2-[ [9-(Aminocarbonyl) -4,7-bis(dimethylamino)-5,5a,6,6a,7,10a,12-octahydro-1,8, 10a,11-tetrahydroxy-10, 12-dioxo-2-naphthacenyl]amino]- 2-oxoethyl]glycine.
92. A compound according to claim 1, [4S-(4alpha,12aalpha)]-4,7-Bis(dimethylamino)-9-[[(dimethylamino)acetyl]amino]-1,4,4a,5,5a,6,11,12a-octahydro- 3,10,12,12a-tetrahydroxy-1,11-dioxo-N-(1-pyrrolidinylmethyl)- 2-naphthacenecarboxamide.
93. A compound according to claim 1, [4S-(4alpha,12aalpha)]-4,7-Bis(dimethylamino)-9-[[(dimethylamino)acetyl]amino]-1,4,4a,5,5a,6,11,12a-octahydro- 3,10,12,12a-tetrahydroxy-1,11-dioxo-N-(4-morpholinylmethyl)- 2-naphthacenecarboxamide.
94. A compound according to claim 1, [4S-(4alpha,12aalpha)]-4,7-Bis(dimethylamino)-9-[[(dimethylamino)acetyl]amino]-1,4,4a,5,5a,6,11,12a-octahydro- 3,10,12,12a-tetrahydroxy-1,11-dioxo-N-(1-piperidinylmethyl)-2-naphthacenecearboxamide.
95. A compound according to claim 1, [7S-(7alpha,10aalpha)]-N-[9-(Aminocarbonyl-4,7-bis(dimethylamino)- 5,5a, 6,6a,7,10,10a,12-octahydro-1,8, 10a,11-tetrahydroxy-10, 12-dioxo-2-naphthacenyl]-1-azetidineacetamide.
96. A compound according to claim 1, [4S-(4alpha,12aalpha)]-9-[[(Cyclobutylamino)acetyl]amino]- 4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro- 3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide hydrochloride.
97. A pharmaceutical composition of matter comprising a compound according to claim 1 in association with a pharmaceutically acceptable carrier.
98. A veterinary composition which comprises a pharmacologically effective amount of a compound of claim 1 and a pharmaceutically acceptable carrier.
99. A compound of the formula
wherein:
X is selected from amino, NR 1 R 2 , or halogen; the halogen is selected from bromine, chlorine, fluorine or iodine; R 1 is selected from hydrogen, methyl, ethyl, n-propyl, 1 -methylethyl, n-butyl and 1 -methylpropyl; R 2 is selected from methyl, ethyl, n-propyl, 1 -methylethyl, n-butyl, 1 -methylpropyl, 2 -methylpropyl, and 1,1 -dimethylethyl such that when X=NR 1 R 2 and R 1 =hydrogen,
R 2 =methyl, ethyl, n-propyl, 1 -methylethyl, n-butyl, 1 -methylpropyl, 2 -methylpropyl or 1,1 -dimethylethyl; and when R 1 =methyl or ethyl,
R 2 =methyl, ethyl, n-propyl, 1 -methylethyl, n-butyl, 1 -methylpropyl or 2 -methylpropyl; and when R 1 =n-propyl,
R 2 =n-propyl, 1 -methylethyl, n-butyl, 1 -methylpropyl or 2 -methylpropyl;
and when R 1 =1 -methylethyl,
R 2 =n-butyl, 1 -methylpropyl or 2 -methylpropyl;
and when R 1 =n-butyl,
R 2 =n-butyl, 1 -methylpropyl or 2 -methypropyl;
and when R 1 =1 -methylpropyl,
R 2 =2 -methylpropyl;
R is selected from R 4 (CH 2)n CO or R 4′ (CH 2)n SO 2 ; and n=0-4;
and when R=R 4 (CH 2)n CO and n=0,
R 4 is selected from amino; monosubstituted amino selected from straight or branched (C 1 -C 6)alkylamino, cyclopropylamino, cyclobutylamino, benzylamino or phenylamino; disubstituted amino selected from dimethylamino, diethylamino, ethyl( 1 -methylethyl)amino, monomethylbenzylamino, piperidinyl, morpholinyl, 1 -imidazolyl, 1 -pyrrolyl, 1 -( 1,2,3 -triazolyl) or 4 -( 1,2,4 -triazolyl); a substituted (C 3 -C 6)cycloalkyl group with substitution selected from cyano, amino or (C 1 -C 3)acyl; a substituted (C 6 -C 10)aryl group with substitution selected from halo, (C 1 -C 4)alkoxy, trihalo (C 1 -C 3)-alkyl, nitro, amino, cyano, (C 1 -C 4)alkoxycarbonyl (C 1 -C 3)alkylamino or carboxy; α-amino-(C 1 -C 4)alkyl selected from aminomethyl, α-aminoethyl, α-aminopropyl or α-amino-butyl; carboxy (C 2 -C 4)-alkylamino selected from aminoacetic acid, α-aminobutyric acid or α-aminopropionic acid and the optical isomers thereof; (C 7 -C 9)aralkylamino; (C 1 -C 4)alkoxycarbonylamino substituted (C 1 -C 4) alkyl group;
α-hydroxy(C 1 -C 3)alkyl selected from hydroxymethyl, α-hydroxyethyl or α-hydroxy- 1 -methylethyl or α-hydroxypropyl; α-mercapto (C 1 -C 3)alkyl selected from mercaptomethyl, α-mercaptoethyl, α-mercapto- 1 -methylethyl or α-mercaptopropyl; halo-(C 1 -C 3)alkyl group; a heterocycle selected from the group consisting of a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto, a five membered aromatic ring with two N, O, S, or Se heteroatoms optionally having a benzo or pyrido ring fused thereto, a six membered aromatic ring with one to three N, O, S or Se heteroatoms, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom; acyl or haloacyl group selected from acetyl, propionyl, chloroacetyl, trifluoroacetyl; (C 3 -C 6)cycloalcylcarbonyl, (C 6 -C 10)aroyl selected from benzoyl or naphthoyl; halo substituted (C 6 -C 10)aroyl; (C 1 -C 4) alkylbenzoyl, or (heterocycle)-carbonyl, the heterocycle as defined hereinabove;
(C 1 -C 4)alkoxycarbonyl selected from methoxycarbonyl, ethoxycarbonyl, straight or branched propoxylcarbonyl, straight or branched butoxycarbonyl or allyloxycarbonyl; a substituted vinyl group with substitution selected from halogen, halo(C 1 -C 3)alkyl, or a substituted (C 6 -C 10)aryl group with substitution selected from halo, (C 1 -C 4)-alkoxy, trihalo(C 1 -C 3)alkyl, nitro, amino, cyano, (C 1 -C 4)alkoxycarbonyl, (C 1 -C 3)alkylamino or carboxy;
(C 1 -C 4)alkoxy group; C 6-aryloxy selected from phenoxy or substituted phenoxy with substitution selected from halo, (C 1 -C 4) alkyl, nitro, cyano, thiol, amino, carboxy, di(C 1 -C 3)alkylamino; (C 7 -C 10)aralkyloxy; vinyloxy or a substituted vinyloxy group with substitution selected from (C 1 -C 4)alkyl, cyano, carboxy, or (C 6 -C 10)aryl selected from phenyl, α-naphthyl or β-naphthyl;
R a R b amino(C 1 -C 4)alkoxy group, wherein R a R b is a straight or branched (C 1 -C 4)alkyl selected from methyl, ethyl, n-propyl, 1 -methylethyl, n-butyl, 1 -methylpropyl, or 2 -methylpropyl or R a R b is (CH 2)m , m=2-6, or (CH 2)2 W(CH 2)2 wherein W is selected from N(C 1 -C 3)alkyl, O, S, NH, NOB and B is selected from hydrogen or (C 1 -C 3)alkyl; or R a R b aminoxy group, wherein R a R b is a straight or branched (C 1 -C 4)alkyl selected from methyl, ethyl, n-propyl, 1 -methylethyl, n-butyl, 1 -methylpropyl, 2 -methylpropyl, or 1,1 -dimethylethyl or R a R b is (CH 2)m , m=2-6, or (CH 2)2 W(CH 2)2 wherein W is selected from N(C 1 -C 3)alkyl, O, S, NH, NOB and B is selected from hydrogen or (C 1 -C 3)alkyl;
and when R=R 4 (CH 2)n CO and n=1-4, R 4 is selected from amino;
a substituted (C 3 -C 6)cycloalkyl group with substitution selected from cyano, amino or (C 1 -C 3)acyl; a substituted(C 6 -C 10)-aryl group with substitution selected from halo, (C 1 -C 4)-alkoxy, trihalo(C 1 -C 3)alkyl, nitro, amino, cyano, (C 1 -C 4)alkoxycarbonyl, (C 1 -C 3)alkylamino or carboxy; acyloxy or haloacyloxy group selected from acetyl, propionyl, chloroacetyl, trichlorocetyl, (C 3 -C 6)cycloalkylcarbonyl, (C 6 -C 10)aroyl selected from benzoyl or naphthoyl, halo substituted (C 6 -C 10)aroyl, (C 1 -C 4)alkylbenzoyl, or (heterocycle)-carbonyl, the heterocycle as defined hereinabove;
(C 1 -C 4)alkoxy; C 6-aryloxy selected from phenoxy or substituted phenoxy with substitution selected from halo, (C 1 -C 4)-alkyl, nitro, cyano, thiol, amino, carboxy, di(C 1 -C 3)-alkylamino; (C 7 -C 10)aralkyloxy; (C 1 -C 3)alkylthio group selected from methylthio, ethylthio, propylthio or allythio; C 6-arylthio group selected from phenylthio or substituted phenylthio with substitution selected from halo, (C 1 -C 4)alkyl, nitro, cyano, thiol, amino, carboxy, di(C 1 -C 3)alkylamino; C 6-arylsulfonyl group selected from phenylsulfonyl or substituted phenylsulfonyl with substitution selected from halo, (C 1 -C 4)alkoxy, trihalo(C 1 -C 3)alkyl, nitro, amino, cyano, (C 1 -C 4)alkoxycarbonyl, (C 1 -C 3)alkylamino or carboxy; (C 7 -C 8)aralkylthio group; a heterocycle as defined hereinabove; hydroxy; mercapto; mono- or di-straight or branched chain (C 1 -C 6)-alkylamino with the alkyl selected from methyl, ethyl, n-propyl, 1 -methylethyl, n-butyl, 1 -methylpropyl, 2 -methylpropyl, 1,1 -dimethylethyl, 2 -methylbutyl, 1,1 -dimethylpropyl, 2,2 -dimethylpropyl, 3 -methylbutyl, n-hexyl, 1 -methylpentyl, 1,1 -dimethylbutyl, 2,2 -dimethylbutyl, 2 -methylpentyl, 1,2 -dimethylbutyl, 1,3 -dimethylbutyl or 1 -methyl- 1 -ethylpropyl; (C 2 -C 5)azacycloalkyl group; a carboxy(C 2 -C 4) alkylamino group with the carboxy alkyl selected from aminoacetic acid, α-aminopropionic acid, α-aminobutyric acid and the optical isomers thereof; α-hydroxy(C 1 -C 3)alkyl selected from hydroxymethyl, α-hydroxyethyl or α-hydroxy- 1 -methylethyl or α-hydroxypropyl; halo(C 1 -C 3)alkyl group; acyl or haloacyl selected from acetyl, propionyl, chloroacetyl, trifluoroacetyl; (C 3 -C 6)cycloalkylcarbonyl; (C 6 -C 10)aroyl selected from benzoyl or naphthoyl; halo substituted (C 6 -C 10)aroyl; (C 1 -C 4)alkylbenzoyl, or (heterocycle)carbonyl, the heterocycle as defined hereinabove;
(C 1 -C 4)alkoxycarbonylamino group selected from tert-butoxycarbonylamino, allyloxycarbonylamino, methoxycarbonylamino, ethoxycarbonylamino or propoxycarbonylamino; (C 1 -C 4)alkoxycarbonyl group selected from methoxycarbonyl, ethoxycarbonyl, straight or branched propoxycarbonyl, allyloxycarbonyl or straight or branched butoxycarbonyl; R a R b-amino(C 1 -C 4)alkoxy group wherein R a R b is a straight or branched (C 1 -C 4)alkyl selected from methyl, ethyl, n-propyl, 1 -methylethyl, n-butyl, 1 -methylpropyl, or 2 -methylpropyl or R a R b is (CH 2)m m=2-6 or (CH 2)2 W(CH 2)2 wherein W is selected from N(C 1 -C 3)-alkyl, O, S, NH, NOB, and B is selected from hydrogen or (C 1 -C 3)alkyl; or R a R b aminoxy group, wherein R a R b is a straight or branched (C 1 -C 4)-alkyl selected from methyl, ethyl, n-propyl, 1 -methylethyl, n-butyl, 1 -methylpropyl, 2 -methylpropyl or R a R b is (CH 2)m , m=2-6, or (CH 2)2 W(CH 2)2 wherein W is selected from N(C 1 -C 3)-alkyl, O, S, NH, NOB and B is selected from hydrogen or (C 1 -C 3)alkyl, and when R=R 4, (CH 2)SO 2 and n=0
R 4′ is selected from amino; monosubstituted amino selected from straight or branched (C 1 -C 6)alkylamino, cyclopropylamino, cyclobutylamino, benzylamino or phenylamino; disubstituted amino selected from dimethylamino, diethylamino, ethyl( 1 -methylethyl)amino, monomethylbenzylamino, piperidinyl, morpholinyl, 1 -imidazoyl, 1 -pyrrolyl, 1 -( 1,2,3 -triazolyl) or 4 -( 1,2,4 -triazolyl); a substituted (C 3 -C 6)cycloalkyl group with substitution selected from cyano, amino or (C 1 -C 3)acyl; halo(C 1 -C 3)alkyl group; a heterocycle as defined hereinabove;
R a R b amino (C 1 -C 4) alkoxy group, wherein R a R b is a straight or branched (C 1 -C 4)-alkyl selected from methyl, ethyl, n-propyl, 1 -methyl-ethyl, n-butyl, 1 -methylpropyl, or 2 -methylpropyl or R a R b is (CH 2)m , m=2-6, or (CH 2)2 W(CH 2)2 wherein W is selected from N(C 1 -C 3) alkyl, O, S, NH, NOB and B is selected from hydrogen or (C 1 -C 3)-alkyl; or R a R b aminoxy group, wherein R a R b is a straight or branched (C 1 -C 4)alkyl selected from methyl, ethyl, n-propyl, 1 -methylethyl, n-butyl, 1 -methyl-propyl, or 2 -methyl-propyl or R a R b is (CH 2)m , m=2-6, or (CH 2)2 W(CH 2)2 wherein W is selected from N(C 1 -C 3) alkyl, O, S, NH, NOB and B is selected from hydrogen or (C 1 -C 3) alkyl; and when R=R 4′ (CH 2)n SO 2 and n=1-4,
R 4′ is selected from (C 1 -C 4)carboxyalkyl; a substituted (C 3 -C 6)cyclalkyl group with substitution selected from cyano, amino or (C 1 -C 3)-acyl; (C 1 -C 4)alkoxy; C 6-aryloxy selected from phenoxy or substituted phenoxy with substitution selected from halo, (C 1 -C 3)alkyl, nitro, cyano, thiol, amino, carboxy, di(C 1 -C 3) alkylamino; (C 7 -C 10)aralkyloxy; R a R b amino (C 1 -C 4) alkoxy, wherein R a R b is a straight or branched (C 1 -C 4)-alkyl selected from methyl, ethyl, n-propyl, 1 -methylethyl, n-butyl, 1 -methylpropyl, or 2 -methylpropyl or R a R b is (CH 2)m , m=2-6, or (CH 2)2 W(CH 2)2 wherein W is selected from N(C 1 -C 3)alkyl, O, S, NH or NOB and B is selected from hydrogen or (C 1 -C 3)alkyl; or R a R b aminoxy group, wherein R a R b is a straight or branched (C 1 -C 4)alkyl selected from methyl, ethyl, n-propyl, 1 -methylethyl, n-butyl, 1 -methylpropyl, or 2 -methylpropyl or R a R b is (CH 2)m , m=2-6, or (CH 2)2 W(CH 2)2 wherein W is selected from N(C 1 -C 3)alkyl, O, S, NH, NOB and B is selected from hydrogen or (C 1 -C 3)alkyl; (C 1 -C 3) alkylthio selected from methylthio, ethylthio or n-propylthio; C 6-arylthio selected from phenylthio or substituted phenylthio with substitution selected from halo, (C 1 -C 3)alkyl, nitro, cyano, thiol, amino, carboxy, di(C 1 -C 3)alkylamino; (C 7 -C 8) aralkylthio; a heterocycle as defined hereinabove; hydroxy; mercapto; mono- or di-straight or branched (C 1 -C 6)alkyl- amino group the alkyl selected from methyl, ethyl, n-propyl, 1 -methylethyl, n-butyl, 1 -methylpropyl, 2 -methylpropyl, 1,1 -dimethylethyl, 2 -methylbutyl, 1,1 -dimethylpropyl, 2,2 -dimethylpropyl, 3 -methylbutyl, n-hexyl, 1 -methylpentyl, 1,1 -dimethylbutyl, 2,2 -dimethylbutyl, 2 -methylpentyl, 1,2 -dimethylbutyl, 1,3 -dimethylbutyl or 1 -methyl- 1 -ethylpropyl; halo (C 1 -C 3) alkyl; acyl or haloacyl selected from acetyl, propionyl, chloro-acetyl, trifluoroacetyl;
(C 3 -C 6) cycloalkylcarbonyl; (C 6 -C 10) aroyl selected from benzoyl or naphthoyl; halo substituted (C 6 -C 10)aroyl, (C 1 -C 4) alkylbenzoyl, or (heterocycle) carbonyl, the heterocycle as defined hereinabove; (C 1 -C 4)alkoxycarbonyl selected from methoxycarbonyl, ethoxycarbonyl, straight or branched propoxycarbonyl, allyloxycarbonyl or straight or branched butoxycarbonyl;
and the pharmacologically acceptable organic and inorganic salts or metal complexes.
100. A compound of formula I
wherein X is selected from amino, NR 1 R 2 , or halogen, the halogen is selected from bromine, chlorine, fluorine or iodine, and when X is NR 1 R 2 , R 1 is methyl or ethyl and R 2 is methyl or ethyl; R is R 4(CH 2)n CO; n=1-4; and R 4 is monosubstituted or disubstituted amino selected from straight or branched (C 1 -C 6)alkylamino, with the alkyl selected from methyl, ethyl, n-propyl, 1 -methylethyl, n-butyl, 1 -methylpropyl, 2 -methylpropyl, 1,1 -dimethylethyl, 2 -methylbutyl, 1,1 -dimethylpropyl, 2,2 -dimethylpropyl, 3 -methylbutyl, n-hexyl, 1 -methylpentyl, 1,1 -dimethylbutyl, 2,2 -dimethylbutyl, 2 -methylpentyl, 1,2 -dimethylbutyl, 1,3 -dimethybutyl or 1 -methyl- 1 -ethylpropyl and pharmacologically acceptable organic and inorganic salts or metal complexes.
101. A compound of formula I
wherein X is N(CH 3)2 and R is R 4(CH 2)n CO where n=1-4 and R 4 is monosubstituted or disubstituted amino selected from straight or branched (C 1 -C 6)alkylamino, with the alkyl selected from methyl, ethyl, n-propyl, 1 -methylethyl, n-butyl, 1 -methylpropyl, 2 -methylpropyl, 1,1 -dimethylethyl, 2 -methylbutyl, 1,1 -dimethylpropyl, 2,2 -dimethylpropyl, 3 -methylbutyl, n-hexyl, 1 -methylpentyl, 1,1 -dimethylbutyl, 2,2 -dimethylbutyl, 2 -methylpentyl, 1,2 -dimethylbutyl, 1,3 -dimethylbutyl or 1 -methyl- 1 -ethylpropyl and pharmacologically acceptable organic and inorganic salts or metal complexes.
102. A compound of formula I
wherein X is N(CH 3)2 and R is R 4(CH 2)n CO where n=1 and R 4 is monosubstituted or disubstituted amino selected from straight or branched (C 1 -C 6)alkylamino, with the alkyl selected from methyl, ethyl, n-propyl, 1 -methylethyl, n-butyl, 1 -methylpropyl, 2 -methylpropyl, 1,1 -dimethylethyl, 2 -methylbutyl, 1,1 -dimethylpropyl, 2,2 -dimethylpropyl, 3 -methylbutyl, n-hexyl, 1 -methylpentyl, 1,1 -dimethylbutyl, 2,2 -dimethylbutyl, 2 -methylpentyl, 1,2 -dimethylbutyl, 1,3 -dimethylbutyl or 1 -methyl- 1 -ethylpropyl and pharmacologically acceptable organic and inorganic salts or metal complexes.
103. A compound of the following structure:
wherein R 4 is a monsubstituted straight or branched C 4-alkylamino, and pharmacologically acceptable organic and inorganic salts or metal complexes.
Description

This application is a continuation of application Ser. No. 07/926,091 filed Aug. 13, 1992, now abandoned, which is a continuation-in-part of application Ser. No. 07/771,576 filed Oct. 4, 1991, now abandoned.

BACKGROUND OF THE INVENTION

1. Field of the Invention

The invention relates to novel [4S-(4,12aα)]-4-(dimethylamino)-7-(substituted)-9-(substituted amino)- 1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12 a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamides hereinafter called 7-(substituted)-9-(substituted amino)-6-dimethyl-6-deoxytetracyclines, which exhibit antibiotic activity against a wide spectrum of organisms including organisms which are resistant to tetracyclines and are useful as antibiotic agents. The invention also relates to novel 7-(substituted)-9-(substituted amino)-6-demethyl-6-deoxytetracycline intermediates useful for making the novel compounds of the present invention and to novel methods for producing the novel compounds and intermediate compounds.

DESCRIPTION OF THE PRIOR ART

A variety of tetracycline antibiotics have been synthesized and described for the treatment of infectious diseases in man and animals since 1947. Tetracyclines inhibit protein synthesis by binding to the 30S substituted of the bacterial ribosome preventing binding of aminoacyl RNA (Chopra, Handbook of Experimental Pharmacology, Vol. 78, 317-392, Springer-Verlag, 1985). Resistance to tetracyclines has emerged among many clinically important microorganisms which limit the utility to these antibiotics. There are two major mechanisms of bacterial resistance to tetracyclines: a) energy-dependent efflux of the antibiotic mediated by proteins located in the cytoplasmic membrane which prevents intracellular accumulation of tetracycline (S. B. Levy et al., Antimicrob. Agents Chemotherapy 33, 1373-1374 (1989); and b) ribosomal protection mediated by a cytoplasmic protein which interacts with the ribosome such that tetracycline no longer binds or inhibits protein synthesis (A. A. Salyers, B. S. Speers and N. B. Shoemaker, Mol. Microbiol, 4:151-156, 1990). The efflux mechanism of resistance is encoded by resistance determinants designated tetA-tetL. They are common in many Gram-negative bacteria (resistance genes Class A-E), such as Enterobacteriaceae, Pseudomonas, Haemophilus and Aeromonas, and in Gram-positive bacteria (resistance genes Class K and L), such as Staphylococcus, Bacillus and Streptococcus. The ribosomal protection mechanism of resistance is encoded by resistance determinants designated TetM, N and O, and is common in Staphylococcus, Streptococcus, Campylobacter, Gardnerella, Haemophilus and Mycoplasma (A. A. Seylers, B. S. Speers and N. B. Shoemaker, Mol. Microbiol, 4:151-156 1990).

A particularly useful tetracycline compound is 7-(dimethylamino)-6-demethyl-6-deoxytetracycline, known as minocycline (see U.S. Pat. No. 3,148,212, U.S. Pat. No. RE 26,253 and U.S. Pat. No. 3,226,436 discussed below). However, strains harboring the tetB (efflux in gram-negative bacteria) mechanism, but not tetK (efflux in Staphylococcus) are resistant to minocycline. Also, strains carrying tetM (ribosomal protection) are resistant to minocycline. This invention describes the synthesis of novel tetracycline compounds which demonstrate significant in vitro and in vivo activity vs. tetracycline and minocycline susceptible strains and some tetracycline and minocycline resistant strains, that is, those harboring the tetM (ribosomal protection) resistance determinants.

Duggar, U.S. Pat. No. 2,482,055, discloses the preparation of Aureomycin (I) by fermentation which have antibacterial activity. Growich et al., U.S. Pat. No. 3,007,965, disclose improvements to the fermentation preparation of I. Neither of these patents teaches or suggests the 6-demethyl-6-deoxytetracyclines.


Beereboom et al., U.S. Pat. No. 3,043,875 discloses tetracycline derivatives of the formulae (II) and (III) where R is H or CH3; R1 is H and when R is CH3, OH; R2 is H and N(CH3)2; X and Y are halogen; Z is H and halogen and B is bromo, chloro and iodo, which have antibacterial activity. This patent does not teach or suggest the inclusion of both di(lower alkyl)amino or mono(layer alkyl)amino substituents (at Y or Z) and an amino function (at B).
Boothe et al., U.S. Pat. No. 3,148,212, reissued as U.S. Pat. No. RE 26,253, and Petisi et al., U.S. Pat. No. 3,226,436, discloses tetracycline derivatives of the formula (IV) wherein R is hydrogen or methyl and R1 and R2 is hydrogen, mono(lower alkyl)amino or di(lower alkyl)amino with the proviso that R1 and R2 cannot both be hydrogen, which are useful for treating bacterial infections. This patent does not teach or suggest the inclusion of a 9-amino functionality (at R2).

Blackwood et al., U.S. Pat. No. 3,200,149 discloses tetracycline derivatives of the formulae (V) and (VI) and reduction products thereof wherein Y may be hydrogen or hydroxyl, X may be hydrogen, chloro, iodo, or bromo, X1 may be hydrogen, amino, and lower alkanoylamino, X2 may be hydrogen or nitro and Z is chloro or fluoro which possess microbiological activity. This patent does not teach or suggest the inclusion of both a di(lower alkyl)amino group (at X) and another nitrogen functionality (at X1) on the 6-demethyl-6-deoxytetracycline nucleus.


Petisi et al., U.S. Pat. No. 3,338,963 discloses tetracycline compounds of the formula (VII) wherein R1 and R2 are hydrogen, nitro, amino, formylamino, acetylamino, p-(dihydroxyboryl)benzoylamino, p-(aminobenzenesulfonyl)amino, chlorine, bromine or diazonium with the proviso that R1 and R2 may not both be hydrogen and with the further proviso that when R1 is chlorine or bromine, R2 may not be hydrogen and vice versa, R3 is hydrogen or methyl and R4 is hydrogen or hydroxy, which have broad-spectrum antibacterial activity. This patent does not teach or suggest the inclusion of di(lower alkyl)amino or mono(lower alkyl)amino substituents (at R1) and amino substituents (at R2).

Bitha et al., U.S. Pat. No. 3,341,585 discloses tetracycline compounds of the formula (VIII) wherein R5 is hydrogen, α-hydroxy or β-hydroxy, R6 is α-methyl or β- methyl, and R7 and R8 are each hydrogen, mono(lower alkyl) amino or di(lower alkyl)amino with the proviso that R7 and R9 cannot both be hydrogen and with the further proviso that when R5 is hydrogen then R6 is α-methyl. A preferred embodiment of the general formula (VIII) is when R5 is α-hydroxy or β-hydroxy, R6 is α-methyl or β-methyl, R7 is di(lower alkyl)amino and R9 is hydrogen, which have broad-spectrum antibacterial activity. This patent does not teach or suggest the inclusion of both di(lower alkyl)amino or mono(lower alkyl)amino substituents (at R7) and amino substituents (at R9).


Shu, U.S. Pat. No. 3,360,557 discloses 9-hydroxytetracyclines of the formula (IX) wherein R1 is hydrogen or hydroxy, R2 is hydrogen or hydroxy, R3 is hydrogen or methyl, R2 and R3 taken together is methylene, and R4 is hydrogen, halogen, nitro, amino, mono(lower alkyl)amino or di(lower alkyl)amino, which have been found to possess antibacterial activity. This patent is restricted to 9-hydroxytetracyclines and does not teach or suggest the presently claimed compounds.
Zambrano, U.S. Pat. No. 3,360,561 discloses a process for preparing 9-nitrotetracyclines of the formula (X) wherein R5 is hydrogen or hydroxy, R1 is hydrogen or hydroxy, R6 is hydrogen or methyl, R1 and R4 taken together is methylene, R2 is hydrogen, chloro or nitro and R9 is hydrogen or nitro with the proviso that R7 and R9 cannot both be hydrogen. This patent does not teach or suggest the inclusion of both a di(lower alkyl)amino or mono(lower alkyl)amino substituent (at R7) and an amino functionality (at R9).
Martell et al., U.S. Pat. No. 3,518,306 discloses 7-and/or 9-(N-nitroalkylamino)-6-demethyl-6-deoxytetracyclines of the formula (XI) which possess in vivo antibacterial activity. This patent does not teach or suggest the inclusion of both a di(lower alkyl)amino or mono(lower alkyl)amino substituent at (C-7) and an amino functionality (at C-9).

In U.S. Pat. No. 5,021,407, a method of overcoming the resistance of tetracycline resistant bacteria is disclosed. The method involves utilizing a blocking agent compound in conjunction with a tetracycline type antibiotic. This patent does not disclose novel tetracycline compounds which themselves have activity against resistant organisms.

In summary, none of the above patents teach or suggest the novel compounds of this application. In addition, none of the above patents teach or suggest novel tetracycline compounds having activity against tetracycline and minocycline resistant strains as well as strains which are normally susceptible to tetracyclines.

SUMMARY OF THE INVENTION

This invention is concerned with novel 7-(substituted)-9-(substituted amino)-6-demethyl-6-deoxytetracyclines, represented by formula I and II, which have antibacterial activity; with method of treating infectious diseases in warm blooded animals employing these new compound; with methods of treating or controlling veterinary diseases; with pharmaceutical preparations containing these compounds; with novel intermediate compounds and processes for the production of these compounds. More particularly, this invention is concerned with compounds of formula I and II which have enhanced in vitro and in vivo antibiotic activity against tetracycline resistant strains as well as a high level of activity against strains which are normally susceptible to tetracyclines.

In formula I and II, X is selected from amino, NR1R2 or halogen; the halogen is selected from bromine, chlorine, fluorine or iodine; and when X=NR1R2 and R1=hydrogen, R2=methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl or 1,1-dimethylethyl; and when R1=methyl or ethyl, R2=methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl or 2-methylpropyl; and when R1=n-propyl, R2=n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl or 2-methylpropyl; and when R1=1-methylethyl, R2=n-butyl, 1-methylpropyl or 2-methylpropyl; and when R1=n-butyl, R2=n-butyl, 1-methylpropyl or 2-methylpropyl; and when R1=1-methylpropyl, R2=2-methylpropyl; R is selected from R4(CH2)nCO or R4′ (CH2)nSO2; and when R=R4(CH2)nCO and n=0, R4 is selected from hydrogen; amino; monosubstituted amino selected from straight or branched (C1-C6)alkylamino, cyclopropylamino, cyclobutylamino, benzylamino or phenylamino; disubstituted amino selected from dimethylamino, diethylamino, ethyl(1-methylethyl)amino, monomethylbenzylamino, piperidinyl, morpholinyl, 1-imidazolyl, 1-pyrrolyl, 1-(1,2,3-triazolyl) or 4-(1,2,4-triazolyl); straight or branched (C1-C4)alkyl group selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl or 1,1-dimethylethyl; (C1-C6)cycloalkyl group selected from cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl; substituted (C3-C6)cycloalkyl group (substitution selected from (C1-C3)alkyl, cyano, amino or (C1-C3)acyl); (C6-C10)aryl group selected from phenyl, α-phenyl, α-naphthyl or β-naphthyl; substituted (C6-C10)aryl group (substitution selected from halo, (C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl; α-amino-(C1-C4)alkyl group selected from aminomethyl, α-aminoethyl, α-aminopropyl or α-aminobutyl; carboxy(C2-C4)akylamino group selected from aminoacetic acid, α-aminobutyric acid or α-aminopropionic acid and their optical isomers; (C7-C9)aralkylamino group such as phenylglycyl; (C1-C4)-alkoxycarbonylamino substituted (C1-C4)alkyl group, substitution selected from phenyl or p-hydroxyphenyl; α-hydroxy(C1-C3)alkyl group selected from hydroxymethyl, α-hydroxyethyl or α-hydroxy-1-methylethyl or α-hydroxypropyl; α-mercapto(C1-C3)alkyl group selected from mercaptomethyl, α-mercaptoethyl, α-mercapto-1-methyl or α-mercaptopropyl; halo(C1-C3)alkyl group such as bromomethyl, fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, 2-fluoroethyl, 2,2-difluoroethyl, 2,2,2-trifluoroethyl, 2-bromoethyl or 2-iodoethyl; a heterocycle group selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:


such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl, or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:
such as imidazolyl, pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, indazolyl, thiazolyl, benzothiazolyl, 3-alkyl-3H-imidazo[4,5-b]pyridyl or pyridylimidazolyl, or a five membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom:
(A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo, (C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)
such as γ-butyrolactam, γ-butyrolactone, imidazolidinone or N-aminoimidazolidinone, or a six membered aromatic ring with one to three N, O, S or Se heteroatoms such as pyridyl, pyridazinyl, pyrazinyl, sym-triazinyl, unsym-triazinyl, pyrimidinyl or (C1-C3)alkylthiopyridazinyl, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom such as 2,3-dioxo-1-piperazinyl, 4-ethyl-2,3-dioxo-1-piperazinyl, 4-methyl-2,3-dioxo-1-piperazinyl, 4-cyclopropyl, 2-dioxo-1-piperazinyl, 2-dioxomorpholinyl or 2-dioxothiomorpholinyl; acyl or haloacyl group selected from acetyl, propionyl, chloroacetyl, trifluoroacetyl, (C3-C6)cycloalkylcarbonyl such as cyclopropylcarbonyl, cyclobutylcarbonyl, cyclopentylcarbonyl, cyclohexylcarbonyl, (2,3-dimethylcyclopropyl)carbonyl, (1,2-dimethylcyclopropyl)carbonyl, (2-ethylcyclopropyl)carbonyl, (2-methylcyclopentyl)carbonyl or (3-ethylcyclobutyl)carbonyl, (C6-C10)aroyl selected from benzoyl or naphthoyl, halo substituted (C6-C10)aroyl such as pentafluorobenzoyl, 4-chlorobenzoyl, 3-bromobenzoyl or 3,4-difluorobenzoyl, (C1-C4)alkylbenzoyl such as 4-toluoyl, 2-toluoyl or 4-(1-methylethyl)benzoyl, or (heterocycle)carbonyl, the heterocycle selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:
such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuran, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl, or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:
such as imidaozly, pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, indazolyl, thiazolyl, benzothiazolyl, 3-alkyl-3H-imidazolyl[4,5-b]pyridyl or pyridylimidazolyl, or a five membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom:
(A is selected from hydrogen; straight or branched (C1-C6)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo,(C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)
such as γ-butyrolactam, γ-butyrolactone, imidazolidinone or N-aminoimidazolidinone, or a six membered aromatic ring with one to three N, O, S or Se heteroatoms such as pyridyl, pyridazinyl, pyrazinyl, sym-triazinyl, unsym-triazinyl, pyrimidinyl or (C1-C3)alkylthiopyridazinyl or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatoms such as 2,3-dioxo-1-piperazinyl, 4-ethyl-2,3-dioxo-1-piperazinyl, 4-methyl-2,3-dioxo-1-piperazinyl, 4-cyclopropyl- 2-dioxo-1-piperazinyl, 2-dioxomorpholinyl or 2-dioxothiomorpholinyl; (C1-C4)alkoxycarbonyl group selected from methoxycarbonyl, ethoxycarbonyl, straight or branched propoxylcarbonyl, straight or branched butoxycarbonyl or allyloxycarbonyl; vinyl or substituted vinyl group [substitution selected from (C1-C3)alkyl group, halogen, (C6-C10)aryl group selected from phenyl, α-naphthyl, β-naphthyl, substituted (C6-C10)aryl group (substitution selection from halo, (C1-C6)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy), halo(C1-C3)alkyl group such as bromomethyl, fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, 2-fluoroethyl, 2,2-difluoroethyl, 2,2,2-trifluoroethyl, 2-bromoethyl or 2-iodoethyl, a heterocycle group selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:
such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuran, furanyl, benzofuranyl, tetrahydrothienyl, thienyl benzothienyl or selenazolyl]; (C1-C4)alkoxy group such as allyloxy, methoxy, ethoxy, n-propoxy, n-butoxy or tert-butoxy; C6-aryloxy group selected from phenoxy or substituted phenoxy (substitution selected from halo, (C1-C4)alkyl, nitro, cyano, thiol, amino, carboxy, di(C1-C3)alkylamino); (C7-C10)aralkyloxy group such as benzyloxy, 1-phenylethyloxy or 2-phenylethyloxy; vinyloxy or substituted vinyloxy group (substitution selected from (C1-C4)alkyl, cyano, carboxy, or (C6-C10)aryl selected from phenyl, α-naphthyl or β-naphthyl); RaRbamino(C1-C4)alkoxy group, wherein RaRb is a straight or branched (C1-C6)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl or 1,1-dimethylethyl or RaRb is (CH2)n, n=2-6, or (CH2)2W(CH2)2 wherein W is selected from N(C1-C3)alkyl [straight or branched], NH, NOB [B is selected from hydrogen or (C1-C3)alkyl], O is S; or RaRbaminoxy group, wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or RaRb is (CH2)n, n=2-6, or (CH2)2W(CH2)2 wherein W is selected from N(C1-C3)alkyl [straight or branched], NH, NOB [B is selected from hydrogen or (C1-C3)alkyl], O or S; and when R=R4(CH2)nCO and n=1-4, R4 is selected from hydrogen; amino; straight or branched (C1-C4)alkyl group selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl or 1,1-dimethylethyl; (C3-C6)cycloalkyl group selected from cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl; substituted (C3-C6)cycloalkyl group (substitution selected from (C1-C3)alkyl, cyano, amino or (C1-C3)acyl); (C6-C10)aryl group selected from phenyl, α-naphthyl or β-naphthyl; substituted(C6-C10)aryl group (substitution selected from halo, (C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group such as benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl; acyloxy or haloacyloxy group, selected from acetyl, propionyl, chloroacetyl, trichloroacetyl, (C3-C6)cycloalkylcarbonyl, (C6-C10)aroyl selected from benzoyl or naphtholyl, halo substituted (C8-C10)aroyl such as pentafluorobenzoyl, 4-chlorobenzoyl, 3-bromobenzoyl or 3,4-difluorobenzoyl, (C1-C4)alkylbenzoyl such as 4-toluoyl, 2-toluoyl or 4-(1-methylethyl)benzoyl, (heterocycle)carbonyl, the heterocycle selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:
such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl, or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:
such as imidazolyl, pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, imidazolyl, thiazolyl, benzothiazolyl, 3-alkyl-3H-imidazo[4,5-b]pyridyl or pyridylimidazolyl, or a five membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom:
(A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo,(C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)
such as γ-butyrolactam, γ-butyrolactone, imidazolidinone or N-aminoimdiazolidinone, or a six membered aromatic ring with one to three N, O, S or Se heteroatoms such as pyridyl, pyridazinyl, pyrazinyl, sym-triazinyl, unsym-triazinyl, pyrimidinyl or (C1-C3)alkylthiopyridazinyl, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom such as 2,3-dioxo-1-piperazinyl, 4-ethyl-2,3-dioxo-1-piperazinyl, 4-methyl-2,3-dioxo-1-piperazinyl, 4-cyclopropyl-2-dioxo-1-piperazinyl, 2-dioxomorpholinyl or 2-dioxothiomorpholinyl; (C1-C4)alkoxy group such as allyloxy, methoxy, ethoxy, n-propoxy,n-butoxy or tert-butoxy; C6-aryloxy group selected from phenoxy or substituted phenoxy (substitution selected from halo, (C1-C4)alkyl, nitro, cyano, thiol, amino, carboxy, di(C1-C3)alkylamino); (C7-C10)aralkyloxy group such as benzyloxy, 1-phenylethyloxy or 2-phenylethyloxy; (C1-C3)alkylthio group selected from methylthio, ethylthio, propylthio or allylthio; C6-arylthio group selected from phenylthio or substituted phenylthio (substitution selected from halo, (C1-C4)alkyl, nitro, cyano, thiol, amino, carboxy, di(C1-C3)alkylamino); C6-arylsulfonyl group selected from phenylsulfonyl or substituted phenylsuflonyl (substitution selected from halo, (C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C8)aralkylthio group such as benzylthio, 1-phenylethylthio or 2-phenylethylthio; a heterocycle group selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:
such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuran, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl, or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:
such as imidazolyl, pyrazolyl, benzimidazolyl, oxaxolyl, benzoxazolyl, indazolyl, thiazolyl, benzothiazolyl, 3-alkyl-3H-imidazo[3,4-b]pyridyl or pyridylimidazolyl, or a five membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heterotom:
(A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo,(C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C6)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)
such as γ-butyrolactam, γ-butyrolactone, imidazolidinone or N-aminoimidazolidinone, or a six membered aromatic ring with one to three N, O,S or Se heteroatoms such as pyridyl, pyridazinyl, pyrazinyl, sym-triazinyl, unsym-triazinyl, pyrimidinyl or (C1-C3)alkylthiopyridazinyl, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom such as 2,3-dioxo-1-piperazinyl, 4-ethyl-2,3-dioxo-1-piperazinyl, 4-methyl-2,3-dioxo-1-piperazinyl, 4-cyclopropyl, 2-dioxo-1-piperazinyl, 2-dioxomorpholinyl or 2-dioxothiomorpholinyl; hydroxy group; mercapto group; mono- or di-straight or branched chain (C1-C6)alkylamino group selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl, 1,1-dimethylethyl, n-pentyl, 2-methylbutyl, 1,1-dimethylpropyl, 2,2-dimethylpropyl, 3-methylbutyl, n-hexyl, 1-methylpentyl, 1,1-dimethylbutyl, 2,2-dimethylbutyl, 3-methylpentyl, 1,2-dimethylbutyl, 1,3-dimethylbutyl or 1-methyl-1-ethylpropylamino; (C2-C5)azacycloalkyl group such as aziridinyl, azetidinyl, pyrrolidinyl, piperidinyl, morpholinyl or 2-methylpyrrolidinyl; carboxy(C2-C4)alkylamino group selected from aminoacetic acid, α-aminopropionic acid, α-aminobutyric acid and their optical isomers; α-hydroxy(C1-C3)alkyl group selected from hydroxymethyl, α-hydroxyethyl or α-hydroxy-1-methylethyl or α-hydroxypropyl; halo(C1-C3)alkyl group such as bromomethyl, fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, 2-fluoroethyl, 2,2-difluoroethyl, 2,2,2-trifluoromethyl, 2-bromoethyl or 2-iodoethyl; acyl or haloacyl group selected from acetyl, propionyl, chloroacetyl, trifluoroacetyl, (C3-C6)cycloalkylcarbonyl, (C6-C10)-aroyl selected from benzoyl or naphthoyl, halo substituted (C6-C10)aroyl such as pentafluorobenzoyl, 4-chlorobenzoyl, 3-bromobenzoyl, 3,4-difluorobenzoyl, (C1-C4)alkylbenzoyl such as 4-toluoyl, 2-toluoyl or 4-(1-methylethyl)benzoyl, or (heterocycle)carbonyl, the heterocycle selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:
such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl,benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl, or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:
such as imidazolyl, pyrazolyl, benzimidazolyl, oxaxolyl, benzoxazolyl, indazolyl, thiazolyl, benzothiazolyl, 3-alkyl-3H-imidazo[4,5-b]pyridyl or pyridylimidazolyl, or a five membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom:
(A is selected from hydrogen; straight or branched (C1-C6)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo,(C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C2) alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenyl propyl) such as γ-butyrolactam, γ-butyrolactone, imidazolidinone or N-aminoimidazolidinone, or a six membered aromatic ring with one to three N, O, S or Se heteroatoms such as pyridyl, pyridazinyl, pyrazinyl, sym-triazinyl, unsym-triazinyl, pyrimidinyl or (C1-C3)alkylthiopyridazinyl, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom such as 2,3-dioxo-1-piperazinyl, 4-ethyl-2,3-dioxo-1-piperazinyl, 4-methyl-2,3-dioxo-1-piperazinyl, 4-cyclopropyl-2-dioxo-1-piperazinyl, 2-dioxomorpholinyl or -dioxothiomorpholinyl; (C1-C4)alkoxycarbonylamino group selected from tert-butoxycarbonylamino, allyloxycarbonylamino, methoxycarbonylamino, ethoxycarbonylamino or propoxycarbonylamino; (C1-C4)alkoxycarbonyl group selected from methoxycarbonyl, ethoxycarbonyl, straight or branched propoxycarbonyl, allyloxycarbonyl or straight or branched butoxycarbonyl; RaRbamino(C1-C4)alkoxy group, wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or RaRb is (CH2)n, n=2-6, or (CH2)2W(CH2)2 wherein W is selected from N(C1-C3)alkyl [straight or branched], NH, NOB [B is selected from hydrogen or (C1-C3)alkyl], O is S; or RaRbaminoxy group, wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or RaRb is (CH2)n, n=2-6, or (CH2)2W(CH2)2 wherein W is selected from N(C1-C3)alkyl [straight or branched], NH, NOB [B is selected from hydrogen or (C1-C3)alkyl], O or S; and when R=R4 (CH2)nSO2 and n=0, R4′ is selected from amino; monosubstituted amino selected from straight or branched (C1-C6)alkylamino, cyclopropylamino, cyclobutylamino, benzylamino or phenylamino; disubstituted amino selected from dimethylamino, diethylamino, ethyl(1-methylethyl)amino, monomethylbenzylamino, piperidinyl, morpholinyl, 1-imidazolyl, 1-pyrrolyl, 1-(1,2,3-triazolyl) or 4-(1,2,4-triazolyl); straight or branched (C1-C4)alkyl group selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl or 1,1-dimethylethyl; (C3-C6)cycloalkyl group selected from cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl; substituted (C3-C6)cycloalkyl group (substitution selected from (C1-C3)alkyl, cyano, amino or (C1-C3)acyl); (C6-C10)aryl group selected from phenyl, α-naphthyl or β-naphthyl; substituted (C6-C10)aryl group (substitution selected from halo, (C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group such as benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl; halo(C1-C3)alkyl group such as bromomethyl, fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl 2-fluoroethyl, 2,2-difluoroethyl, 2,2,2-trifluoroethyl, 2-chloroethyl, 2,2-dichloroethyl, 2,2,2-trichloroethyl, 2-bromoethyl or 2-iodoethyl; a heterocycle group selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:
such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl, or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:
such as imidazolyl, pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, indazolyl, thiazolyl, benzothiazolyl, 3-alkyl-3H-imidazo[4,5-b]pyridyl or pyridylimidazolyl, or a five membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom:
(A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo,(C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl) or phenylpropyl)
such as γ-butyrolactam, γ-butyrolactone, imidazolidinone or N-aminoimidazolidinone, or a six membered aromatic ring with one to three, N, O, S or Se heteroatoms such as pyridyl, pyridazinyl, pyrazinyl, sym-triazinyl, unsym-triazinyl, pyrimidinyl or (C1-C3)alkylthiopyridazinyl, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom such as 2,3-dioxo-1-piperazinyl, 4-ethyl-2,3-dioxo-1-piperazinyl, 4methyl-2,3-dioxo-1-piperazinyl, 4-cyclopropyl-2-dioxo-1-piperazinyl, 2-dioxomorpholinyl or 2-dioxothiomorpholinyl; RaRbamino(C1-C4)alkoxy group, wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or RaRb is (CH2)n, n=2-6, or (CH2)2W(CH2)2 wherein W is selected from N(C1-C3)alkyl [straight or branched], NH, NOB [B is selected from hydrogen or (C1-C3)alkyl], O or S; or RaRbaminoxy group, wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or RaRb is (CH2)n, n=2-6, or (CH2)2W(CH2)2 wherein W is selected from N(C1C3)alkyl [straight or branched], NH, NOB [B is selected from hydrogen or (C1-C3)alkyl], O or S; and when R=R4′ (CH2)nSO2 and n=1-4, R4′ is selected from hydrogen; amino; straight or branched (C1-C4)alkyl group selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl or 1,1-dimethylethyl; (C1-C4)carboxylalkyl group; (C3-C6)cycloalkyl group selected from cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl; substituted (C3-C6)cycloalkyl group (substitution selected from (C1-C3)alkyl, cyano, amino or (C1-C3)acyl); (C6-C10)aryl group selected from phenyl, α-naphthyl or β-naphthyl; substituted (C6-C10)aryl group (substitution selected from halo, (C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl; (C1-C4)alkoxy group such as allyloxy, methoxy, ethoxy, n-propoxy or tert-butoxy; C6-aryloxy group selected from phenoxy or substituted phenoxy (substitution selected from halo, (C1-C3)alkyl, nitro, cyano, thiol, amino, carboxy, di(C1-C3)alkylamino); (C7-C10)aralkyloxy group such as benzyloxy, 1-phenylethyloxy or 2-phenylethyloxy; RaRbamino(C1-C4)alkoxy group, wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or RaRb is (CH2)n, n=2-6, or (CH2)2W(CH2)2 wherein W is selected from N(C1-C3)alkyl [straight or branched], NH, NOB [B is selected from hydrogen or (C1-C2)alkyl], O or S; or RaRbaminoxy group, wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or RaRb is (CH2)n, n=2-6, or (CH2)2W(CH2)2 wherein W is selected from N(C1-C3)alkyl [straight or branched], NH, NOB [B is selected from hydrogen or (C1-C3)alkyl], O or S; (C1-C3)alkylthio group selected from methylthio, ethylthio or n-propylthio; C6-arylthio group selected from phenylthio or substituted phenylthio (substitution selected from halo, (C1-C3)alkyl, nitro, cyano, thiol, amino, carboxy, di(C1-C3)alkylamino); (C7-C8)aralkylthio group such as benzylthio, 1-phenylethylthio or 2-phenylethylthio; a heterocycle group selected from a five membered aromatic or saturated ring with one N, O, S or S heteroatom optionally having a benzo or pyrido ring fused thereto.
such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl, or selenazolyl, or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:
such as imidazolyl, pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, indazolyl[4,5-b]pyridyl or pyridylimidazolyl, or a five membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom:
(A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo,(C1-C6)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C6)-alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)-aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)
such as γ-butyrolactam, γ-butyrolactone, imidazolidinone or N-aminoimidazolidinone, or a six membered aromatic ring with one to three N, O,S or Se heteroatoms such as pyridyl, pyridazinyl, pyrazinyl, sym-triazinyl, unsym-triazinyl, pyrimidinyl or (C1-C3)alkylthiopyridazinyl, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatoms such as 2,3-dioxo-1-piperazinyl, 4-ethyl-2,3-dioxo-1-piperazinyl, 4-methyl-2,3-dioxo-1-piperazinyl, 4 -cyclopropyl-2-dioxo-1-piperazinyl, 2-dioxomorpholinyl or 2-dioxothiomorpholinyl; hydroxy group, mercapto group; mono- or di- straight or branched (C1-C6) alkylamino group selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl, 1,1-dimethylethyl, 2-methylbutyl, 1,1-dimethylpropyl, 2,2-dimethylpropyl, 3-methylbutyl, n-hexyl, 1-methylpentyl, 1,1-dimethylbutyl, 2,2-dimethylbutyl, 2-methylpentyl, 1,2-dimethylbutyl, 1,3-dimethylbutyl or 1-methyl-1-ethylpropyl amino, halo(C1-C3)alkyl group such as bromomethyl, fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, 2-fluoroethyl, 2,2-difluoroethyl, 2,2,2-trifluoroethyl, 2-chloroethyl, 2,2-dichloroethyl, 2,2,2-trichloroethyl, 2-bromoethyl or 2-iodoethyl; acyl or haloacyl group selected from acetyl, propionyl, chloroacetyl, trifluoroacetyl, (C3-C6)-cycloalkylcarbonyl, (C6-C10)aroyl selected from benzoyl or naphthyl, halo substituted (C6-C10)aroyl such as pentafluorobenzyl, 4-chlorobenzoyl, 3-bromobenzoyl or 3,4-difluorobenzyl, (C1-C4)-alkylbenzoyl such as 4-toluoyl, 2-toluoyl or 4-(1-methylethyl)benzoyl, or (heterocycle)carbonyl, the heterocycle selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused therein:
such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl, or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:
such as imidazolyl, pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, indazolyl, thiazolyl, benzothiazonyl, 3-alkyl-3H-imidazo[4,5-b]pyridyl or pyridylimidazolyl, or a five membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom:
(A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo,(C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)akylamino or carboxy); (C7-C9)-aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)
such as γ-butyrolactam, γ-butyrolactone, imidazolidizinone or N-aminoimidazolidinone, or a six membered aromatic ring with one to three N, O, S or Se heteroatoms such as pyridyl, pyridazinyl, pyrazinyl, sym-triazinyl, unsym-triazinyl, pyrimidinyl or (C1-C3)alkylthiopyridazinyl, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom such as 2,3-dioxo-1-piperazinyl, 4-ethyl-2,3-dioxo-1-piperazinyl, 4-methyl-2,3-dioxo-1-piperazinyl, 4-cyclopropyl- 2-dioxo-1-piperazinyl, 2-dioxomorpholinyl or 2-dioxothiomorpholinyl; (C1-C4)alkoxycarbonyl group selected from methoxycarbonyl, ethoxycarbonyl, straight or branched propoxycarbonyl, allyloxycarbonyl or straight or branched butoxycarbonyl; R5 is selected from hydrogen; straight or branched (C1-C3)alkyl group selected from methyl, ethyl, n-propyl or 1-methylethyl; (C6-C10)aryl group selected from phenyl, α-naphthyl or β-naphthyl; (C7-C9)aralkyl group such as benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl; a heterocycle group selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:
such as pyrrolyl, N-methylimidolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl, or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:
such as imidazolyl, pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, indazolyl, thiazolyl, benzothiazolyl, 3-alkyl-3H-imidazo[4,5b-]pyridyl or pyridylimidazolyl, or a five membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom:
(A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo,(C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxyl; (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)
such as γ-butyrolactam, γ-butyrolactone, imidazolidinone or N-aminoimidazolidinone, or a six membered aromatic ring with one to three N, O, S or Se heteroatoms such as pyridyl, pyridazinyl, pyrazinyl, sym-triazinyl, unsym-triazinyl, pyrimidinyl or (C1-C3) alkylthiopyridazinyl, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom such as 2,3-dioxo-1-piperazinyl, 4-ethyl-2,3-dioxo-1-piperazinyl, 4-methyl-2,3-dioxo-1-piperazinyl, 4-cyclopropyl, 2-dioxo-1-piperazinyl, 2-dioxomorpholinyl, 2-dioxothiomorpholinyl; or (CH2)nCOOR7 where n=0-4 and R7 is selected from hydrogen; straight or branched (C1-C3)alkyl group selected from methyl, ethyl, n-propyl, or 1-methylethyl; or (C6-C10)aryl group selected from phenyl, α-naphthyl, β-naphthyl; R6 is selected from hydrogen; straight or branched (C1-C3)alkyl group selected from methyl, ethyl, n-propyl, or 1-methylethyl; (C6-C10)aryl group selected from phenyl, α-naphthyl or β-naphthyl; (C7-C9)aralkyl group such as benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl; a heterocycle group selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:
such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl, or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:
such as imidazolyl, pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, indazolyl, thiazolyl, benzothiazolyl, 3-alkyl-3H-imidazo[4,5-b]pyridyl or pyridylimidazolyl, or a five membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom:
(A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl (substitution selected from halo,(C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)
such as γ-butyrolactam, γ-butyrolactone, imidazolidinone or N-aminoimidazolidinone, or a six membered aromatic ring with one to three N, O, S or Se heteroatoms such as pyridyl, pyridazinyl, pyrazinyl, sym-triazinyl, unsym-triazinyl, pyrimidinyl or (C1-C3)alkylthiopyridazinyl, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom such as 2,3-dioxo-1-piperazinyl, 4-ethyl-2,3-dioxo-1-piperazinyl, 4-methyl-2,3-dioxo-1-piperazinyl, 4-cyclopropyl, 2-dioxo-1-piperazinyl, 2-dioxomorpholinyl, 2-dioxothiomorpholinyl; or (CH2)nCOORT where n=0-4 and RT is selected from hydrogen; straight or branched (C1-C3)alkyl selected from methyl, ethyl, n-propyl or 1-methylethyl; or (C6-C10)aryl selected from phenyl, α-naphthyl or β-naphthyl; with the proviso that R5 and R6 cannot both be hydrogen; or R5 and R6 taken together are (CH2)2W(CH2)2, wherein W is selected from (CH2)n and n=0-1, NH, (C1-C3)alkyl [straight or branched], N(C1-C4)alkoxy, oxygen, sulfur or substituted congeners selected from (L or D)proline, ethyl(L or D)prolinate, morpholine, pyrrolidine or piperidine; and the pharmacologically acceptable organic and inorganic salts or metal complexes.

Preferred compounds are compounds according to the above formula I and II in which X is selected from amino, NR1R2, or halogen; the halogen is selected from bromine, chlorine, fluorine or iodine; and when X=NR1R2 and R1=hydrogen, R2=methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl or 1,1-dimethylethyl; and when R1=methyl or ethyl, R2=methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl or 2-methylpropyl; R is selected from R6(CH2)nCO or R4′ (CH2)nSO2; and when R=R4(CH2)nCO and n=0, R4 is selected from hydrogen; amino; monosubstituted amino selected from straight or branched (C1-C6)alkylamino, cyclopropylamino, cyclobutylamino, benzylamino or phenylamino; disubstituted amino selected from dimethylamino, diethylamino, ethyl(1-methylethyl)amino, monomethylbenzylamino, piperidinyl, morpholinyl, 1-imidazolyl, 1-pyrrolyl, 1-(1,2,3-triazolyl) or 4-(1,2,4-triazolyl); straight or branched (C1-C3)alkyl group selected from methyl, ethyl, n-propyl or 1-methylethyl; (C1-C6)cycloalkyl group selected from cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl; substituted (C3-C6)cycloalkyl group (substitution selected from (C1-C3)alkyl, cyano, amino or (C1-C3)acyl); (C6-C10)aryl group selected from phenyl, α-naphthyl or β-naphthyl; substituted (C6-C10)aryl group (substitution selected from halo,(C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); α-amino(C1-C4)alkyl group selected from aminomethyl, α-aminoethyl, α-aminopropyl or α-aminobutyl; carboxy(C2-C4)alkylamino group selected from aminoacetic acid, α-aminobutyric acid or α-aminopropionic acid and their optical isomers; (C7-C9)aralkylamino group such as phenylglycyl; (C1-C4)alkoxycarbonylamino substituted (C1-C4)alkyl group, substitution selected from phenyl or p-hydroxyphenyl; α-hydroxy(C1-C3)alkyl group selected from hydroxymethyl, α-hydroxyethyl or α-hydroxy-1-methylethyl or α-hydroxyprop; halo(C1-C3)alkyl group such as bromomethyl, fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, 2-fluoroethyl, 2,2-difluoroethyl, 2,2,2-trifluoroethyl, 2-bromoethyl or 2-iodoethyl; a heterocycle group selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:


such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahyrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl, or a five membered aromatic ring with two N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:
such as imidazolyl, pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, indazolyl, thiazolyl, benzothiazolyl, 3-alkyl-3H-imidazo[4,5-b]pyridyl or pyridylimidazolyl, or a five membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended heteroatom:
(A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo, (C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C6)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)
such as γ-butyrolactam, γ-butyrolactone, imidazolidinone or N-aminoimidazolidinone, or a six membered aromatic ring with one to three N, O, S or Se heteroatoms such as pyridyl, pyridazinyl, pyrazinyl, sym-triazinyl, unsym-triazinyl, pyrimidinyl or (C1-C3)alkylthiopyridazinyl, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom such as 2,3-dioxo-1-piperazinyl, 4-ethyl-2,3-dioxo-1-piperazinyl, 4-methyl-2,3-dioxo-1-piperazinyl, 4-cyclopropyl, 2-dioxo-1-piperazinyl, 2-dioxomorpholinyl or 2-dioxothiomorpholinyl; acyl or haloacyl group selected from acetyl, propionyl, chloroacetyl, trifluoroacetyl, (C3-C6)cycloalkylcarbonyl such as cyclopropylcarbonyl, cyclobutylcarbonyl, cyclopentylcarbonyl, cyclohexylcarbonyl, (2,3-dimethylcyclopropyl)carbonyl, (1,2-dimethylcyclopropyl)carbonyl, (2-ethylcyclopropyl)carbonyl, (3-ethylcyclobutyl)carbonyl, (C6-C10)aroyl selected from benzoyl or naphthoyl, halo substituted (C6-C10)aroyl such as pentafluorobenzoyl, 4-chlorobenzoyl, 3-bromobenzoyl or 3,4-difluorobenzoyl, (C1-C4)alkylbenozyl such as 4-toluoyl, 2-methyltoluoyl or 4-(1-methylethyl)benzoyl, or (heterocycle)carbonyl, the heterocycle selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:
such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl, or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto.
such as imidazolyl, pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, indazolyl, thiazolyl, benzothiazolyl, 3-alkyl-3H-imidazo[4,5-b]pyridyl or pyridylimidazolyl, or a five membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom:
(A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo, (C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)
such as γ-butyrolactam, γ-butyrolactone, imidazolidinone or N-aminoimidazolidinone, or a six membered aromatic ring with one to three N, O, S or Se heteroatoms such as pyridyl, pyridazinyl, pyrazinyl, sym-triazinyl, unsym-triazinyl, pyrimidinyl or (C1-C3)alkylthiopyridazinyl, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom such as 2,3-dioxo-1-piperazinyl, 4-ethyl-2,3-dioxo-1-piperazinyl, 4-methyl-2,3-dioxo-1-piperazinyl, 4-cyclopropyl, 2-dioxo-1-piperazinyl, 2-dioxomorpholinyl or 2-dioxothiomorpholinyl; (C1-C4)alkoxycarbonyl group selected from methoxycarbonyl, ethoxycarbonyl, straight or branched propoxylcarbonyl, straight or branched butoxycarbonyl or allyloxycarbonyl; vinyl or substituted vinyl group [substitution selected from (C1-C3)alkyl group, halogen, (C6-C10)aryl group selected from phenyl, α-naphthyl, β-naphthyl, substituted (C6-C10)aryl group (substitution selected from halo, (C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy), halo(C1-C3)alkyl group such as bromomethyl, fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, 2-fluoroethyl, 2,2-difluoroethyl, 2,2,2-trifluoroethyl, 2-bromoethyl or 2-iodoethyl, a heterocycle group selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:
such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl]; (C1-C4)alkoxy group such as allyloxy, methoxy, ethoxy, n-propoxy,n-butoxy or tert-butoxy; C6-aryloxy group selected from phenoxy or substituted phenoxy (substitution selected from halo, (C1-C4)alkyl, nitro, cyano, thiol, amino, carboxy, di(C1-C3)alkylamino); (C7-C10)aralkyloxy group such as benzyloxy, 1-phenylethyloxy or 2-phenylethyloxy; vinyloxy or substituted vinyloxy group (substitution selected from (C1-C4)alkyl, cyano, carboxy, or (C6-C10)aryl selected from phenyl, α-naphthyl or β-naphthyl); RaRbamino(C1-C4)alkoxy group, wherein RaRb is a straight chain or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or RaRb is (CH2)n, n=2-6, or (CH2)2W(CH2)2 wherein W is selected from N(C1-C3)alkyl [straight or branched], NH, NOB [B is selected from hydrogen or (C1-C3)alkyl], O or S; or RaRbaminoxy group, wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or RaRb (CH2)n, n=2-6, or (CH2)2 W(CH2)2 wherein W is selected from N(C1-C3)alkyl [straight or branched], NH1, NOB [B is selected from hydrogen or (C1-C3)alkyl], O or S; and when R=R4(CH2)nCO and n=1-4, R4 is selected from hydrogen; (C1-C3)alkyl group selected from methyl, ethyl, n-propyl or 1-methylethyl; amino; monosubstituted amino selected from straight or branched (C1-C6)alkylamino, cyclopropylamino, cyclobutylamino, benzylamino or phenylamino; disubstituted amino selected from dimethylamino, diethylamino, ethyl(1-methylethyl)amino, monomethylbenzylamino, piperidinyl, morpholinyl, 1-imidazolyl, 1-pyrrolyl, 1-(1,2,3-triazolyl) or 4-(1,2,4-triazolyl); (C6-C10)aryl group selected from phenyl, α-naphthyl or β-naphthyl; substituted (C6-C10)aryl group (substitution selected from halo, (C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); acryloxy or haloacryloxy group selected from acetyl, propionyl, chloroacetyl, trichloroacetyl, (C3-C6)cycloalkylcarbonyl, (C6-C10)aroyl selected from benzoyl or naphthyl, halo substituted (C6-C10)aroyl such as pentafluorobenzoyl, 4-chlorobenzoyl, 3-bromobenzoyl or 3,4-difluorobenzoyl, (C1-C4)alkylbenzoyl such as 4-toluoyl, 2-toluoyl, 4-(1-methylethyl)benzoyl or (heterocycle)carbonyl, the heterocycle selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:
such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl, or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:
such as imidaozly, pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, indazolyl, thiazolyl, benzothiazolyl, 3-alkyl-3H-imidazolyl[4,5-b]pyridyl or pyridylimidazolyl, or a five membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom:
(A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo, (C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)
such as γ-butyrolactam, γ-butyrolactone, imidazolidinone or N-aminoimidazolidinone, or a six membered aromatic ring with one to three N, O, S or Se heteroatoms such as pyridyl, pyridazinyl, pyrazinyl, sym-triazinyl, unsym-triazinyl, pyrimidinyl or (C1-C3)alkylthiopyridazinyl, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom such as 2,3-dioxo-1-piperazinyl, 4-ethyl-2,3-dioxo-1-piperazinyl, 4-methyl-2,3-dioxo-1-piperazinyl, 4-cyclopropyl, 2-dioxo-1-piperazinyl, 2-dioxomorpholinyl or 2-dioxothiomorpholinyl; (C1-C4)alkoxy group such as allyloxy, methoxy, ethoxy, n-propoxy, n-butoxy or tert-butoxy; RaRbamino(C1-C4)alkoxy group, wherein RaRb is a straight or branched (C1-C6)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or RaRb is (CH2)n, n=2-6, or (CH2)2W(CH2)2 wherein W is selected from N(C1-C3)alkyl [straight or branched], NH, NOB [B is selected from hydrogen or (C1-C3)alkyl], O, or S; or RaRbaminoxy group, wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methoxypropyl or RaRb is (CH2)n, n=2-6, or (CH2)2W(CH2)2 wherein W is selected from N(C1-C3)alkyl [straight or branched], NH, NOB [B is selected from hydrogen or (C1-C3)alkyl], O or S; C6-aryloxy group selected from phenoxy or substituted phenoxy (substitution selected from halo, (C1-C6)alkyl, nitro, cyano, thiol, amino, carboxy, di(C1-C3)alkylamino); (C1-C3)alkylthio group selected from methylthio, ethylthio, propylthio or allylthio; C6-arylthio group selected from phenylthio or substituted phenylthio (substitution selected from halo, (C1-C4)alkyl, nitro, cyano, thiol, amino, carboxy, di(C1-C3)alkylamino); C6-arylsulfonyl group selected from phenylsulfonyl or substituted phenylsuflonyl (substitution selected from halo, (C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); a heterocycle group selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:
such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl, or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:
such as imidazolyl, pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, indazolyl, thiazolyl, benzothiazolyl, 3-alkyl-3H-imidazo[4,5-b]pyridyl or pyridylimidazolyl, or a five membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom:
(A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo, (C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)
such as γ-butyrolactam, γ-butyrolactone, imidazolidinone or N-aminoimidazolidinone, or a six membered aromatic ring with one to three N, O, S or Se heteroatoms such as pyridyl, pyridazinyl, pyrazinyl, sym-triazinyl, unsym-triazinyl, pyrimidinyl or (C1-C3)alkylthiopyridazinyl, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom such as 2,3-dioxo-1-piperazinyl, 4-ethyl-2,3-dioxo-1-piperazinyl, 4-methyl-2,3-dioxo-1-piperazinyl, 4-cyclopropyl, 2-dioxo-1-piperazinyl, 2-dioxomorpholinyl or 2-dioxothiomorpholinyl; hydroxy group; α-hydroxy(C1-C3)alkyl group selected from hydroxymethyl, α-hydroxyethyl or α-hydroxy-1-methylethyl or α-hydroxypropyl; halo(C1-C3)alkyl group such as bromomethyl, fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, 2-fluoroethyl, 2,2-difluoroethyl, 2,2,2-trifluoromethyl, 2-bromoethyl or 2-iodoethyl; acyl or haloacyl group selected from acetyl, propionyl, chloroacetyl, trifluoracetyl, (C3-C6)cycloalkylcarbonyl, (C6-C10)aroyl selected from benzoyl or naphthoyl, halo substituted (C6-C10)aroyl such as pentafluorobenzyl, 4-chlorobenzoyl, 3-bromobenzoyl or 3,4-difluorobenozyl, (C1-C4)alkylbenzoyl such as 4-toluoyl, 2-toluoyl, or 4-(1-methylethyl)benzoyl or (heterocycle)carbonyl, the heterocycle selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:
such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl, or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:
such as imidazolyl, pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, indazolyl, thiazolyl, benzothiazolyl, 3-alkyl-3H-imidazo[4,5-b]pyridyl or pyridylimidazolyl, or a five membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom:
(A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo,(C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)
such as γ-butyrolactam, γ-butyrolactone, imidazolidinone or N-aminoimidazolidinone, or a six membered aromatic ring with one to three N, O, S or Se heteroatoms such as pyridyl, pyridazinyl, pyrazinyl, sym-triazinyl, unsym-triazinyl, pyrimidinyl or (C1-C3)alkylthiopyridazinyl, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom such as 2,3-dioxo-1-piperazinyl, 4-ethyl-2,3-dioxo-1-piperazinyl, 4-methyl-2,3-dioxo-1-piperazinyl, 4-cyclopropyl, 2-dioxo-1-piperazinyl, 2-dioxomorpholinyl or 2-dioxothiomorpholinyl; (C1-C4)alkoxycarbonylamino group selected from tert-butoxycarbonylamino, allyloxycarbonylamino, methoxycarbonylamino, ethoxycarbonylamino or propoxycarbonylamino; and when R=R4 (CH2)nSO2 and n=0, R4′ is selected from amino; monosubstituted amino selected from as straight or branched (C1-C6)alkylamino, cyclopropylamino, cyclobutylamino, benzylamino or phenylamino; disubstituted amino selected from dimethylamino, diethylamino, ethyl(1-methylethyl)amino, monomethylbenzylamino, piperidinyl, morpholinyl, 1-imidazolyl, 1-pyrrolyl, 1-(1,2,3-triazolyl) or 4-(1,2,4-triazolyl); straight or branched (C1-C3)alkyl group selected from methyl, ethyl, n-propyl or 1-methylethyl; (C6-C10)aryl group selected from phenyl, α-naphthyl or β-naphthyl; substituted (C6-C10)aryl group (substitution selected from halo, (C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); a heterocycle group selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:
such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl, or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:
such as imidazolyl, pyrazolyl, benzimidazolyl, oxaxolyl, benzoxazolyl, indazolyl, thiazolyl, benzothiazolyl, 3-alkyl-3H-imidazo[4,5-b]pyridyl or pyridylimidazol, or a five membered saturated ring with one or two, N, O, S or Se heteroatoms and an adjacent appended O heteroatom:
(A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo,(C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)
such as γ-butyrolactam, γ-butyrolactone, imidazolidinone or N-aminoimidazolidinone, or a six membered aromatic ring with one to three N, O, S or Se heteroatoms such as pyridyl, pyridazinyl, pyrazinyl, sym-triazinyl, unsym-triazinyl, pyrimidinyl or (C1-C3)alkylthiopyridazinyl, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom such as 2,3-dioxo-1-piperazinyl, 4-ethyl-2,3-dioxo-1-piperazinyl, 4-methyl-2,3-dioxo-1-piperazinyl, 4-cyclopropyl-2-dioxo-1-piperazinyl, 2-dioxomorpholinyl or 2-dioxothiomorpholinyl; and when R=R4′(CH2)nSO2 and n=1-4, R4′ is selected from hydrogen; amino; monosubstituted amino selected from straight or branched (C1-C6)alkylamino, cyclopropylamino, cyclobutylamino, benzylamino or phenylamino; disubstituted amino selected from dimethylamino, diethylamino, ethyl(1-methylethyl)amino, monomethylbenzylamino, piperidinyl, morpholinyl, 1-imidazolyl, 1-pyrrolyl, 1-(1,2,3-triazolyl) or 4-(1,2,4-triazolyl); straight or branched (C1-C3)alkyl group selected from methyl, ethyl, n-propyl or 1-methylethyl; (C6-C10)aryl group selected from phenyl, α-naphthyl or β-naphthyl; substituted (C6-C10)aryl group (substitution selected from halo, (C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C4)alkylamino or carboxy); (C1-C4)alkoxy group such as allyloxy, methoxy, ethoxy, n-propoxy, n-butoxy, isobutoxy or tert-butoxy; C6-aryloxy group selected from phenoxy or substituted phenoxy (substitution selected from halo, (C1-C4)alkyl, nitro cyano, thiol, amino, carboxy, di(C1-C3)alkylamino; (C7-C10)aralkyloxy group such as benzyloxy, 1-phenylethyloxy or 2-phenylethyloxy; (C1-C10)carboxyalkyl group; R3 is selected from hydrogen; straight or branched (C1-C3)alkyl group selected from methyl, ethyl, n-propyl or 1-methylethyl; (C6-C10)aryl group selected from phenyl, α-naphthyl or β-naphthyl; (C7-C9)aralkyl group such as benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl; a heterocycle group selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:
such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl, or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:
such as imidazolyl, pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, indazolyl, thiazolyl, benzothiazolyl, 3-alkyl-3H-imidazo[4,5-b]pyridyl or pyridylimidazolyl, or a five membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom:
(A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo, (C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)
such as γ-butyrolactam, γ-butyrolactone, imidazolidinone or N-aminoimidazolidinone, or a six membered aromatic ring with one to three N, O, S or Se heteroatoms such as pyridyl, pyridazinyl, pyrazinyl, sym-triazinyl, unsym-triazinyl, pyrimidinyl or (C1-C3)alkylthiopyridazinyl, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom such as 2,3-dioxo-1-piperazinyl, 4-ethyl-2,3-dioxo-1-piperazinyl, 4-methyl-2,3-dioxo-1-piperazinyl, 4-cyclopropyl, 2-dioxo-1-piperazinyl, 2-dioxomorpholinyl or 2-dioxothiomorpholinyl; or (CH2)nCOOR7 where n=0-4 and R7 is selected from hydrogen; straight or branched (C1-C3)alkyl group selected from methyl, ethyl, n-propyl or 1-methylethyl; or (C6-C10)aryl group selected from phenyl, α-naphthyl or β-naphthyl; R6 is selected from hydrogen; straight or branched (C1-C3)alkyl group selected from methyl, ethyl, n-propyl or 1-methylethyl; (C6-C10)aryl group selected from phenyl, α-naphthyl or β-naphthyl; (C7-C9)aralkyl group such as benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl; a heterocycle group selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:
such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl, or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:
such as imidazolyl, pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, indazolyl, thiazolyl, benzothiazolyl, 3-alkyl-3H-imidazo[4,5-b]pyridyl or pyridylimidazolyl, or a five membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom:
(A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo, (C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)
such as γ-butyrolactam, γ-butyrolactone, imidazolidinone or N-aminoimidazolidinone, or a six membered aromatic ring with one to three N, O, S or Se heteroatoms such as pyridyl, pyridazinyl, pyrazinyl, sym-triazinyl, unsym-triazinyl, pyrimidinyl or (C1-C3)alkylthiopyridazinyl, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom such as 2,3-dioxo-1-piperazinyl, 4-ethyl-2,3-dioxo-1-piperazinyl, 4-methyl-2,3-dioxo-1-piperazinyl, 4-cyclopropyl, 2-dioxo-1-piperazinyl, 2-dioxomorpholinyl, 2-dioxothiomorpholinyl; or (CH2)nCOORT where n=0-4 and RT is selected from hydrogen; straight or branched (C1-C3)alkyl selected from methyl, ethyl, n-propyl or 1-methylethyl; or (C6-C10)aryl selected from phenyl, α-naphthyl or β-naphthyl; with the proviso that R5 and R6 cannot both be hydrogen; or R5 and R6 taken together are (CH2)2W(CH2)2, wherein W is selected from (CH2)n and n=0-1, NH, (C1-C3)alkyl [straight or branched], N(C1-C4)alkoxy, oxygen, sulfur or substituted congeners selected from (L or D)proline, ethyl(L or D)prolinate, morpholine, pyrrolidine or piperidine; and the pharmacologically acceptable organic and inorganic salts or metal complexes.

Particularly preferred compounds are compounds according to the above formula I and II in which X is selected from amino, NR1R2, or halogen; the halogen is selected from bromine, chlorine, fluorine or iodine; and when X=NR1R2 and R1=hydrogen, R2=methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl or 1,1-dimethylethyl; and when R1=methyl or ethyl, R2=methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methoxypropyl or 2-methylpropyl; R is selected from R4(CH2)nCO or R4′ (CH2)nSO2; and when R=R4(CH2)nCO and n=0, R4 is selected from hydrogen; amino; monosubstituted amino selected from straight or branched (C1-C6)alkylamino, cyclopropylamino, cyclobutylamino, benzylamino or phenylamino; disubstituted amino selected from dimethylamino, diethylamino, ethyl(1-methylethyl)amino, monomethylbenzylamino, piperidinyl, morpholinyl, 1-imidazolyl, 1-pyrrolyl, 1-(1,2,3-triazolyl) or 4-(1,2,4-triazolyl); straight or branched (C1-C3)alkyl group selected from methyl, ethyl, n-propyl or 1-methylethyl; (C3-C6)cycloalkyl group selected from cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl; substituted (C3-C6)cycloalkyl group (substitution selected from (C1-C3)alkyl, cyano, amino or (C1-C3)acyl); (C6-C10)aryl group selected from phenyl, α-naphthyl or β-naphthyl; substituted (C6-C10)aryl group (substitution selected from halo, (C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); α-amino-(C1-C4)alkyl, group selected from aminomethyl, α-aminoethyl, α-aminopropyl or α-aminobutyl; carboxy(C2-C4)alkylamino group selected from aminoacetic acid, α-aminobutyric acid or α-aminopropionic acid and their optical isomers, (C7-C9)aralkylamino group such as phenylglycyl; (C1-C4)alkoxycarbonylamino substituted (C1-C4)alkyl group, substitution selected from phenyl or p-hydroxyphenyl; α-hydroxy(C1-C3)alkyl group selected from hydroxymethyl, α-hydroxyethyl or α-hydroxy-1-methylethyl or α-hydroxypropyl; halo(C1-C3)alkyl group such as bromomethyl, fluoromethyl, difluoromethyl, trifluoroethyl, chloromethyl, dichlorometyl, trichloromethyl, 2-fluoroethyl, 2,2-difluoroethyl, 2,2,2-trifluoroethyl, 2-bromoethyl or 2-indoethyl, a heterocycle group selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:


such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl, or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:
such as imidazolyl, pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, indazolyl, thiazolyl, benzothiazolyl, 3-alkyl-3H-imidazo[4,5-b]pyridyl or pyridylimidazolyl, or a five membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom:
(A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo, (C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)
such as γ-butyrolactam, γ-butyrolactone, imidazolidinone or N-aminoimidazolidinone, or a six membered aromatic ring with one to three N, O, S or Se heteroatoms such as pyridyl, pyridazinyl, pyrazinyl, sym-triazinyl, unsym-triazinyl, pyrimidinyl or (C1-C3)alkylthiopyridazinyl, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom such as 2,3-dioxo-1-piperazinyl, 4-ethyl-2,3-dioxo-1-piperazinyl, 4-methyl-2,3-dioxo-1-piperazinyl, 4-cyclopropyl, 2-dioxo-1-piperazinyl, 2-dioxomorpholinyl or 2-dioxothiomorpholinyl; acyl or haloacyl group selected from acetyl, propionyl, chloroacetyl, trifluoroacetyl, (C3-C6)cycloalkylcarbonyl such as cyclopropylcarbonyl, cyclobutylcarbonyl, cyclopentylcarbonyl, cyclohexylcarbonyl, (2,3-dimethylcyclopropyl)carbonyl, (1,2-dimethylcyclopropyl)carbonyl, (2-ethylcyclopropyl)carbonyl, (2-methylcyclopentyl)carbonyl or (3-ethylcyclobutyl)carbonyl, (C6-C10)aroyl selected from benzoyl or naphthoyl, halo substituted (C6-C10)aroyl such as pentafluorobenzoyl, 4-chlorobenzoyl, 3-bromobenzoyl or 3,4-difluorobenzoyl, (C1-C4)alkylbenzoyl such as 4-toluoyl, 2-toluoyl or 4-(1-methylethyl)benzoyl, or (heterocycle)carbonyl, the heterocycle selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:
such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl, or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:
such as imidazolyl, pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, indazolyl, thiazolyl, benzothiazolyl, 3-alkyl-3H-imidazo[4,5-b]pyridyl or pyridylimidazolyl, or a five membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom:
(A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo, (C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C 9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)
such as γ-butyrolactam, γ-butyrolactone, imidazolidinone or N-aminoimidazolidinone, or a six membered aromatic ring with one to three N, O, S or Se heteroatoms such as pyridyl, pyridazinyl, pyrazinyl, sym-triazinyl, unsym-triazinyl, pyrimidinyl or (C1-C3)alkylthiopyridazinyl, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom such as 2,3-dioxo-1-piperazinyl, 4-ethyl-2,3-dioxo-1-piperazinyl, 4-methyl-2,3-dioxo-1-piperazinyl, 4-cyclopropyl, 2-dioxo-1-piperazinyl, 2-dioxomorpholinyl or 2-dioxothiomorpholinyl; (C1-C4)alkoxycarbonyl group selected from methoxy carbonyl, ethoxycarbonyl, straight or branched propoxycarbonyl, straight or branched butoxycarbonyl or allyloxycarbonyl; vinyl or substituted vinyl group [substitution selected from (C1-C3)alkyl group, halogen, (C6-C10)aryl group selected from phenyl, α-naphthyl, β-naphthyl, substituted (C6-C10)aroyl group (substituted selected from halo, (C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy), halo(C1-C3)alkyl group such as bromomethyl, fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, 2-fluoroethyl, 2,2-difluoroethyl, 2,2,2-trifluoromethyl, 2-bromomethyl or 2-iodoethyl, a heterocycle group selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:
such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl]; (C1-C4)alkoxy group such as allyloxy, methoxy, ethoxy, n-propoxy, n-butoxy or tert-butoxy; C6-aryloxy group selected from phenoxy or substituted phenoxy (substitution selected from halo, (C1-C4)alkyl, nitro, cyano, thiol, amino, carboxy, di(C1-C3)alkylamino); (C7-C10)aralkyloxy group such as benzyloxy, 1-phenylethyloxy or 2-phenylethyloxy; vinyloxy or substituted vinyloxy group (substitution selected from (C1-C4)alkyl, cyano, carboxy, or (C6-C10)aryl selected from phenyl, α-naphthyl or β-naphthyl); RaRbamino(C1-C4)alkoxy group, wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or RaRb is (CH2)n, n=2-6, or (CH2)2W(CH2)2 wherein W is selected from N(C1-C3)alkyl [straight or branched], NH, NOB [B is selected from hydrogen or (C1-C3)alkyl], O or S; or RaRbaminoxy group, wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or RaRb is (CH2)n, n=2-6, or (CH2)2W(CH2)2 wherein W is selected from N(C1-C3)alkyl [straight or branched], NH, NOB [B is selected from hydrogen or (C1-C3)alkyl], O or S; and when R=R4(CH2)nCO and n=1-4, R4 is selected from hydrogen; (C1C3)alkyl group selected from methyl, ethyl, n-propyl or 1-methylethyl; amino; monosubstituted amino selected from straight or branched (C1-C6)alkylamino, cyclopropylamino, cyclobutylamino, benzylamino or phenylamino; distributed amino selected from dimethylamino, diethylamino, ethyl(1-methylethyl)amino, monomethylbenzylamino, piperidinyl, morpholinyl, 1-imidazolyl, 1-pyrrolyl, 1-(1,2,3-triazolyl) or 4-(1,2,4-triazolyl); (C6-C10)aryl group selected from phenyl, α-naphthyl or β-naphthyl; substituted (C6-C10) aryl group (substitution selected from halo, (C1-C6)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); acryloxy or haloacryloxy group, selected from acetyl, propionyl, chloroacetyl, trichloroacetyl, (C3-C8)cycloalkylcarbonyl, (C6-C10)aroyl selected from benzoyl or naphthoyl, halo substituted (C6-C10)aroyl such as pentafluorobenzoyl, 4-chlorobenzoyl, 3-bromobenzoyl or 3,4-difluorobenzoyl, (C1-C4)alkylbenzoyl such as 4-toluoyl, 2-toluoyl, 4-(1-methylethyl)benzoyl or (heterocycle)carbonyl, the heterocycle selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto;
such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl, or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:
such as imidazolyl, pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, indazolyl, thiazolyl, benzothiazolyl, 3-alkyl-3H-imidazo[4,5-b]pyridyl or pyridylimidazolyl, or a five membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom:
(A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo,(C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)
such as γ-butyrolactam, γ-butyrolactone, imidazolidinone or N-aminoimidazolidinone, or a six membered aromatic ring with one to three N, O, S or Se heteroatoms such as pyridyl, pyridazinyl, pyrazinyl, sym-triazinyl, unsym-triazinyl, pyrimidinyl or (C1-C3)alkylthiopyridazinyl, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom such as 2,3-dioxo-1-piperazinyl, 4-ethyl-2,3-dioxo-1-piperazinyl, 4-methyl-2,3-dioxo-1-piperazinyl, 4-cyclopropyl- 2-dioxo-1-piperazinyl, 2-dioxomorpholinyl or 2-dioxothiomorpholinyl; (C1-C4)alkoxy group such as allyloxy, methoxy, ethoxy, n-propoxy, n-butoxy or tert-butoxy; C6-aryloxy group selected from phenoxy or substituted phenoxy (substitution selected from halo, (C1-C4)alkyl, nitro, cyano, thiol, amino, carboxy, di(C1-C3)alkylamino); RaRbamino(C1-C4)alkoxy group, wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or RaRb is (CH2)n, n=2-6, or (CH2)2W(CH2)2 wherein W is selected from N(C1-C3)alkyl [straight or branched], NH, NOB [B is selected from hydrogen or (C1-C3)alkyl], O or S; or RaRbaminoxy group, wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or RaRb is (CH2)n, n=2-6, or (CH2)2W(CH2)2 wherein W is selected from N(C1-C3)alkyl [straight or branched], NH, NOB [B is selected from hydrogen or (C1-C3)alkyl], O or S; (C1-C3)alkylthio group selected from methylthio, ethylthio, propylthio or allylthio; C6-arylthio group selected from phenylthio or substituted phenylthio (substitution selected from halo, (C1-C4)alkyl, nitro, cyano, thiol, amino, carboxy, di(C1-C3)alkylamino); C6-arylsulfonyl group selected from phenylsulfonyl or substituted phenylsulfonyl (substitution selected from halo, (C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); a heterocycle group selected from a five membered aromatic or saturated ring one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:
such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl, or a five membered aromatic ring with two N, O,S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:
such as imidazolyl, pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, indazolyl, thiazolyl, benzothiazolyl, 3-alkyl-3H-imidazo[4,5-b]pyridyl or pyridylimidazolyl, or a five membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom:
(A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo,(C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)
such as γ-butyrolactam, γ-butyrolactone, imidazolidinone or N-aminoimidazolidinone, or a six membered aromatic ring with one to three N, O,S or Se heteroatoms such as pyridyl, pyridazinyl, pyrazinyl, sym-triazinyl, unsym-triazinyl, pyrimidinyl (C1-C3)alkylthiopyridazinyl, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom such as 2,3-dioxo-1-piperazinyl, 4-ethyl-2,3-dioxo-1-piperazinyl, 4-methyl-2,3-dioxo-1-piperazinyl, 4-cyclopropyl- 2-dioxo-1-piperazinyl, 2-dioxomorpholinyl or 2-dioxothiomorpholinyl; hydroxy group; α-hydroxy(C1-C3)alkyl group selected from hydroxymethyl, α-hydroxyethyl or α-hydroxy-1-methylethyl or α-hydroxypropyl; halo(C1-C3)alkyl group such as bromomethyl, fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, 2-fluoroethyl, 2,2-difluoroethyl, 2,2,2-trifluoromethyl, 2-bromoethyl or 2-iodoethyl; acyl or haloacyl group selected from acetyl, propionyl, chloroacetyl, trifluoroacetyl, (C3-C6)cycloalkylcarbonyl, (C6-C10)aroyl selected from benzoyl or naphthoyl, halo substituted (C6-C10)aroyl such as pentafluorobenzoyl, 4-chlorobenzoyl, 3-bromophenylcarbonyl or 3,4-difluorobenzoyl, (C1-C4)alkylbenzoyl such as from 4-toluoyl, 2-toluoyl or 4-(1-methylethyl)benzoyl, or (heterocycle)carbonyl, the heterocycle selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:
such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl, or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:
such as imidazolyl, pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, indazolyl, thiazolyl, benzothiazolyl, 3-alkyl-3H-imidazo[4,5-b]pyridyl or pyridylimidazolyl, or a five membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom:
(A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo,(C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)
such as γ-butyrolactam, γ-butyrolactone, imidazolidinone or N-aminoimidazolidinone, or a six membered aromatic ring with one to three N, O, S or Se heteroatoms such as pyridyl, pyridazinyl, pyrazinyl, sym-triazinyl, unsym-triazinyl, pyrimidinyl or (C1-C3)alkylthiopyridazinyl, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom such as 2,3-dioxo-1-piperazinyl, 4-ethyl-2,3-dioxo-1-piperazinyl, 4-methyl-2,3-dioxo-1-piperazinyl, 4-cyclopropyl- 2-dioxo-1-piperazinyl, 2-dioxomorpholinyl or 2-dioxothiomorpholinyl; (C1-C4)alkoxycarbonylamino group selected from tert-butoxycarbonylamino, allyloxycarbonylamino, methoxycarbonylamino, ethoxycarbonylamino or propoxycarbonylamino; and when R=R4′(CH2)nSO2 and n=0, R4′ is selected from amino; monosubstituted amino selected from as straight or branched (C1-C6) alkylamino, cyclopropylamino, cyclobutylamino, benzylamino or phenylamino; disubstituted amino selected from dimethylamino, diethylamino, ethyl(1-methylethyl)amino, monomethylbenzylamino, piperidinyl, morpholinyl, 1-imidazolyl, 1-pyrrolyl, 1-(1,2,3-triazolyl) or 4-(1,2,4-triazolyl); straight or branched (C1-C3)alkyl group selected from methyl, ethyl, n-propyl or 1-methylethyl; (C6-C10)aryl group selected from phenyl, α-naphthyl or β-naphthyl; substituted (C6-C10)aryl group (substitution selected from halo, (C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); a heterocycle group selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:
such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl, or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:
such as imidazolyl, pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, indazolyl, thiazolyl, benzothiazolyl, 3-alkyl-3H-imidazo[4,5-b]pyridyl or pyridylimidazolyl, or a five membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom:
(A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo,(C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)
such as γ-butyrolactam, γ-butyrolactone, imidazolidinone or N-aminoimidazolidinone, or a six membered aromatic ring with one to three N, O, S or Se heteroatoms such as pyridyl, pyridazinyl, pyrazinyl, sym-triazinyl, unsym-triazinyl, pyrimidinyl or (C1-C3)alkylthiopyridazinyl, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom such as 2,3-dioxo-1-piperazinyl, 4-ethyl-2,3-dioxo-1-piperazinyl, 4-methyl-2,3-dioxo-1-piperazinyl, 4-cyclopropyl- 2-dioxo-1-piperazinyl, 2-dioxomorpholinyl or 2-dioxothiomorpholinyl; and when R=R4′(CH2)nSO2 and n=1-4, R4′ is selected from hydrogen; amino; monosubstituted amino selected from straight or branched (C1-C6)alkylamino, cyclopropylamino, cyclobutylamino, benzylamino or phenylamino; disubstituted amino selected from dimethylamino, diethylamino, ethyl(1-methylethyl)amino, monomethylbenzylamino, piperidinyl, morpholinyl, 1-imidazolyl, 1-pyrrolyl, 1-(1,2,3-triazolyl) or 4-(1,2,4-triazolyl); straight or branched (C1-C3)alkyl group selected from methyl, ethyl, n-propyl or 1-methylethyl; RaRbamino(C1-C6)alkoxy group, wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or RaRb is (CH2)n, n=2-6, or (CH2)2W(CH2)2 wherein W is selected from N(C1-C3)alkyl [straight or branched], NH, NOB [B is selected from hydrogen or (C1-C3)alkyl], O or S; or RaRbaminoxy group, wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or RaRb is (CH2)n, n=2-6, or (CH2)2W(CH2)2 wherein W is selected from N(C1-C3)alkyl [straight or branched], NH, NOB [B is selected from hydrogen or (C1-C3)alkyl], O or S; R5 is selected from hydrogen; straight or branched (C1-C3)alkyl group selected from methyl, ethyl, n-propyl or 1-methylethyl; (C6-C10)aryl group selected from phenyl, α-naphthyl or β-naphthyl; (C7-C9)aralkyl group such as benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl; a heterocycle group selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:
such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl, or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:
such as imidazolyl, pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, indazolyl, thiazolyl, benzothiazolyl, 3-alkyl-3H-imidazo[4,5-b]pyridyl or pyridylimidazolyl, or a five membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom:
(A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo,(C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)
such as γ-butyrolactam, γ-butyrolactone, imidazolidinone or N-aminoimidazolidinone, or a six membered aromatic ring with one to three N, O, S or Se heteroatoms such as pyridyl, pyridazinyl, pyrazinyl, sym-triazinyl, unsym-triazinyl, pyrimidinyl or (C1-C3)alkylthiopyridazinyl, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom such as 2,3-dioxo-1-piperazinyl, 4-ethyl-2,3-dioxo-1-piperazinyl, 4-methyl-2,3-dioxo-1-piperazinyl, 4-cyclopropyl- 2-dioxo-1-piperazinyl, 2-dioxomorpholinyl, 2-dioxothiomorpholinyl; or (CH2)nCOOR7 where n=0-4 and R7 is selected from hydrogen; straight or branched (C1-C3)alkyl group selected from methyl, ethyl, n-propyl or 1-methylethyl; or (C6-C10)aryl group selected from phenyl, α-naphthyl or β-naphthyl; R6 is selected from hydrogen; straight or branched (C1-C 3)alkyl group selected from methyl, ethyl, n-propyl or 1-methylethyl; (C6-C10)aryl group selected from phenyl, α-naphthyl or β-naphthyl; (C7-C9)aralkyl group such as benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl; a heterocycle group selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:
such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl, or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:
such as imidazolyl, pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, indazolyl, thiazolyl, benzothiazolyl, 3-alkyl-3H-imidazo[4,5-b]pyridyl or pyridylimidazolyl, or a five membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom:
(A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo, (C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)
such as γ-butyrolactam, γ-butyrolactone, imidazolidinone or N-aminoimidazolidinone, or a six membered aromatic ring with one to three N, O, S or Se heteroatoms such as pyridyl, pyridazinyl, pyrazinyl, sym-triazinyl, unsym-triazinyl, pyrimidinyl or (C1-C3)alkylthiopyridazinyl, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom such as 2,3-dioxo-1-piperazinyl, 4-ethyl-2,3-dioxo-1-piperazinyl, 4-methyl-2,3-dioxo-1-piperazinyl, 4-cyclopropyl- 2-dioxo-1-piperazinyl, 2-dioxomorpholinyl, 2-dioxothiomorpholinyl; or (CH2)nCOOR7′ where n=0-4 and R7′ is selected from hydrogen; straight or branched (C1-C3)alkyl selected from methyl, ethyl, n-propyl or 1-methylethyl; or (C6-C10)aryl selected from phenyl, α-naphthyl or β-naphthyl; with the proviso that R5 and R6 cannot both be hydrogen; or R5 and R6 taken together are (CH2)2W(CH2)2, wherein W is selected from (CH2)n and n=0-1, NH, N(C1-C3)alkyl [straight or branched], N(C1-C6)alkoxy, oxygen, sulfur or substituted congeners selected from (L or D)proline, ethyl(L or D)prolinate, morpholine, pyrrolidine or piperidine; and the pharmacologically acceptable organic and inorganic salts or metal complexes.

Most particularly preferred compounds are compounds according to the above formula I and II in which X is selected from amino, NR1R2, or halogen; the halogen is selected from bromine, chlorine, fluorine or iodine; and when X=NR1R2 and R1=hydrogen, R2=methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl or 1,1-dimethylethyl; and when R1=methyl or ethyl, R2=methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl or 2-methylpropyl; R is selected from R4(CH2)nCO or R4 (CH2)nSO2; and when R=R4(CH2)nCO and n=0, R4 is selected from hydrogen; amino; monosubstituted amino selected from straight or branched (C1-C6)alkylamino, cyclopropylamino, cyclobutylamino, benzylamino or phenylamino; disubstituted amino selected from dimethylamino, diethylamino, ethyl(1-methylethyl)amino, monomethylbenzylamino, piperidinyl, morpholinyl, 1-imidazolyl, 1-pyrrollyl, 1-(1,2,3-triazolyl) or 4-(1,2,4-triazolyl); straight or branched (C1-C2)alkyl group selected from methyl or ethyl; (C6-C10)aryl group selected from phenyl, α-naphthyl or α-naphthyl; substituted (C6-C10)aryl group (substitution selected from halo, (C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); carboxy(C2-C4)alkylamino group selected from aminoacetic acid, α-aminobutyric acid or α-aminopropionic acid and their optical isomers; α-hydroxy(C1-C3)alkyl group selected from hydroxymethyl, α-hydroxyethyl or α-hydroxy-1-methylethyl or α-hydroxypropyl; halo(C1-C3)alkyl group such as bromomethyl, fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, 2-fluoroethyl, 2,2-difluoroethyl, 2,2,2-trifluoroethyl, 2-bromoethyl or 2-iodoethyl; a heterocycle group selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:


such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl, or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:
such as imidazolyl, pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, indazolyl, thiazolyl, benzothiazolyl, 3-alkyl-3H-imidazo[4,5-b]pyridyl or pyridylimidazolyl, or a five membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom:
(A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo,(C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)
such as γ-butyrolactam, γ-butyrolactone, imidazolidinone or N-aminoimidazolidinone, or a six membered aromatic ring with one to three N, O, S or Se heteroatoms such as pyridyl, pyridazinyl, pyrazinyl, sym-triazinyl, unsym-triazinyl, pyrimidinyl or (C1-C3)alkylthiopyridazinyl, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom such as 2,3-dioxo-1-piperazinyl, 4-ethyl-2,3-dioxo-1-piperazinyl, 4-methyl-2,3-dioxo-1-piperazinyl, 4-cyclopropyl- 2-dioxo-1-piperazinyl, 2-dioxomorpholinyl or 2-dioxothiomorpholinyl; (C1-C4)alkoxycarbonyl group selected from methoxycarbonyl, ethoxycarbonyl, straight or branched propoxylcarbonyl, straight or branched butoxycarbonyl or allyloxycarbonyl; vinyl or substituted vinyl group [substitution selected from (C1-C3)alkyl group, halogen, (C6-C10)aryl group selected from phenyl, α-naphthyl, β-naphthyl, substituted (C6-C10)aryl group (substitution selected from halo, (C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino, or carboxy), halo(C1-C3)alkyl group such as bromomethyl, fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, 2-fluoroethyl, 2,2-difluoroethyl, 2,2,2-trifluoroethyl, 2-bromoethyl or 2-iodoethyl, a heterocycle group selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:
such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl]; (C1-C4)alkoxy group such as allyloxy, methoxy, ethoxy, n-propoxy, n-butoxy or tert-butoxy; C6-aryloxy group selected from phenoxy or substituted phenoxy (substitution selected from halo, (C1-C4)alkyl, nitro, cyano, thiol, amino, carboxy, di(C1-C3)alkylamino); (C7-C10)aralkyloxy group such as benzyloxy, 1-phenylethyloxy or 2-phenylethyloxy; vinyloxy or substituted vinyloxy group (substitution selected from (C1-C4)alkyl, cyano, carboxy, or (C6-C10)aryl selected from phenyl, α-naphthyl or β-naphthyl); RaRbamino(C1-C4)alkoxy group, wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or RaRb is (CH2)n, n=2-6, or (CH2)2W(CH2)2 wherein W is selected from N(C1-C3)alkyl [straight or branched], NH, NOB [B is selected from hydrogen or (C1-C3)alkyl], O or S; or RaRbaminoxy group, wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or RaRb is (CH2)n, n=2-6, or (CH2)2W(CH2)2 wherein W is selected from N(C1-C3)alkyl [straight or branched], NH, NOB [B is selected from hydrogen or (C1-C3)alkyl], O or S; and when R=R4(CH2)nCO and n=1-4, R4 is selected from hydrogen; (C1-C2)alkyl group selected from methyl or ethyl; amino; monosubstituted amino selected from straight or branched (C1-C6)alkylamino, cyclopropylamino, cyclobutylamino, benzylamino or phenylamino; disubstituted amino selected from dimethylamino, diethylamino, ethyl(1-methylethyl)amino, monomethylbenzylamino, piperidinyl, morpholinyl, 1-imidazolyl, 1-pyrrolyl, 1-(1,2,3-triazolyl) or 4-(1,2,4-triazolyl); (C6-C10)aryl group selected from phenyl, α-naphthyl or β-naphthyl; substituted(C6-C10)aryl group (substitution selected from halo, (C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); acyloxy or haloacyloxy group, selected from acetyl, propionyl, chloroacetyl, trichloroacetyl, (C3-C6)cycloalkylcarbonyl, (C6-C10)aroyl selected from benzoyl or naphthoyl, halo substituted (C6-C10)aroyl such as pentafluorobenzoyl, 4-chlorobenzoyl, 3-bromobenzoyl or 3,4-difluorobenzoyl, (C1-C4)alkylbenzoyl such as 4-toluoyl, 2-toluoyl, 4-(1-methylethyl)benzoyl or (heterocycle)carbonyl, the heterocycle selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:
such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl, or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:
such as imidazolyl, pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, indazolyl, thiazolyl, benzothiazolyl, 3-alkyl-3H-imidazo[4,5-b]pyridyl or pyridylimidazolyl, or a five membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom:
(A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo,(C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)
such as γ-butyrolactam, γ-butyrolactone, imidazolidinone or N-aminoimidazolidinone, or a six membered aromatic ring with one or two N, O, S or Se heteroatoms such as pyridyl, pyridazinyl, pyrazinyl, sym-triazinyl, unsym-triazinyl, pyrimidinyl or (C1-C3)alkylthiopyridazinyl, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom such as 2,3-dioxo-1-piperazinyl, 4-ethyl-2,3-dioxo-1-piperazinyl, 4-methyl-2,3-dioxo-1-piperazinyl, 4-cyclopropyl- 2-dioxo-1-piperazinyl, 2-dioxomorpholinyl or 2-dioxothiomorpholinyl; (C1-C4)alkoxy group such as allyloxy, methoxy, ethoxy, n-propoxy, n-butoxy or tert-butoxy; RaRbamino(C1-C4)alkoxy group, wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or RaRb is (CH2)n, n=2-6, or (CH2)2W(CH2)2 wherein W is selected from N(C1-C3)alkyl [straight or branched], NH, NOB [B is selected from hydrogen or (C1-C3)alkyl], O or S; or RaRbaminoxy group, wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or RaRb is (CH2)n, n=2-6, or (CH2)2W(CH2)2 wherein W is selected from N(C1-C3)alkyl [straight or branched], NH, NOB [B is selected from hydrogen or (C1-C3)alkyl], O or S; α-hydroxy(C1-C3)alkyl group selected from hydroxymethyl, α-hydroxyethyl or α-hydroxy-1-methylethyl or α-hydroxypropyl; halo(C1-C3)alkyl group such as bromomethyl, fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, 2-fluoroethyl, 2,2-difluoroethyl, 2,2,2-trifluoromethyl, 2-bromoethyl or 2-iodoethyl; (C1-C4)alkoxycarbonylamino group selected from tert-butoxycarbonylamino, allyloxycarbonylamino, methoxycarbonylamino, ethoxycarbonylamino or propoxycarbonylamino; and when R=R4′(CH2)nSO2 and n=0, R4′ is selected from amino; monosubstituted amino selected from as straight or branched (C1-C6)alkylamino, cyclopropylamino, cyclobutylamino, benzylamino or phenylamino; disubstituted amino selected from dimethylamino, diethylamino, ethyl(1-methylethyl)amino, monomethylbenzylamino, piperidinyl, morpholinyl, 1-imidazolyl, 1-pyrrolyl, 1-(1,2,3-triazolyl) or 4-(1,2,4-triazolyl); straight or branched (C1-C2)alkyl group selected from methyl or ethyl; (C6-C10)aryl group selected from phenyl, α-naphthyl or β-naphthyl; substituted (C6-C10)aryl group (substitution selected from halo, (C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); a heterocycle group selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:
such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl, or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:
such as imidazolyl, pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, indazolyl, thiazolyl, benzothiazolyl, 3-alkyl-3H-imidazo[4,5-b]pyridyl or pyridylimidazolyl, or a five membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom:
(A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo,(C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)
such as γ-butyrolactam, γ-butyrolactone, imidazolidinone or N-aminoimidazolidinone, or a six membered aromatic ring with one to three N, O, S or Se heteroatoms such as pyridyl, pyridazinyl, pyrazinyl, sym-triazinyl, unsym-triazinyl, pyrimidinyl or (C1-C3)alkylthiopyridazinyl, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom such as 2,3-dioxo-1-piperazinyl, 4-ethyl-2,3-dioxo-1-piperazinyl, 4-methyl-2,3-dioxo-1-piperazinyl, 4-cyclopropyl- 2-dioxo-1-piperazinyl, 2-dioxomorpholinyl or 2-dioxothiomorpholinyl; and when R=R4′(CH2)nSO2 and n=1-4, R4′ is selected from hydrogen; straight or branched (C1-C2)alkyl group selected from methyl or ethyl; R5 is selected from hydrogen; straight or branched (C1-C3)alkyl group selected from methyl, ethyl, n-propyl or 1-methylethyl; (C6-C10)aryl group selected from phenyl, α-naphthyl or β-naphthyl; (C7-C9)aralkyl group such as benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl; a heterocycle group selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:
such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl, or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:
such as imidazolyl, pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, indazolyl, thiazolyl, benzothiazolyl, 3-alkyl-3H-imidazo[4,5-b]pyridyl or pyridylimidazolyl, or a five membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom:
(A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo,(C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)
such as γ-butyrolactam, γ-butyrolactone, imidazolidinone or N-aminoimidazolidinone, or a six membered aromatic ring with one to three N, O, S or Se heteroatoms such as pyridyl, pyridazinyl, pyrazinyl, sym-triazinyl, unsym-triazinyl, pyrimidinyl or (C1-C3)alkylthiopyridazinyl, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom such as 2,3-dioxo-1-piperazinyl, 4-ethyl-2,3-dioxo-1-piperazinyl, 4-methyl-2,3-dioxo-1-piperazinyl, 4-cyclopropyl- 2-dioxo-1-piperazinyl, 2-dioxomorpholinyl, 2-dioxothiomorpholinyl; or (CH2)nCOOR7 where n=0-4 and R7 is selected from hydrogen; straight or branched (C1-C3)alkyl group selected from methyl, ethyl, n-propyl or 1-methylethyl; or (C6-C10)aryl group selected from phenyl, α-naphthyl, β-naphthyl; R6 is selected from hydrogen; straight or branched (C1-C3)alkyl group selected from methyl, ethyl, n-propyl or 1-methylethyl; (C6-C10)aryl group selected from phenyl, α-naphthyl or β-naphthyl; (C7-C9)aralkyl group such as benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl; a heterocycle group selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:
such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl, or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:
such as imidazolyl, pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, indazolyl, thiazolyl, benzothiazolyl, 3-alkyl-3H-imidazo[4,5-b]pyridyl or pyridylimidazolyl, or a five membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom:
(A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo,(C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)
such as γ-butyrolactam, γ-butyrolactone, imidazolidinone or N-aminoimidazolidinone, or a six membered aromatic ring with one to three N, O, S or Se heteroatoms such as pyridyl, pyridazinyl, pyrazinyl, sym-triazinyl, unsym-triazinyl, pyrimidinyl or (C1-C3)alkylthiopyridazinyl, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom such as 2,3-dioxo-1-piperazinyl, 4-ethyl-2,3-dioxo-1-piperazinyl, 4-methyl-2,3-dioxo-1-piperazinyl, 4-cyclopropyl- 2-dioxo-1-piperazinyl, 2-dioxomorpholinyl, 2-dioxothiomorpholinyl; or (CH2)nCOOR7′ where n=0-4 and R7′ is selected from hydrogen; straight or branched (C1-C3)alkyl selected from methyl, ethyl, n-propyl or 1-methylethyl; or (C6-C10)aryl selected from phenyl, α-naphthyl or β-naphthyl; with the proviso that R5 and R6 cannot both be hydrogen; or R5 and R6 taken together are (CH2)2W(CH2)2, wherein W is selected from (CH2)n and n=0-1, NH, N(CH1-C3)alkyl [straight or branched], N(C1-C4)alkoxy, oxygen, sulfur or substituted congeners selected from (L or D)proline, ethyl(L or D)prolinate, morpholine, pyrrolidine or piperidine; and the pharmacologically acceptable organic and inorganic salts or metal complexes.

Compounds of special interest are compounds according to the above formula I and II in which X is selected from amino, NR1R2 or halogen; the halogen is selected from bromine, chlorine, fluorine or iodine; and when X=NR1R2 and R1=methyl or ethyl; R2=methyl or ethyl, R is selected from R4(CH2)nCO or R4′ (CH2)nSO2; and when R=R4(CH2)nCO and n=0, R4 is selected from hydrogen; straight or branched (C1-C2)alkyl group selected from methyl or ethyl; a heterocycle group selected from a five membered aromatic or saturated ring with one N, O, or S heteroatom optionally having a benzo or pyrido ring fused thereto:


such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl, or a five membered aromatic ring with two N, O, or S heteroatoms optionally having a benzo or pyrido ring fused thereto:
such as imidazolyl, pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, indazolyl, thiazolyl, benzothiazolyl, 3-alkyl-3H-imidazo[4,5-b]pyridyl or pyridylimidazolyl, or a five membered saturated ring with one or two N, O or S heteroatoms and an adjacent appended O heteroatom:
(A is selected from hydrogen; straight or branched (C1-C2)alkyl; C6-aryl)
such as γ-butyrolactam, γ-butyrolactone, imidazolidinone or N-aminoimidazolidinone, (C1-C4)alkoxycarbonyl group selected from methoxycarbonyl, ethoxycarbonyl, straight or branched propoxylcarbonyl, straight or branched butoxycarbonyl or allyloxycarbonyl; vinyl or substituted vinyl group [substitution selected from (C1-C2)alkyl group, (C6-C10)aryl group selected from phenyl, α-naphthyl, β-naphthyl, substituted (C6-C10)aryl group (substitution selected from halo, (C1-C4)alkoxy, (C1-C4)alkoxycarbonyl), halo(C1-C3)alkyl group such as bromomethyl, fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, 2-fluoroethyl, 2,2-difluoroethyl, 2,2,2-trifluoroethyl, 2-bromoethyl or 2-iodoethyl, (C1-C4)alkoxy group such as allyloxy, methoxy, ethoxy, n-propoxy, n-butoxy or tert-butoxy; C6-aryloxy group selected from phenoxy or substituted phenoxy (substitution selected from halo, (C1-C4)alkyl; (C7-C10)aralkyloxy group such as benzyloxy, 1-phenylethyloxy or 2-phenylethyloxy; vinyloxy or substituted vinyloxy group (substitution selected from (C1-C2)alkyl); RaRbamino(C1-C4)alkoxy group, wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl; or RaRbaminoxy group, wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl; and when R=R4(CH2)nCO and n=1-4, R4 is selected from hydrogen; (C1-C2)alkyl group selected from methyl or ethyl; amino; monosubstituted amino selected from straight or branched (C1-C6)alkylamino, cyclopropylamino, cyclobutylamino, benzylamino or phenylamino; disubstituted amino selected from dimethylamino, diethylamino, ethyl(1-methylethyl)amino, monomethylbenzylamino, piperidinyl, morpholinyl, 1-imidazolyl, 1-pyrrolyl, or 1-(1,2,3-triazolyl); (C6-C10)aryl group selected from phenyl, α-naphthyl or β-naphthyl; substituted(C6-C10)aryl group (substitution selected from halo, (C1-C4)alkoxy, nitro, amino, (C1-C4)alkoxycarbonyl); acyloxy or haloacyloxy group selected from acetyl, propionyl or chloroacetyl; (C1-C4)alkoxy group such as allyloxy, methoxy, ethoxy, n-propoxy, n-butoxy or tert-butoxy; RaRbamino(C1-C4)alkoxy group, wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or RaRb is (CH2)n, n=2-6, or (CH2)2W(CH2)2 wherein W is selected from N(C1-C3)alkyl [straight or branched], NH, NOB [B is selected from hydrogen or (C1-C3)alkyl], O or S; or RaRbaminoxy group, wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or RaRb is (CH2)n, n=2-6, or (CH2)2W(CH2)2 wherein W is selected from N(C1-C3)alkyl [straight or branched], NH, NOB [B is selected from hydrogen or (C1-C3)alkyl], O or S; halo(C1-C3)alkyl group such as bromomethyl, fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, 2-fluoroethyl, 2,2-difluoroethyl, 2,2,2-trifluoromethyl, 2-bromoethyl or 2-iodoethyl; (C1-C4) alkoxycarbonylamino group selected from tert-butoxycarbonylamino, allyloxycarbonylamino, methoxycarbonylamino, ethoxycarbonylamino or propoxycarbonylamino; and when R=R4′(CH2)nSO2 and n=0, R4′ is selected from straight or branched (C1-C2)alkyl group selected from methyl or ethyl; (C6-C10)aryl group selected from phenyl, α-naphthyl or β-naphthyl; substituted (C6-C10)aryl group (substitution selected from halo, (C1-C4)alkoxy, nitro, (C1-C4)alkoxycarbonyl); a heterocycle group selected from a five membered aromatic or saturated ring with one N, O or S heteroatom optionally having a benzo or pyrido ring fused thereto:
such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl, or a five membered aromatic ring with two N, O or S heteroatoms optionally having a benzo or pyrido ring fused thereto:
such as imidazolyl, pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, indazolyl, thiazolyl, benzothiazolyl, 3-alkyl-3H-imidazo[4,5-b]pyridyl or pyridylimidazolyl; and when R=R4′(CH2)nSO2 and n=1-4, R4′ is selected from hydrogen; straight or branched (C1-C2)alkyl group selected from methyl or ethyl; R5 is selected from hydrogen; straight or branched (C1-C3)alkyl group selected from methyl, ethyl, n-propyl or 1-methylethyl; R6 is selected from hydrogen; straight or branched (C1-C3)alkyl group selected from methyl, ethyl, n-propyl or 1-methylethyl; with the proviso that R5 and R6 cannot both be hydrogen; or R5 and R6 taken together are (CH2)2W(CH2)2, wherein W is selected from (CH2)n and n=0-1, NH, N(C1-C3)alkyl [straight or branched], N(C1-C4)alkoxy, oxygen, sulfur or substituted congeners selected from (L or D)proline, ethyl(L or D)prolinate, morpholine, pyrrolidine or piperidine; and the pharmacologically acceptable organic and inorganic salts or metal complexes.

Also included in the present invention are compounds useful as intermediates for producing the above compounds of formula I and II. Such intermediate compounds include those having the formula:


wherein formula III and IV, Y is NO2; R is selected from R4(CH2)nCO or R4′(CH2)nSO2; and when R=R4(CH2)nCO and n=0, R4 is selected from hydrogen; amino; monosubstituted amino selected from straight or branched (C1-C6)alkylamino, cyclopropylamino, cyclobutylamino, benzylamino or phenylamino; disubstituted amino selected from dimethylamino, diethylamino, ethyl(1-methylethyl)amino, monomethylbenzylamino, piperidinyl, morpholinyl, 1-imidazolyl, 1-pyrrolyl, 1-(1,2,3-triazolyl) or 4-(1,2,4-triazolyl); straight or branched (C1-C4)alkyl group selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl or 1,1-dimethylethyl; (C3-C6)cycloalkyl group selected from cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl; substituted (C3-C6)cycloalkyl group (substitution selected from (C1-C3)alkyl, cyano, amino or (C1-C3)acyl); (C6-C10)aryl group selected from phenyl, α-naphthyl or β-naphthyl; substituted (C6-C10)aryl group (substitution selected from halo, (C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl; α-amino(C1-C4)alkyl group selected from aminomethyl, α-aminoethyl, α-aminopropyl or αaminobutyl; carboxy(C2-C4)alkylamino group selected from aminoacetic acid, α-aminobutyric acid or α-aminopropionic acid and their optical isomers; (C7-C9)aralkylamino group such as phenylglycyl; (C1-C4)alkoxycarbonylamino substituted (C1-C4)alkyl group, substitution selected from phenyl or p-hydroxyphenyl; α-hydroxy(C1-C3)alkyl group selected from hydroxymethyl, α-hydroxyethyl or α-hydroxy-1-methylethyl or α-hydroxypropyl; α-mercapto(C1-C3)alkyl group selected from mercaptomethyl, α-mercaptoethyl, α-mercapto-1-methylethyl or α-mercaptopropyl; halo(C1-C3)alkyl group such as bromomethyl, fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, 2-fluoroethyl, 2,2-difluoroethyl, 2,2,2-trifluoroethyl, 2-bromoethyl or 2-iodoethyl; a heterocycle group selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:
such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl, or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:
such as imidazolyl, pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, indazolyl, thiazolyl, benzothiazolyl, 3-alkyl-3H-imidazo[4,5-b]pyridyl or pyridylimidazolyl, or a five membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom:
(A is selected from hydrogen; straight or branched (C1-C4) alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo, (C1-C4) alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)
such as γ-butyrolactam, γ-butyrolactone, imidazolidinone or N-aminoimidazolidinone, or a six membered aromatic ring with one to three N, O, S or Se heteroatoms such as pyridyl, pyridazinyl, pyrazinyl, sym-triazinyl, unsym-triazinyl, pyrimidinyl or (C1-C3)alkylthiopyridazinyl, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom such as 2,3-dioxo-1-piperazinyl, 4-ethyl-2,3-dioxo-1-piperazinyl, 4-methyl-2,3-dioxo-1-piperazinyl, 4-cyclopropyl- 2-dioxo-1-piperazinyl, 2-dioxomorpholinyl or 2-dioxothiomorpholinyl; acyl or haloacyl group selected from acetyl, propionyl, chloroacetyl, trifluoroacetyl, (C3-C6)cycloalkylcarbonyl such as cyclopropylcarbonyl, cyclobutylcarbonyl, cyclopentylcarbonyl, cyclohexylcarbonyl, (2,3-dimethylcyclopropyl)carbonyl, (1,2-dimethylcyclopropyl)carbonyl, (2-ethylcyclopropyl)carbonyl, (2-methylcyclopentyl)carbonyl or (3-ethylcyclobutyl)carbonyl, (C6-C10)aroyl selected from benzoyl or naphthoyl, halo substituted (C6-C10)aroyl such as pentafluorobenzoyl, 4-chlorobenzoyl, 3-bromobenzoyl or 3,4-difluorobenzoyl, (C1-C4)alkylbenzoyl such as 4-toluoyl, 2-toluoyl or 4-(1-methylethyl)benzoyl, or (heterocycle)carbonyl, the heterocycle selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:
such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl, or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:
such as imidazolyl, pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, indazolyl, thiazolyl, benzothiazolyl, 3-alkyl-3H-imidazo[4,5-b]pyridyl or pyridylimidazolyl, or a five membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom:
(A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo,(C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)

such as γ-butyrolactam, γ-butyrolactone, imidazolidinone or N-aminoimidazolidinone, or a six membered aromatic ring with one to three N, O, S or Se heteroatoms such as pyridyl, pyridazinyl, pyrazinyl, sym-triazinyl, unsym-triazinyl, pyrimidinyl or (C1-C3)alkylthiopyridazinyl, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom such as 2,3-dioxo-1-piperazinyl, 4-ethyl-2,3-dioxo-1-piperazinyl, 4-methyl-2,3-dioxo-1-piperazinyl, 4-cyclopropyl- 2-dioxo-1-piperazinyl, 2-dioxomorpholinyl or 2-dioxothiomorpholinyl; (C1-C4)alkoxycarbonyl group selected from methoxycarbonyl, ethoxycarbonyl, straight or branched propoxylcarbonyl, straight or branched butoxycarbonyl or allyloxycarbonyl; vinyl or substituted vinyl group [substitution selected from (C1-C3)alkyl group, halogen, (C6-C10)aryl group selected from phenyl, α-naphthyl, β-naphthyl, substituted (C6-C10)aryl group (substitution selected from halo, (C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy), halo(C1-C3)alkyl group such as bromomethyl, fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, 2-fluoroethyl, 2,2-difluoroethyl, 2,2,2-trifluoroethyl, 2-bromoethyl or 2-iodoethyl, a heterocycle group selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:


such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl];

(C1-C4)alkoxy group such as allyloxy, methoxy, ethoxy, n-propoxy, n-butoxy or tert-butoxy; C6-aryloxy group selected from phenoxy or substituted phenoxy (substitution selected from halo, (C1-C4)alkyl, nitro, cyano, thiol, amino, carboxy, di(C1-C3)alkylamino); (C7-C10)aralkyloxy group such as benzyloxy, 1-phenylethyloxy or 2-phenylethyloxy; vinyloxy or substituted vinyloxy group (substitution selected from (C1-C4)alkyl, cyano, carboxy, or (C6-C10)aryl selected from phenyl, α-naphthyl or β-naphthyl); RaRbamino(C1-C4)-alkoxy group, wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or RaRb is (CH2)n, n=2-6, or (CH2)2W(CH2)2 wherein W is selected from N(C1-C3)alkyl [straight or branched], NH, NOB [B is selected from hydrogen or (C1-C3)alkyl], O or S; or RaRbaminoxy group, wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or RaRb is (CH2)n, n=2-6, or (CH2)2W(CH2)2 wherein W is selected from N(C1-C3)alkyl [straight or branched], NH, NOB [B is selected from hydrogen or (C1-C3)alkyl], O or S; and when R=R4(CH2)nCO and n=1-4, R4 is selected from hydrogen; amino; straight or branched (C1-C4)alkyl group selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl or 1,1-dimethylethyl; (C3-C6)cycloalkyl group selected from cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl; substituted (C3-C6)cycloalkyl group (substitution selected from (C1-C3)alkyl, cyano, amino or (C1-C3)acyl); (C6-C10)aryl group selected from phenyl, α-naphthyl or β-naphthyl; substituted(C6-C10)aryl group (substitution selected from halo, (C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxyl); (C7-C9)aralkyl group such as benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl; acyloxy or haloacyloxy group, selected from acetyl, propionyl, chloroacetyl, trichloroacetyl, (C3-C6)cycloalkylcarbonyl, (C6-C10)aroyl selected from benzoyl or naphthoyl, halo substituted (C6-C10)aroyl such as pentafluorobenzoyl, 4-chlorobenzoyl, 3-bromobenzoyl or 3,4-difluorobenzoyl, (C1-C4)alkylbenzoyl such as 4-toluoyl, 2-toluoyl or 4-(1-methylethyl)benzoyl, (heterocycle)carbonyl, the heterocycle selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:


such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl, or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:
such as imidazolyl, pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, indazolyl, thiazolyl, benzothiazolyl, 3-alkyl-3H-imidazo[4,5-b]pyridyl or pyridylimidazolyl, or a five membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom:
(A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo,(C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)

such as γ-butyrolactam, γ-butyrolactone, imidazolidinone or N-aminoimidazolidinone, or a six membered aromatic ring with one to three N, O, S or Se heteroatoms such as pyridyl, pyridazinyl, pyrazinyl, sym-triazinyl, unsym-triazinyl, pyrimidinyl or (C1-C3)alkylthiopyridazinyl, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom such as 2,3-dioxo-1-piperazinyl, 4-ethyl-2,3-dioxo-1-piperazinyl, 4-methyl-2,3-dioxo-1-piperazinyl, 4-cyclopropyl- 2-dioxo-1-piperazinyl, 2-dioxomorpholinyl or 2-dioxothiomorpholinyl; (C1-C4)alkoxy group such as allyloxy, methoxy, ethoxy, n-propoxy, n-butoxy or tert-butoxy; C6-aryloxy group selected from phenoxy or substituted phenoxy (substitution selected from halo, (C1-C4)alkyl, nitro, cyano, thiol, amino, carboxy, di(C1-C3)alkylamino); (C7-C10)aralkyloxy group such as benzyloxy, 1-phenylethyloxy or 2-phenylethyloxy; (C1-C3)alkylthio group selected from methylthio, ethylthio, propylthio or allylthio; C6-arylthio group selected from phenylthio or substituted phenylthio (substitution selected from halo, (C1-C4)alkyl, nitro, cyano, thiol, amino, carboxy, di(C1-C3)alkylamino); C6-arylsulfonyl group selected from phenylsulfonyl or substituted phenylsulfonyl (substitution selected from halo, (C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C8)aralkylthio group such as benzylthio, 1-phenylethylthio or 2-phenylethylthio; a heterocycle group selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:


such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl, or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:
such as imidazolyl, pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, indazolyl, thiazolyl, benzothiazolyl, 3-alkyl-3H-imidazo[4,5-b]pyridyl or pyridylimidazolyl, or a five membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom:
(A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo,(C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl) such as γ-butyrolactam, γ-butyrolactone, imidazolidinone or N-aminoimidazolidinone, or a six membered aromatic ring with one to three N, O, S or Se heteroatoms such as pyridyl, pyridazinyl, pyrazinyl, sym-triazinyl, unsym-triazinyl, pyrimidinyl or (C1-C3)alkylthiopyridazinyl, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom such as 2,3-dioxo-1-piperazinyl, 4-ethyl-2,3-dioxo-1-piperazinyl, 4-methyl-2,3-dioxo-1-piperazinyl, 4-cyclopropyl- 2-dioxo-1-piperazinyl, 2-dioxomorpholinyl or 2-dioxothiomorpholinyl; hydroxy group; mercapto group; mono- or di-straight or branched chain (C1-C6)alkylamino group selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl, 1,1-dimethylethyl, 2-methylbutyl, 1,1-dimethylpropyl, 2,2-dimethylpropyl, 3-methylbutyl, n-hexyl, 1-methylpentyl, 1,1-dimethylbutyl, 2,2-dimethylbutyl, 2-methylpentyl, 1,2-dimethylbutyl, 1,3-dimethylbutyl or 1-methyl-1-ethylpropyl amino; (C2-C3)azacycloalkyl group such as aziridinyl, azetidinyl, pyrrolidinyl, piperidinyl, morpholinyl or 2-methylpyrrolidinyl; carboxy(C2-C4) alkylamino group selected from aminoacetic acid, α-aminopropionic acid, α-aminobutyric acid and their optical isomers; α-hydroxy(C1-C3)alkyl group selected from hydroxymethyl, α-hydroxyethyl or α-hydroxy-1methylethyl or α-hydroxypropyl; halo(C1-C3)alkyl group such as bromomethyl, fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, 2-fluoroethyl, 2,2-difluoroethyl, 2,2,2-trifluoromethyl, 2-bromoethyl or 2-iodoethyl; acyl or haloacyl group selected from acetyl, propionyl, chloroacetyl, trifluoroacetyl, (C3-C6)cycloalkylcarbonyl, (C6-C10)-aroyl selected from benzoyl or naphthoyl halo substituted (C6-C10)aroyl such as pentafluorobenzoyl, 4-chlorobenzoyl, 3-bromobenzoyl, 3,4-difluorobenzoyl, (C1-C4)alkylbenzoyl such as 4-toluoyl, 2-toluoyl or 4-(1-methylethyl)benzoyl, or (heterocycle)carbonyl, the heterocycle selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:
such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl, or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:
such as imidazolyl, pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, indazolyl, thiazolyl, benzothiazolyl, 3-alkyl-3H-imidazo[4,5-b]pyridyl or pyridylimidazolyl, or a five membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom:
(A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo,(C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)

such as γ-butyrolactam, γ-butyrolactone, imidazolidinone or N-aminoimidazolidinone, or a six membered aromatic ring with one to three N, O, S or Se heteroatoms such as pyridyl, pyridazinyl, pyrazinyl, sym-triazinyl, unsym-triazinyl, pyrimidinyl or (C1-C3)alkylthiopyridazinyl, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom such as 2,3-dioxo-1-piperazinyl, 4-ethyl-2,3-dioxo-1-piperazinyl, 4-methyl-2,3-dioxo-1-piperazinyl, 4-cyclopropyl- 2-dioxo-1-piperazinyl, 2-dioxomorpholinyl or 2-dioxothiomorpholinyl; (C1-C4)alkoxycarbonylamino group selected from tert-butoxycarbonylamino, allyloxycarbonylamino, methoxycarbonylamino, ethoxycarbonylamino or propoxycarbonylamino; (C1-C4)alkoxycarbonyl group selected from methoxycarbonyl, ethoxycarbonyl, straight or branched propoxycarbonyl, allyloxycarbonyl or straight or branched butoxycarbonyl; RaRbamino(C1-C4)alkoxy group, wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or RaRb is (CH2)n, n=2-6, or (CH2)2W(CH2)2 wherein W is selected from N(C1-C3)alkyl [straight or branched], NH, NOB [B is selected from hydrogen or (C1-C3)alkyl], O or S; or RaRbaminoxy group, wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or RaRb is (CH2)n, n=2-6, or (CH2)2W(CH2)2 wherein W is selected from N(C1-C3)alkyl [straight or branched], NH, NOB [B is selected from hydrogen or (C1-C3)alkyl], O or S; and when R=R4′(CH2)nSO2 and n=0, R4′ is selected from amino; monosubstituted amino selected from straight or branched (C1-C6)alkylamino, cyclopropylamino, cyclobutylamino, benzylamino or phenylamino; disubstituted amino selected from dimethylamino, diethylamino, ethyl(1-methylethyl)amino, monomethylbenzylamino, piperidinyl, morpholinyl, 1-imidazolyl, 1-pyrrolyl, 1-(1,2,3-triazolyl) or 4-(1,2,4-triazolyl); straight or branched (C1-C4)alkyl group selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl or 1,1-dimethylethyl; (C3-C6)cycloalkyl group selected from cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl; substituted (C3-C6)cycloalkyl group (substitution selected from (C1-C3)alkyl, cyano, amino or (C1-C3)acyl); (C6-C10)aryl group selected from phenyl, α-naphthyl or β-naphthyl; substituted (C6-C10)aryl group (substitution selected from halo, (C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group such as benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl; halo(C1-C3)alkyl group such as bromomethyl, fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, 2-fluoroethyl, 2,2-difluoroethyl, 2,2,2-trifluoroethyl, 2-chloroethyl, 2,2-dichloroethyl, 2,2,2-trichloroethyl, 2-bromoethyl or 2-iodoethyl; a heterocycle group selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:


such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl, or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:
such as imidazolyl, pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, indazolyl, thiazolyl, benzothiazolyl, 3-alkyl-3H-imidazo[4,5-b]pyridyl or pyridylimidazolyl, or a five membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom:
(A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo, (C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)

such as γ-butyrolactam, γ-butyrolactone, imidazolidinone or N-aminoimidazolidinone, or a six membered aromatic ring with one to three N, O, S or Se heteroatoms such as pyridyl, pyridazinyl, pyrazinyl, sym-triazinyl, unsym-triazinyl, pyrimidinyl or (C1-C3)alkylthiopyridazinyl, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom such as 2,3-dioxo-1-piperazinyl, 4-ethyl-2,3-dioxo-1-piperazinyl, 4-methyl-2,3-dioxo-1-piperazinyl, 4-cyclopropyl- 2-dioxo-1-piperazinyl, 2-dioxomorpholinyl or 2-dioxothiomorpholinyl; RaRbamino(C1-C4)alkoxy group, wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or RaRb is (CH2)n, n=2-6, or (CH2)2W(CH2)2 wherein W is selected from N(C1-C3)alkyl [straight or branched], NH, NOB [B is selected from hydrogen or (C1-C3)alkyl], O or S; or RaRbaminoxy group, wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or RaRb is (CH2)n, n=2-6, or (CH2)2W(CH2)2 wherein W is selected from N(C1-C3)alkyl [straight or branched], NH, NOB [B is selected from hydrogen or (C1-C3)alkyl], O or S; and when R=R4 (CH2)nSO2 and n=1-4, R4′ is selected from hydrogen; amino; straight or branched (C1-C4)alkyl group selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl or 1,1-dimethylethyl; (C1-C4)carboxyalkyl group; (C3-C6)cycloalkyl group selected from cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl; substituted (C3-C6)cycloalkyl group (substitution selected from (C1-C3)alkyl, cyano, amino or (C1-C3)acyl); (C6-C10)aryl group selected from phenyl, α-naphthyl or β-naphthyl; substituted (C6-C10)aryl group (substitution selected from halo, (C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl; (C1-C4)alkoxy group such as allyloxy, methoxy, ethoxy, n-propoxy or tert-butoxy; C6-aryloxy group selected from phenoxy or substituted phenoxy (substitution selected from halo, (C1-C3)alkyl, nitro, cyano, thiol, amino, carboxy, di(C1-C3)alkylamino); (C7-C10)aralkyloxy group such as benzyloxy, 1-phenylethyloxy or 2phenylethyloxy; RaRbamino(C1-C4)alkoxy group, wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or RaRb is (CH2)n, n=2-6, or (CH2)2W(CH2)2 wherein W is selected from N(C1-C3)alkyl [straight or branched], NH, NOB [B is selected from hydrogen or (C1-C3)alkyl], O or S; or RaRbaminoxy group, wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or RaRb is (CH2)n, n=2-6, or (CH2)2W(CH2)2 wherein W is selected from N(C1-C3)alkyl [straight or branched], NH, NOB [B is selected from hydrogen or (C1-C3)alkyl], O or S; (C1-C3)alkylthio group selected from methylthio, ethylthio, or n-propylthio; C6-arylthio group selected from phenylthio or substituted phenylthio (substitution selected from halo, (C1-C3)alkyl, nitro, cyano, thiol, amino, carboxy, di(C1-C3)alkylamino); (C7-C8)aralkylthio group such as benzylthio, 1-phenylethylthio or 2-phenylethylthio; a heterocycle group selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:


such as pyrrolyl, N-methyl indolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl, or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:
such as imidazolyl, pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, indazolyl, thiazolyl, benzothiazolyl, 3-alkyl-3H-imidazo[4,5-b]pyridyl or pyridylimidazolyl, or a five membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom:
(A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo,(C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)

such as γ-butyrolactam, γ-butyrolactone, imidazolidinone or N-aminoimidazolidinone, or a six membered aromatic ring with one to three N, O, S or Se heteroatoms such as pyridyl, pyridazinyl, pyrazinyl, sym-triazinyl, unsym-triazinyl, pyrimidinyl or (C1-C3)alkylthiopyridazinyl, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom such as 2,3-dioxo-1-piperazinyl, 4-ethyl- 2,3-dioxo-1-piperazinyl, 4-methyl-2,3-dioxo-1-piperazinyl, 4-cyclopropyl- 2-dioxo-1-piperazinyl, 2-dioxomorpholinyl or 2-dioxothiomorpholinyl; hydroxy group, mercapto group; mono- or di- straight or branched (C1-C6)alkylamino group selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl, 1,1-dimethylethyl, 2-methylbutyl, 1,1-dimethylpropyl, 2,2-dimethylpropyl, 3-methylbutyl, n-hexyl, 1-methylpentyl, 1,1-dimethylbutyl, 2,2-dimethylbutyl, 2-methylpentyl, 1,2-dimethylbutyl, 1,3-dimethylbutyl or 1-methyl-1-ethylpropyl amino; halo(C1-C3)alkyl group such as bromomethyl, fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, 2-fluoroethyl, 2,2-difluoroethyl, 2,2,2-trifluoroethyl, 2-chloroethyl, 2,2-dichloroethyl, 2,2,2-trichloroethyl, 2-bromoethyl or 2-iodoethyl; acyl or haloacyl group selected from acetyl, propionyl, chloroacetyl, trifluoroacetyl, (C3-C6)cycloalkylcarbonyl, (C6-C10)aroyl selected from benzoyl or naphthoyl, halo substituted (C6-C10)aroyl such as pentafluorobenzoyl, 4-chlorobenzoyl, 3-bromobenzoyl or 3,4-difluorobenzoyl, (C1-C4)alkylbenzoyl such as 4-toluoyl, 2-toluoyl or 4-(1-methylethyl)benzoyl, or (heterocycle)carbonyl, the heterocycle selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:


such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl, or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:
such as imidazolyl, pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, indazolyl, thiazolyl, benzothiazolyl, 3-alkyl-3H-imidazo[4,5-b]pyridyl or pyridylimidazolyl, or a five membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom:
(A is selected from hydrogen; straight or branched (C1-C4) alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo, (C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)

such as γ-butyrolactam, γ-butyrolactone, imidazolidinone or N-aminoimidazolidinone, or a six membered aromatic ring with one to three N, O, S or Se heteroatoms such as pyridyl, pyridazinyl, pyrazinyl, sym-triazinyl, unsym-triazinyl, pyrimidinyl or (C1-C3)alkylthiopyridazinyl, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom such as 2,3-dioxo-1-piperazinyl, 4-ethyl-2,3-dioxo-1-piperazinyl, 4-methyl-2,3-dioxo-1-piperazinyl, 4-cyclopropyl- 2-dioxo-1-piperazinyl, 2-dioxomorpholinyl or 2-dioxothiomorpholinyl; (C1-C4)alkoxycarbonyl group selected from methoxycarbonyl, ethoxycarbonyl, straight or branched propoxycarbonyl, allyloxycarbonyl or straight or branched butoxycarbonyl; R5 is selected from hydrogen; straight or branched (C1-C3)alkyl group selected from methyl, ethyl, n-propyl or 1-methylethyl; (C6-C10)aryl group selected from phenyl, α-naphthyl or β-naphthyl; (C7-C9)aralkyl group such as benzyl, 1-phenylethyl, 1-phenylethyl or phenylpropyl; a heterocycle group selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:


such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl, or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:
such as imidazolyl, pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, indazolyl, thiazolyl, benzothiazolyl, 3-alkyl-3H-imidazo[4,5-b]pyridyl or pyridylimidazolyl, or a five membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom:
(A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo, (C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)

such as γ-butyrolactam, γ-butyrolactone, imidazolidinone or N-aminoimidazolidinone, or a six membered aromatic ring with one to three N, O, S or Se heteroatoms such as pyridyl, pyridazinyl, pyrazinyl, sym-triazinyl, unsym-triazinyl, pyrimidinyl or (C1-C3)alkylthiopyridazinyl, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom such as 2,3-dioxo-1-piperazinyl, 4-ethyl-2,3-dioxo-1-piperazinyl, 4-methyl-2,3-dioxo-1-piperazinyl, 4-cyclopropyl- 2-dioxo-1-piperazinyl, 2-dioxomorpholinyl, 2-dioxothiomorpholinyl; or (CH2)nCOOR7 where n=0-4 and R7 is selected from hydrogen; straight or branched (C1-C3)alkyl group selected from methyl, ethyl, n-propyl or 1-methylethyl; or (C6-C10)aryl group selected from phenyl, α-naphthyl, β-naphthyl; R6 is selected from hydrogen; straight or branched (C1-C3)alkyl group selected from methyl, ethyl, n-propyl or 1-methylethyl; (C6-C10)aryl group selected from phenyl, α-naphthyl or β-naphthyl; (C7-C9)aralkyl group such as benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl; a heterocycle group selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:


such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl, or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:
such as imidazolyl, pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, indazolyl, thiazolyl, benzothiazolyl, 3-alkyl-3H-imidazo[4,5-b]pyridyl or pyridylimidazolyl, or a five membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom:
(A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo,(C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)

such as γ-butyrolactam, γ-butyrolactone, imidazolidinone or N-aminoimidazolidinone, or a six membered aromatic ring with one to three N, O, S or Se heteroatoms such as pyridyl, pyridazinyl, pyrazinyl, sym-triazinyl, unsym-triazinyl, pyrimidinyl or (C1-C3)alkylthiopyridazinyl, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom such as 2,3-dioxo-1-piperazinyl, 4-ethyl-2,3-dioxo-1-piperazinyl, 4-methyl-2,3-dioxo-1-piperazinyl, 4-cyclopropyl- 2-dioxo-1-piperazinyl, 2-dioxomorpholinyl, 2-dioxothiomorpholinyl; or (CH2)nCOOR7′ where n=0-4 and R7′ is selected from hydrogen; straight or branched (C1-C3)alkyl selected from methyl, ethyl, n-propyl or 1-methylethyl; or (C6-C10)aryl selected from phenyl, α-naphthyl or β-naphthyl; with the proviso that R5 and R6 cannot both be hydrogen; or R5 and R6 taken together are (CH2)2W(CH2)2, wherein W is selected from (CH2)n and n=0-1, NH, N(C1-C3)alkyl [straight or branched], N(C1-C4)alkoxy, oxygen, sulfur or substituted congeners selected from (L or D)proline, ethyl(L or D)prolinate, morpholine, pyrrolidine or piperidine; and the pharmacologically acceptable organic and inorganic salts or metal complexes.

Preferred compounds are compounds according to the above formula III and IV in which Y is NO2; R is selected from R4(CH2)nCO or R4′(CH2)nSO2; and when R=R4(CH2)nCO and n=0, R4 is selected from hydrogen; amino; monosubstituted amino selected from straight or branched (C1-C6)alkylamino, cyclopropylamino, cyclobutylamino, benzylamino or phenylamino; disubstituted amino selected from dimethylamino, diethylamino, ethyl(1-methylethyl)amino, monomethylbenzylamino, piperidinyl, morpholinyl, 1-imidazolyl, 1-pyrrolyl, 1-(1,2,3-triazolyl) or 4-(1,2,4-triazolyl); straight or branched (C1-C3)alkyl group selected from methyl, ethyl, n-propyl or 1-methylethyl; (C3-C6)cycloalkyl group selected from cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl; substituted (C3-C6)cycloalkyl group (substitution selected from (C1-C3)alkyl, cyano, amino or (C1-C3)acyl); (C6-C10)aryl group selected from phenyl, α-naphthyl or β-naphthyl; substituted (C6-C10)aryl group (substitution selected from halo, (C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); α-amino(C1-C4)alkyl group selected from aminomethyl, α-aminoethyl, β-aminopropyl or α-aminobutyl; carboxy(C2-C4)alkylamino group selected from aminoacetic acid, α-aminobutyric acid or α-aminopropionic acid and their optical isomers; (C7-C9)aralkylamino group such as phenylglycyl; (C1-C4)alkoxycarbonylamino substituted (C1-C4)alkyl group, substitution selected from phenyl or p-hydroxyphenyl; α-hydroxy(C1-C3)alkyl group selected from hydroxymethyl, α-hydroxyethyl or α-hydroxy-1-methylethyl or α-hydroxypropyl; halo(C1-C3)alkyl group such as bromomethyl, fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, 2-fluoroethyl, 2,2-difluoroethyl, 2,2,2-trifluoroethyl, 2-bromoethyl or 2-iodoethyl; a heterocycle group selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:


such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolidinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl, or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:
such as imidazolyl, pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, indazolyl, thiazolyl, benzothiazolyl, 3-alkyl-3H-imidazo[4,5-b]pyridyl or pyridylimidazolyl, or a five membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom:
(A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo,(C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)-alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)-aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)

such as γ-butyrolactam, γ-butyrolactone, imidazolidinone or N-aminoimidazolidinone, or a six membered aromatic ring with one to three N, O, S or Se heteroatoms such as pyridyl, pyridazinyl, pyrazinyl, sym-triazinyl, unsym-triazinyl, pyrimidinyl or (C1-C3)alkylthiopyridazinyl, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom such as 2,3-dioxo-1-piperazinyl, 4-ethyl-2,3-dioxo-1-piperazinyl, 4-methyl-2,3-dioxo-1-piperazinyl, 4-cyclopropyl-2-dioxo-1-piperazinyl, 2-dioxomorpholinyl or 2-dioxothiomorpholinyl; acyl or haloacyl group selected from acetyl, propionyl, chloroacetyl, trifluoroacetyl, (C3-C6)cycloalkylcarbonyl such as cyclopropylcarbonyl, cyclobutylcarbonyl, cyclopentylcarbonyl, cyclohexylcarbonyl, (2,3-dimethylcyclopropyl)carbonyl, (1,2-dimethylcyclopropyl)carbonyl, (2-ethylcyclopropyl)carbonyl, (2-methylcyclopentyl)carbonyl or (3-ethylcyclobutyl)carbonyl, (C6-C10)aroyl selected from benzoyl or naphthoyl, halo substituted (C6-C10)aroyl such as pentafluorobenzoyl, 4-chlorobenzoyl, 3-bromobenzoyl or 3,4-difluorobenzoyl, (C1-C4)alkylbenzoyl such as 4-toluoyl, 2-methyltoluoyl or 4-(1-methylethyl)benzoyl, or (heterocycle)carbonyl, the heterocycle selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:


such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl, or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:
such as imidazolyl, pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, indazolyl, thiazolyl, benzothiazolyl, 3-alkyl-3H-imidazo[4,5-b]pyridyl or pyridylimidazolyl, or a five membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom:
(A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo,(C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)-alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)

such as γ-butyrolactam, γ-butyrolactone, imidazolidinone or N-aminoimidazolidinone, or a six membered aromatic ring with one to three N, O, S or Se heteroatoms such as pyridyl, pyridazinyl, pyrazinyl, sym-triazinyl, unsym-triazinyl, pyrimidinyl, or (C1-C3)alkylthiopyridazinyl, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom such as 2,3-dioxo-1-piperazinyl, 4-ethyl-2,3-dioxo-1-piperazinyl, 4-methyl-2,3-dioxo-1-piperazinyl, 4-cyclopropyl-2-dioxo-1-piperazinyl, 2-dioxomorpholinyl or 2-dioxothiomorpholinyl; (C1-C4)alkoxycarbonyl group selected from methoxycarbonyl, ethoxycarbonyl, straight or branched propoxylcarbonyl, straight or branched butoxycarbonyl or allyloxycarbonyl; vinyl or substituted vinyl group [substitution selected from (C1-C3)alkyl group, halogen, (C6-C10)aryl group selected from phenyl, α-naphthyl, β-naphthyl, substituted (C6-C10)aryl group (substitution selected from halo, (C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy), halo(C1-C3)alkyl group such as bromomethyl, fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, 2-fluoroethyl, 2,2-difluoroethyl, 2,2,2-trifluoroethyl, 2-bromoethyl or 2-iodoethyl, a heterocycle group selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:


such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl]; (C1-C4)alkoxy group such as allyloxy, methoxy, ethoxy, n-propoxy, n-butoxy or tert-butoxy; C6-aryloxy group selected from phenoxy or substituted phenoxy (substitution selected from halo, (C1-C4)alkyl, nitro, cyano, thiol, amino, carboxy, di(C1-C3)alkylamino); (C7-C10)aralkyloxy group such as benzyloxy, 1-phenylethyloxy or 2-phenylethyloxy; vinyloxy or substituted vinyloxy group (substitution selected from (C1-C4)alkyl, cyano, carboxy, or (C6-C10)aryl selected from phenyl, α-naphthyl or β-naphthyl); RaRbamino(C1-C4)alkoxy group, wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or RaRb is (CH2)n, n=2-6, or (CH2)2W(CH2)2 wherein W is selected from N(C1-C3)alkyl [straight or branched], NH, NOB [B is selected from hydrogen or (C1-C3)alkyl], O or S; or RaRbaminoxy group, wherein is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or RaRb is (CH2)n, n=2-6, or (CH2)2W(CH2)2 wherein W is selected from N(C1-C3)alkyl [straight or branched], NH, NOB [B is selected from hydrogen or (C1-C3)alkyl], O or S; and when R═R4(CH2)nCO and n=1-4, R4 is selected from hydrogen; (C1-C3)alkyl group selected from methyl, ethyl, n-propyl or 1-methylethyl; amino; monosubstituted amino selected from straight or branched (C1-C6)alkylamino, cyclopropylamino, cyclobutylamino, benzylamino or phenylamino; disubstituted amino selected from dimethylamino, diethylamino, ethyl(1-methylethyl)amino, monomethylbenzylamino, piperidinyl, morpholinyl, 1-imidazolyl, 1-pyrrolyl, 1-(1,2,3-triazolyl) or 4-(1,2,4-triazolyl); (C6-C10)aryl group selected from phenyl, α-naphthyl or β-naphthyl; substituted (C6-C10)aryl group (substitution selected from halo, (C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); acyloxy or haloacyloxy group, selected from acetyl, propionyl, chloroacetyl, trichloroacetyl, (C3-C6)cycloalkylcarbonyl, (C6-C10)aroyl selected from benzoyl or naphthoyl, halo substituted (C6-C10)aroyl such as pentafluorobenzoyl, 4-chlorobenzoyl, 3-bromobenzoyl or 3,4-difluorobenzoyl, (C1-C4)alkylbenzoyl such as 4-toluoyl, 2-toluoyl, 4-(1-methylethyl)benzoyl or (heterocycle)carbonyl, the heterocycle selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom opionally having a benzo or pyrido ring fused thereto:
such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl, or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:
such as imidazolyl, pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, indazolyl, thiazolyl, benzothiazolyl, 3-alkyl-3H-imidazo[4,5-b]pyridyl or pyridylimidazolyl, or a five membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom:
(A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo,(C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)

such as γ-butyrolactam, γ-butyrolactone, imidazolidinone or N-aminoimidazolidinone, or a six membered aromatic ring with one to three N, O, S or Se heteroatoms such as pyridyl, pyridazinyl, pyrazinyl, sym-triazinyl, unsym-triazinyl, pyrimidinyl or (C1-C3)alkylthiopyridazinyl, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom such as 2,3-dioxo-1-piperazinyl, 4-ethyl-2,3-dioxo-1-piperazinyl, 4-methyl-2,3-dioxo-1-piperazinyl, 4-cyclopropyl-2-dioxo-1-piperazinyl, 2-dioxomorpholinyl or 2-dioxothiomorpholinyl; (C1-C4)alkoxy group such as allyloxy, methoxy, ethoxy, n-propoxy, n-butoxy or tert-butoxy; RaRbamino(C1-C4)alkoxy group, wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or RaRb is (CH2)n, n=2-6, or (CH2)2W(CH2)2 wherein W is selected from N(C1-C3)alkyl [straight or branched], NH, NOB [B is selected from hydrogen or (C1-C3)alkyl], O or S; or RaRbaminoxy group, wherein is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or RaRb is (CH2)n, n=2-6, or (CH2)2W(CH2)2 wherein W is selected from N(C1-C3)alkyl [straight or branched], NH, NOB [B is selected from hydrogen or (C1-C3)alkyl], O or S; C6-aryloxy group selected from phenoxy or substituted phenoxy (substitution selected from halo, (C1-C4)alkyl, nitro, cyano, thiol, amino, carboxy, di(C1-C3)alkylamino); (C1-C3)alkylthio group selected from methylthio, ethylthio, propylthio or allylthio; C6-arylthio group selected from phenylthio or substituted phenylthio (substitution selected from halo, (C1-C4)alkyl, nitro, cyano, thiol, amino, carboxy, di(C1-C3)alkylamino); C6-arylsulfonyl group selected from phenylsulfonyl or substituted phenylsulfonyl (substitution selected from halo, (C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); a heterocycle group selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:


such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl, or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:
such as imidazolyl, pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, indazolyl, thiazolyl, benzothiazolyl, 3-alkyl-3H-imidazo[4,5-b]pyridyl or pyridylimidazolyl, or a five membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom:
(A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo,(C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)-alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)-aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)

such as γ-butyrolactam, γ-butyrolactone, imidazolidinone or N-aminoimidazolidinone, or a six membered aromatic ring with one to three N, O, S or Se heteroatoms such as pyridyl, pyridazinyl, pyrazinyl, sym-triazinyl, unsym-triazinyl, pyrimidinyl or (C1-C3)alkylthiopyridazinyl, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom such as 2,3-dioxo-1-piperazinyl, 4-ethyl-2,3-dioxo-1-piperazinyl, 4-methyl-2,3-dioxo-1-piperazinyl, 4-cyclopropyl-2-dioxo-1-piperazinyl, 2-dioxomorpholinyl or 2-dioxothiomorpholinyl; hydroxy group; α-hydroxy(C1-C3)alkyl group selected from hydroxymethyl, α-hydroxyethyl or α-hydroxy-1-methylethyl or α-hydroxypropyl; halo(C1-C3)alkyl group such as bromomethyl, fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, 2-fluoroethyl, 2,2-difluoroethyl, 2,2,2-trifluoromethyl, 2-bromoethyl or 2-iodoethyl; acyl or haloacyl group selected from acetyl, propionyl, chloroacetyl, trifluoroacetyl, (C3-C6)cycloalkylcarbonyl, (C6-C10)aroyl selected from benzoyl or naphthoyl, halo substituted (C6-C10)aroyl such as pentafluorobenzoyl, 4-chlorobenzoyl, 3-bromobenzoyl or 3,4-difluorobenzoyl, (C1-C4)alkylbenzoyl such as 4-toluoyl, 2-toluoyl, or 4-(1-methylethyl)benzoyl, or (heterocycle)carbonyl, the heterocycle selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:


such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl, or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:
such as imidazolyl, pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, indazolyl, thiazolyl, benzothiazolyl, 3-alkyl-3H-imidazo[4,5-b]pyridyl or pyridylimidazolyl, or a five membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom:
(A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo, (C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl) such as γ-butyrolactam, γ-butyrolactone, imidazolidinone or N-aminoimidazolidinone, or a six membered aromatic ring with one to three N, O, S or Se heteroatoms such as pyridyl, pyridazinyl, pyrazinyl, sym-triazinyl, unsym-triazinyl, pyrimidinyl or (C1-C3)alkylthiopyridazinyl, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom such as 2,3-dioxo-1-piperazinyl, 4-ethyl-2,3-dioxo-1-piperazinyl, 4-methyl-2,3-dioxo-1-piperazinyl, 4-cyclopropyl-2-dioxo-1-piperazinyl, 2-dioxomorpholinyl or 2-dioxothiomorpholinyl; (C1-C4)alkoxycarbonylamino group selected from tert-butoxycarbonylamino, allyloxycarbonylamino, methoxycarbonylamino, ethoxycarbonylamino or propoxycarbonylamino; and when R═R4′ (CH2)2SO2 and n=0, R4′ is selected from amino; monosubstituted amino selected from as straight or branched (C1-C6)alkylamino, cyclopropylamino, cyclobutylamino, benzylamino or phenylamino; disubstituted amino selected from dimethylamino, diethylamino, ethyl(1-methylethyl)amino, monomethylbenzylamino, piperidinyl, morpholinyl, 1-imidazolyl, 1-pyrrolyl, 1-(1,2,3-triazolyl) or 4-(1,2,4-triazolyl); straight or branched (C1-C3)alkyl group selected from methyl, ethyl, n-propyl or 1-methylethyl; (C6-C10)aryl group selected from phenyl, α-naphthyl or β-naphthyl; substituted (C6-C10)aryl group (substitution selected from halo, (C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); a heterocycle group selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:
such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl, or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:
such as imidazolyl, pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, indazolyl, thiazolyl, benzothiazolyl, 3-alkyl-3H-imidazo[4,5-b]pyridyl or pyridylimidazolyl, or a five membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom:
(A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo,(C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)

such as γ-butyrolactam, γ-butyrolactone, imidazolidinone or N-aminoimidazolidinone, or a six membered aromatic ring with one to three N, O, S or Se heteroatoms such as pyridyl, pyridazinyl, pyrazinyl, sym-triazinyl, unsym-triazinyl, pyrimidinyl or (C1-C3)alkylthiopyridazinyl, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom such as 2,3-dioxo-1-piperazinyl, 4-ethyl-2,3-dioxo-1-piperazinyl, 4-methyl-2,3-dioxo-1-piperazinyl, 4-cyclopropyl-2-dioxo-1-piperazinyl, 2-dioxomorpholinyl or 2-dioxothiomorpholinyl; and when R═R4′(CH2)nSO2 and n=1-4, R4′ is selected from hydrogen; amino; monosubstituted amino selected from straight or branched (C1-C6)alkylamino, cyclopropylamino, cyclobutylamino, benzylamino or phenylamino; disubstituted amino selected from dimethylamino, diethylamino, ethyl(1-methylethyl)amino, monomethylbenzylamino, piperidinyl, morpholinyl, 1-imidazolyl, 1-pyrrolyl, 1-(1,2,3-triazolyl) or 4-(1,2,4-triazolyl); straight or branched (C1-C3)alkyl group selected from methyl, ethyl, n-propyl or 1-methylethyl; (C6-C10)aryl group selected from phenyl, α-naphthyl or β-naphthyl; substituted (C6-C10)aryl group (substitution selected from halo, (C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C1-C4)alkoxy group such as allyloxy, methoxy, ethoxy, n-propoxy, n-butoxy, iso-butoxy or tert-butoxy; C6-aryloxy group selected from phenoxy or substituted phenoxy (substitution selected from halo, (C1-C4)alkyl, nitro cyano, thiol, amino, carboxy, di(C1-C3)alkylamino; (C7-C10)aralkyloxy group such as benzyloxy, 1-phenylethyloxy or 2-phenylethyloxy; (C1-C4)carboxyalkyl group; R5 is selected from hydrogen; straight or branched (C1-C3)alkyl group selected from methyl, ethyl, n-propyl or 1-methylethyl; (C6-C10)aryl group selected from phenyl, α-naphthyl or β-naphthyl; (C7-C9)aralkyl group such as benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl; a heterocycle group selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:


such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl, or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:
such as imidazolyl, pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, indazolyl, thiazolyl, benzothiazolyl, 3-alkyl-3H-imidazo[4,5-b]pyridyl or pyridylimidazolyl, or a five membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom:
(A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo, (C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)

such as γ-butyrolactam, γ-butyrolactone, imidazolidinone or N-aminoimidazolidinone, or a six membered aromatic ring with one to three N, O, S or Se heteroatoms such as pyridyl, pyridazinyl, pyrazinyl, sym-triazinyl, unsym-triazinyl, pyrimidinyl or (C1-C3)alkylthiopyridazinyl, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom such as 2,3-dioxo-1-piperazinyl, 4-ethyl-2,3-dioxo-1-piperazinyl, 4-methyl-2,3-dioxo-1-piperazinyl, 4-cyclopropyl-2-dioxo-1-piperazinyl, 2-dioxomorpholinyl, 2-dioxothiomorpholinyl; or (CH2)nCOOR7 where n=0-4 and R7 is selected from hydrogen; straight or branched (C1-C3)alkyl group selected from methyl, ethyl, n-propyl or 1-methylethyl; or (C6-C10)aryl group selected from phenyl, α-naphthyl or β-naphthyl;

R6 is selected from hydrogen; straight or branched (C1-C3)alkyl group selected from methyl, ethyl, n-propyl or 1-methylethyl; (C6-C10)aryl group selected from phenyl, α-naphthyl or β-naphthyl; (C7-C9)aralkyl group such as benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl; a heterocycle group selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:


such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl, or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:
such as imidazolyl, pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, indazolyl, thiazolyl, benzothiazolyl, 3-alkyl-3H-imidazo[4,5-b]pyridyl or pyridylimidazolyl, or a five membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom:
(A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo, (C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)

such as γ-butyrolactam, γ-butyrolactone, imidazolidinone or N-aminoimidazolidinone, or a six membered aromatic ring with one to three N, O, S or Se heteroatoms such as pyridyl, pyridazinyl, pyrazinyl, sym-triazinyl, unsym-triazinyl, pyrimidinyl or (C1-C3)alkylthiopyridazinyl, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom such as 2,3-dioxo-1-piperazinyl, 4-ethyl-2,3-dioxo-1-piperazinyl, 4-methyl-2,3-dioxo-1-piperazinyl, 4-cyclopropyl-2-dioxo-1-piperazinyl, 2-dioxomorpholinyl, 2-dioxothiomorpholinyl; or (CH2)nCOOR7′ where n=0-4 and R7′ is selected from hydrogen; straight or branched (C1-C3)alkyl selected from methyl, ethyl, n-propyl or 1-methylethyl; or (C6-C10)aryl selected from phenyl, α-naphthyl or β-naphthyl; with the proviso that R5 and R6 cannot both be hydrogen; or R5 and R6 taken together are (CH2)2W(CH2)2, wherein W is selected from (CH2)n and n=0-1, NH, N(C1-C3)alkyl [straight or branched], N(C1-C4)alkoxy, oxygen, sulfur or substituted congeners selected from (L or D)proline, ethyl(L or D)prolinate, morpholine, pyrrolidine or piperidine; and the pharmacologically acceptable organic and inorganic salts or metal complexes.

Particularly preferred compounds are compounds according to the above formula III and IV in which Y is NO2;

R is selected from R4(C2)nCO or R4′(CH2)nSO2; and when R═R4(CH2)nCO and n=0, R4 is selected from hydrogen; amino; monosubstituted amino selected from straight or branched (C1-C6)alkylamino, cyclopropylamino, cyclobutylamino, benzylamino or phenylamino; disubstituted amino selected from dimethylamino, diethylamino, ethyl(1-methylethyl)amino, monomethylbenzylamino, piperidinyl, morpholinyl, 1-imidazolyl, 1-pyrrolyl, 1-(1,2,3-triazolyl) or 4-(1,2,4-triazolyl); straight or branched (C1-C3)alkyl group selected from methyl, ethyl, n-propyl or 1-methylethyl; (C3-C6)cycloalkyl group selected from cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl; substituted (C3-C6)cycloalkyl group (substitution selected from (C1-C3)alkyl, cyano, amino or (C1-C3)acyl); (C6-C10)aryl group selected from phenyl, α-naphthyl or β-naphthyl; substituted (C6-C10)aryl group (substitution selected from halo,(C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); α-amino-(C1-C4)alkyl group selected from aminomethyl, α-aminoethyl, α-aminopropyl or α-aminobutyl; carboxy(C2-C4)alkylamino group selected from aminoacetic acid, α-aminobutyric acid or α-aminopropionic acid and their optical isomers; (C7-C9)aralkylamino group such as phenylglycyl; (C1-C4)alkoxycarbonylamino substituted (C1-C4)alkyl group, substitution selected from phenyl or p-hydroxyphenyl; α-hydroxy(C1-C3)alkyl group selected from hydroxymethyl, α-hydroxyethyl or α-hydroxy-1-methylethyl or α-hydroxypropyl; halo(C1-C3)alkyl group such as bromomethyl, fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, 2-fluoroethyl, 2,2-difluoroethyl, 2,2,2-trifluoroethyl, 2-bromoethyl or 2-iodoethyl; a heterocycle group selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:


such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl, or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:
such as imidazolyl, pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, indazolyl, thiazolyl, benzothiazolyl, 3-alkyl-3H-imidazo[4,5-b]pyridyl or pyridylimidazolyl, or a five membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom:
(A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo,(C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)-alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)-aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)

such as γ-butyrolactam, γ-butyrolactone, imidazolidinone or N-aminoimidazolidinone, or a six membered aromatic ring with one to three N, O, S or Se heteroatoms such as pyridyl, pyridazinyl, pyrazinyl, sym-triazinyl, unsym-triazinyl, pyrimidinyl or (C1-C3)alkylthiopyridazinyl, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom such as 2,3-dioxo-1-piperazinyl, 4-ethyl-2,3-dioxo-1-piperazinyl, 4-methyl-2,3-dioxo-1-piperazinyl, 4-cyclopropyl-2-dioxo-1-piperazinyl, 2-dioxomorpholinyl or 2-dioxothiomorpholinyl; acyl or haloacyl group selected from acetyl, propionyl, chloroacetyl, trifluoroacetyl, (C3-C6)cycloalkylcarbonyl such as cyclopropylcarbonyl, cyclobutylcarbonyl, cyclopentylcarbonyl, cyclohexylcarbonyl, (2,3-dimethylcyclopropyl)carbonyl, (1,2-dimethylcyclopropyl)carbonyl, (2-ethylcyclopropyl)carbonyl, (2-methylcyclopentyl)carbonyl or (3-ethylcyclobutyl)carbonyl, (C6-C10)aroyl selected from benzoyl or naphthoyl, halo substituted (C6-C10)aroyl such as pentafluorobenzoyl, 4-chlorobenzoyl, 3-bromobenzoyl or 3,4-difluorobenzoyl, (C1-C4)alkylbenzoyl such as 4-toluoyl, 2-methylbenzoyl or 4-(1-methylethyl)benzoyl, or (heterocycle)carbonyl, the heterocycle selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:


such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl, or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:
such as imidazolyl, pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, indazolyl, thiazolyl, benzothiazolyl, 3-alkyl-3H-imidazo[4,5-b]pyridyl or pyridylimidazolyl, or a five membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom:
(A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo,(C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)

such as γ-butyrolactam, γ-butyrolactone, imidazolidinone or N-aminoimidazolidinone, or a six membered aromatic ring with one to three N, O, S or Se heteroatoms such as pyridyl, pyridazinyl, pyrazinyl, sym-triazinyl, unsym-triazinyl, pyrimidinyl or (C1-C3)alkylthiopyridazinyl, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom such as 2,3-dioxo-1-piperazinyl, 4-ethyl-2,3-dioxo-1-piperazinyl, 4-methyl-2,3-dioxo-1-piperazinyl, 4-cyclopropyl-2-dioxo-1-piperazinyl, 2-dioxomorpholinyl or 2-dioxothiomorpholinyl; (C1-C4)alkoxycarbonyl group selected from methoxycarbonyl, ethoxycarbonyl, straight or branched propoxylcarbonyl, straight or branched butoxycarbonyl or allyloxycarbonyl; vinyl or substituted vinyl group [substitution selected from (C1-C3)alkyl group, halogen, (C6-C10)aryl group selected from phenyl, α-naphthyl, β-naphthyl, substituted (C6-C10)aryl group (substitution selected from halo, (C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkyl amino or carboxy), halo(C1-C3)alkyl group such as bromomethyl, fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, 2-fluoroethyl, 2,2-difluoroethyl, 2,2,2-trifluoroethyl, 2-bromoethyl or 2-iodoethyl, a heterocycle group selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:


such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl];

(C1-C4)alkoxy group such as allyloxy, methoxy, ethoxy, n-propoxy,n-butoxy or tert-butoxy; C6-aryloxy group selected from phenoxy or substituted phenoxy (substitution selected from halo, (C1-C4)alkyl, nitro, cyano, thiol, amino, carboxy, di(C1-C3)alkylamino); (C7-C10)aralkyloxy group such as benzyloxy, 1-phenylethyloxy or 2-phenylethyloxy; vinyloxy or substituted vinyloxy group (substitution selected from (C1-C4)alkyl, cyano, carboxy, or (C6-C10)aryl selected from phenyl, α-naphthyl or β-naphthyl); RaRbamino(C1-C4)alkoxy group, wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or RaRb is (CH2)n, n=2-6, or (CH2)2W(CH2)2 wherein W is selected from N(C1-C3)alkyl [straight or branched], NH, NOB [B is selected from hydrogen or (C1-C3)alkyl], O or S; or RaRbaminoxy group, wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or RaRb is (CH2)n, n=2-6, or (CH2)2W(CH2)2 wherein W is selected from N(C1-C3)alkyl [straight or branched], NH, NOB [B is selected from hydrogen or (C1-C3)alkyl], O or S; and when R═R4(CH2)nCO and n=1-4, R4 is selected from hydrogen; (C1-C3)alkyl group selected from methyl, ethyl, n-propyl or 1-methylethyl; amino; monosubstituted amino selected from straight or branched (C1-C6)alkylamino, cyclopropylamino, cyclobutylamino, benzylamino or phenylamino; disubstituted amino selected from dimethylamino, diethylamino, ethyl(1-methylethyl)amino, monomethylbenzylamino, piperidinyl, morpholinyl, 1-imidazolyl, 1-pyrrolyl, 1-(1,2,3-triazolyl) or 4-(1,2,4-triazolyl); (C6-C10)aryl group selected from phenyl, α-naphthyl or β-naphthyl; substituted (C6-C10) aryl group (substitution selected from halo, (C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); acyloxy or haloacyloxy group, selected from acetyl, propionyl, chloroacetyl, trichloroacetyl, (C3-C6)cycloalkylcarbonyl, (C6-C10)aroyl selected from benzoyl or naphthoyl, halo substituted (C6-C10)aroyl such as pentafluorobenzoyl, 4-chlorobenzoyl, 3-bromobenzoyl or 3,4-difluorobenzoyl, (C1-C4)alkylbenzoyl such as 4-toluoyl, 2-toluoyl, 4-(1-methylethyl)benzoyl or (heterocycle)carbonyl, the heterocycle selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:


such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl, or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:
such as imidazolyl, pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, indazolyl, thiazolyl, benzothiazolyl, 3-alkyl-3H-imidazo[4,5-b]pyridyl or pyridylimidazolyl, or a five membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom:
(A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo,(C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)

such as γ-butyrolactam, γ-butyrolactone, imidazolidinone or N-aminoimidazolidinone, or a six membered aromatic ring with one to three N, O, S or Se heteroatoms such as pyridyl, pyridazinyl, pyrazinyl, sym-triazinyl, unsym-triazinyl, pyrimidinyl or (C1-C3)alkylthiopyridazinyl, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom such as 2,3-dioxo-1-piperazinyl, 4-ethyl-2,3-dioxo-1-piperazinyl, 4-methyl-2,3-dioxo-1-piperazinyl, 4-cyclopropyl-2-dioxo-1-piperazinyl, 2-dioxomorpholinyl or 2-dioxothiomorpholinyl; (C1-C4)alkoxy group such as allyloxy, methoxy, ethoxy, n-propoxy, n-butoxy or tert-butoxy; C6-aryloxy group selected from phenoxy or substituted phenoxy (substitution selected from halo, (C1-C4)alkyl, nitro, cyano, thiol, amino, carboxy, di(C1-C3)alkylamino); RaRbamino(C1-C4)alkoxy group, wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or RaRb is (CH2)n, n=2-6, or CH2)2W(CH2)2 wherein W is selected from N(C1-C3)alkyl [straight or branched], NH, NOB [B is selected from hydrogen or (C1-C3)alkyl], O or S; or RaRbaminoxy group, wherein is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or RaRb is (CH2)n, n=2-6, or (CH2)2W(CH2)2 wherein W is selected from N(C1-C3)alkyl [straight or branched], NH, NOB [B is selected from hydrogen or (C1-C3)alkyl], O or S; (C1-C3)alkylthio group selected from methylthio, ethylthio, propylthio or allylthio; C6-arylthio group selected from phenylthio or substituted phenylthio (substitution selected from halo, (C1-C4)alkyl; nitro, cyano, thiol, amino, carboxy, di(C1-C3)alkylamino); C6-arylsulfonyl group selected from phenylsulfonyl or substituted phenylsulfonyl (substitution selected from halo, (C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); a heterocycle group selected from a five membered aromatic or saturated ring one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:


such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl, or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:
such as imidazolyl, pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, indazolyl, thiazolyl, benzothiazolyl, 3-alkyl-3H-imidazo[4,5-b]pyridyl or pyridylimidazolyl, or a five membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom:
(A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo,(C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl) such as γ-butyrolactam, γ-butyrolactone, imidazolidinone or N-aminoimidazolidinone, or a six membered aromatic ring with one to three N, O, S or Se heteroatoms such as pyridyl, pyridazinyl, pyrazinyl, sym-triazinyl, unsym-triazinyl, pyrimidinyl (C1-C3)alkylthiopyridazinyl, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom such as 2,3-dioxo-1-piperazinyl, 4-ethyl-2,3-dioxo-1-piperazinyl, 4-methyl-2,3-dioxo-1-piperazinyl, 4-cyclopropyl-2-dioxo-1-piperazinyl, 2-dioxomorpholinyl or 2-dioxothiomorpholinyl; hydroxy group; α-hydroxy(C1-C3)alkyl group selected from hydroxymethyl, α-hydroxyethyl or α-hydroxy-1-methylethyl or α-hydroxypropyl; halo(C1-C3)alkyl group such as bromomethyl, fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, 2-fluoroethyl, 2,2-difluoroethyl, 2,2,2-trifluoromethyl, 2-bromoethyl or 2-iodoethyl; acyl or haloacyl group selected from acetyl, propionyl, chloroacetyl, trifluoroacetyl, (C3-C6)cycloalkylcarbonyl, (C6-C10)aroyl selected from benzoyl or naphthoyl, halo substituted (C6-C10)aroyl such as pentafluorobenzoyl, 4-chlorobenzoyl, 3-bromophenylcarbonyl or 3,4-difluorobenzoyl, (C1-C4)alkylbenzoyl such as from 4-toluoyl, 2-toluoyl or 4-(1-methylethyl)benzoyl, or (heterocycle)carbonyl, the heterocycle selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:
such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl, or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo-or pyrido ring fused thereto:
such as imidazolyl, pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, indazolyl, thiazolyl, benzothiazolyl, 3-alkyl-3H-imidazo[4,5-b]pyridyl or pyridylimidazolyl, or a five membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom:
(A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo,(C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)

such as γ-butyrolactam, γ-butyrolactone, imidazolidinone or N-aminoimidazolidinone, or a six membered aromatic ring with one to three N, O, S or Se heteroatoms such as pyridyl, pyridazinyl, pyrazinyl, sym-triazinyl, unsym-triazinyl, pyrimidinyl or (C1-C3)alkylthiopyridazinyl, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom such as 2,3-dioxo-1-piperazinyl, 4-ethyl-2,3-dioxo-1-piperazinyl, 4-methyl-2,3-dioxo-1-piperazinyl, 4-cyclopropyl-2-dioxo-1-piperazinyl, 2-dioxomorpholinyl or 2-dioxothiomorpholinyl; (C1-C4)alkoxycarbonylamino group selected from tert-butoxycarbonylamino, allyloxycarbonylamino, methoxycarbonylamino, ethoxycarbonylamino or propoxycarbonylamino;

and when R═R4′ (CH2)nSO2 and n=0, R4′ is selected from amino; monosubstituted amino selected from as straight or branched (C1-C6)alkylamino, cyclopropylamino, cyclobutylamino, benzylamino or phenylamino; disubstituted amino selected from dimethylamino, diethylamino, ethyl(1-methylethyl)amino, monomethylbenzylamino, piperidinyl, morpholinyl, 1-imidazolyl, 1-pyrrolyl, 1-(1,2,3-triazolyl) or 4-(1,2,4-triazolyl); straight or branched (C1-C3)alkyl group selected from methyl, ethyl, n-propyl or 1-methylethyl; (C6-C10)aryl group selected from phenyl, α-naphthyl or β-naphthyl; substituted (C6-C10)aryl group (substitution selected from halo, (C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); a heterocycle group selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:


such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl, or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:
such as imidazolyl, pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, indazolyl, thiazolyl, benzothiazolyl, 3-alkyl-3H-imidazo[4,5-b]pyridyl or pyridylimidazolyl, or a five membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom:
(A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo,(C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)

such as γ-butyrolactam, γ-butyrolactone, imidazolidinone or N-aminoimidazolidinone, or a six membered aromatic ring with one to three N, O, S or Se heteroatoms such as pyridyl, pyridazinyl, pyrazinyl, sym-triazinyl, unsym-triazinyl, pyrimidinyl or (C1-C3)alkylthiopyridazinyl, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom such as 2,3-dioxo-1-piperazinyl, 4-ethyl-2,3-dioxo-1-piperazinyl, 4-methyl-2,3-dioxo-1-piperazinyl, 4-cyclopropyl-2-dioxo-1-piperazinyl, 2-dioxomorpholinyl or 2-dioxothiomorpholinyl; and when R═R4′(CH2)nSO2 and n=1-4, R4′ is selected from hydrogen; amino; monosubstituted amino selected from straight or branched (C1-C6)alkylamino, cyclopropylamino, cyclobutylamino, benzylamino or phenylamino; disubstituted amino selected from dimethylamino, diethylamino, ethyl(1-methylethyl)amino, monomethylbenzylamino, piperidinyl, morpholinyl, 1-imidazolyl, 1-pyrrolyl, 1-(1,2,3-triazolyl) or 4-(1,2,4-triazolyl); straight or branched (C1-C3)alkyl group selected from methyl, ethyl, n-propyl or 1-methylethyl; RaRbamino(C1-C4)alkoxy group, wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or RaRb is (CH2)n, n=2-6, or (CH2)2W-(CH2)2 wherein W is selected from N(C1-C3)alkyl [straight or branched], NH, NOB [B is selected from hydrogen or (C1-C3)alkyl], O or S; or RaRbaminoxy group, wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or RaRb is (CH2)n, n=2-6, or (CH2)2W(CH2)2 wherein W is selected from N(C1-C3)alkyl [straight or branched], NH, NOB [B is selected from hydrogen or (C1-C3)alkyl], O or S; R5 is selected from hydrogen; straight or branched (C1-C3)alkyl group selected from methyl, ethyl, n-propyl or 1-methylethyl; (C6-C10)aryl group selected from phenyl, α-naphthyl or β-naphthyl; (C7-C9)aralkyl group such as benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl; a heterocycle group selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:


such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl, or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:
such as imidazolyl, pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, indazolyl, thiazolyl, benzothiazolyl, 3-alkyl-3H-imidazo[4,5-b]pyridyl or pyridylimidazolyl, or a five membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom:
(A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo,(C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)

such as γ-butyrolactam, γ-butyrolactone, imidazolidinone or N-aminoimidazolidinone, or a six membered aromatic ring with one to three N, O, S or Se heteroatoms such as pyridyl, pyridazinyl, pyrazinyl, sym-triazinyl, unsym-triazinyl, pyrimidinyl or (C1-C3)alkylthiopyridazinyl, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom such as 2,3-dioxo-1-piperazinyl, 4-ethyl-2,3-dioxo-1-piperazinyl, 4-methyl-2,3-dioxo-1-piperazinyl, 4-cyclopropyl-2-dioxo-1-piperazinyl, 2-dioxomorpholinyl, 2-dioxothiomorpholinyl; or (CH2)nCOOR7 where n=0-4 and R7 is selected from hydrogen; straight or branched (C1-C3)alkyl group selected from methyl, ethyl, n-propyl or 1-methylethyl; or (C6-C10)aryl group selected from phenyl, α-naphthyl or β-naphthyl; R6 is selected from hydrogen; straight or branched (C1-C3)alkyl group selected from methyl, ethyl, n-propyl or 1-methylethyl; (C6-C10)aryl group selected from phenyl, α-naphthyl or β-naphthyl; (C7-C9)aralkyl group such as benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl; a heterocycle group selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:


such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl, or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:
such as imidazolyl, pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, indazolyl, thiazolyl, benzothiazolyl, 3-alkyl-3H-imidazo[4,5-b]pyridyl or pyridylimidazolyl, or a five membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom:
(A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo,(C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)

such as γ-butyrolactam, γ-butyrolactone, imidazolidinone or N-aminoimidazolidinone, or a six membered aromatic ring with one to three N, O, S or Se heteroatoms such as pyridyl, pyridazinyl, pyrazinyl, sym-triazinyl, unsym-triazinyl, pyrimidinyl or (C1-C3)alkylthiopyridazinyl, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom such as 2,3-dioxo-1-piperazinyl, 4-ethyl-2,3-dioxo-1-piperazinyl, 4-methyl-2,3-dioxo-1-piperazinyl, 4-cyclopropyl-2-dioxo-1-piperazinyl, 2-dioxomorpholinyl, 2-dioxothiomorpholinyl; or (CH2)nCOOR7′ where n=0-4 and R7′ selected from hydrogen; straight or branched (C1-C3)alkyl selected from methyl, ethyl, n-propyl or 1-methylethyl; or (C6-C10)aryl selected from phenyl, α-naphthyl or β-naphthyl; with the proviso that R5 and R6 cannot both be hydrogen; or R5 and R6 taken together are (CH2)2W(CH2)2, wherein W is selected from (CH2)n and n=0-1, NH, N(C1-C3)alkyl [straight or branched], N(C1-C4)alkoxy, oxygen, sulfur or substituted congeners selected from (L or D)proline, ethyl(L or D)prolinate, morpholine, pyrrolidine or piperidine; and the pharmacologically acceptable organic and inorganic salts or metal complexes.

Most particularly preferred compounds are compounds according to the above formula III and IV in which Y is NO2;

R is selected from R4(CH2)nCO or R4′(CH2)nSO2; and when R═R4(CH2)nCO and n=0, R4 is selected from hydrogen; amino; monosubstituted amino selected from straight or branched (C1-C6)alkylamino, cyclopropylamino, cyclobutylamino, benzylamino or phenylamino; disubstituted amino selected from dimethylamino, diethylamino, ethyl(1-methylethyl)amino, monomethylbenzylamino, piperidinyl, morpholinyl, 1-imidazolyl, 1-pyrrollyl, 1-(1,2,3-triazolyl) or 4-(1,2,4-triazolyl); straight or branched (C1-C2)alkyl group selected from methyl or ethyl; (C6-C10)aryl group selected from phenyl, α-naphthyl or β-naphthyl; substituted (C6-C10)aryl group (substitution selected from halo, (C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); carboxy(C2-C4)alkylamino group selected from aminoacetic acid, α-aminobutyric acid or α-aminopropionic acid and their optical isomers; α-hydroxy(C1-C3)alkyl group selected from hydroxymethyl, α-hydroxyethyl or α-hydroxy-1-methylethyl or α-hydroxypropyl; halo(C1-C3)alkyl group such as bromomethyl, fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, 2-fluoroethyl, 2,2-difluoroethyl, 2,2,2-trifluoroethyl, 2-bromoethyl or 2-iodoethyl; a heterocycle group selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:


such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl, or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:
such as imidazolyl, pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, indazolyl, thiazolyl, benzothiazolyl, 3-alkyl-3H-imidazo[4,5-b]pyridyl or pyridylimidazolyl, or a five membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom:
(A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo,(C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)

such as γ-butyrolactam, γ-butyrolactone, imidazolidinone or N-aminoimidazolidinone, or a six membered aromatic ring with one to three N, O, S or Se heteroatoms such as pyridyl, pyridazinyl, pyrazinyl, sym-triazinyl, unsym-triazinyl, pyrimidinyl or (C1-C3)alkylthiopyridazinyl, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom such as 2,3-dioxo-1-piperazinyl, 4-ethyl-2,3-dioxo-1-piperazinyl, 4-methyl-2,3-dioxo-1-piperazinyl, 4-cyclopropyl-2-dioxo-1-piperazinyl, 2-dioxomorpholinyl or 2-dioxothiomorpholinyl; (C1-C4)alkoxycarbonyl group selected from methoxycarbonyl, ethoxycarbonyl, straight or branched propoxylcarbonyl, straight or branched butoxycarbonyl or allyloxycarbonyl; vinyl or substituted vinyl group [substitution selected from (C1-C3)alkyl group, halogen, (C6-C10)aryl group selected from phenyl, α-naphthyl, β-naphthyl, substituted (C6-C10)aryl group (substitution selected from halo, (C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy), halo(C1-C3)alkyl group such as bromomethyl, fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, 2-fluoroethyl, 2,2-difluoroethyl, 2,2,2-trifluoroethyl, 2-bromoethyl or 2-iodoethyl, a heterocycle group selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:


such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl]; (C1-C4)alkoxy group such as allyloxy, methoxy, ethoxy, n-propoxy, n-butoxy or tert-butoxy; C6-aryloxy group selected from phenoxy or substituted phenoxy (substitution selected from halo, (C1-C4)alkyl, nitro, cyano, thiol, amino, carboxy, di(C1-C3)alkylamino); (C7-C10)aralkyloxy group such as benzyloxy, 1-phenylethyloxy or 2-phenylethyloxy; vinyloxy or substituted vinyloxy group (substitution selected from (C1-C4)alkyl, cyano, carboxy, or (C6-C10)aryl selected from phenyl, α-naphthyl or β-naphthyl); RaRbamino(C1-C4)alkoxy group, wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or RaRb is (CH2)n, n=2-6, or (CH2)2W(CH2)2 wherein W is selected from N(C1-C3)alkyl [straight or branched], NH, NOB [B is selected from hydrogen or (C1-C3)alkyl], O or S; or RaRbaminoxy group, wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or RaRb is (CH2)n, n=2-6, or (CH2)2W(CH2)2 wherein W is selected from N(C1-C3)alkyl [straight or branched], NH, NOB [B is selected from hydrogen or (C1-C3)alkyl], O or S; and when R═R4(CH2)nCO and n=1-4, R4 is selected from hydrogen; (C1-C2)alkyl group selected from methyl or ethyl; amino; monosubstituted amino selected from straight or branched (C1-C6)alkylamino, cyclopropylamino, cyclobutylamino, benzylamino or phenylamino; disubstituted amino selected from dimethylamino, diethylamino, ethyl(1-methylethyl)amino, monomethylbenzylamino, piperidinyl, morpholinyl, 1-imidazolyl, 1-pyrrolyl, 1-(1,2,3-triazolyl) or 4-(1,2,4-triazolyl); (C6-C10)aryl group selected from phenyl, α-naphthyl or β-naphthyl; substituted (C6-C10)aryl group (substitution selected from halo, (C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); acyloxy or haloacyloxy group, selected from acetyl, propionyl, chloroacetyl, trichloroacetyl, (C3-C6)cycloalkylcarbonyl, (C6-C10)aroyl selected from benzoyl or naphthoyl, halo substituted (C6-C10)aroyl such as pentafluorobenzoyl, 4-chlorobenzoyl, 3-bromobenzoyl or 3,4-difluorobenzoyl, (C1-C4)alkylbenzoyl such as 4-toluoyl, 2-toluoyl, 4-(1-methylethyl)benzoyl or (heterocycle)carbonyl, the heterocycle selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:
such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl, or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:
such as imidazolyl, pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, indazolyl, thiazolyl, benzothiazolyl, 3-alkyl-3H-imidazo[4,5-b]pyridyl or pyridylimidazolyl, or a five membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended heteroatom:
(A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo,(C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)

such as γ-butyrolactam, γ-butyrolactone, imidazolidinone or N-aminoimidazolidinone, or a six membered aromatic ring with one to three N, O, S or Se heteroatoms such as pyridyl, pyridazinyl, pyrazinyl, sym-triazinyl, unsym-triazinyl, pyrimidinyl or (C1-C3)alkylthiopyridazinyl, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom such as 2,3-dioxo-1-piperazinyl, 4-ethyl-2,3-dioxo-1-piperazinyl, 4-methyl-2,3-dioxo-1-piperazinyl, 4-cyclopropyl-2-dioxo-1-piperazinyl, 2-dioxomorpholinyl or 2-dioxothiomorpholinyl; (C1-C4)alkoxy group such as allyloxy, methoxy, ethoxy, n-propoxy, n-butoxy or tert-butoxy; RaRbamino(C1-C4)alkoxy group, wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or RaRb is (CH2)n, n=2-6, or (CH2)2W(CH2)2 wherein W is selected from N(C1-C3)alkyl [straight or branched], NH, NOB [B is selected from hydrogen or (C1-C3)alkyl], O or S; or RaRbaminoxy group, wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or RaRb is (CH2)n, n=2-6, or (CH2)2W(CH2)2 wherein W is selected from N(C1-C3)alkyl [straight or branched], NH, NOB [B is selected from hydrogen or (C1-C3)alkyl], O or S; α-hydroxy(C1-C3)alkyl group selected from hydroxymethyl, α-hydroxyethyl or α-hydroxy-1-methylethyl or α-hydroxypropyl; halo(C1-C3)alkyl group such as bromomethyl, fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, 2-fluoroethyl, 2,2-difluoroethyl, 2,2,2-trifluoromethyl, 2-bromoethyl or 2-iodoethyl; (C1-C4)alkoxycarbonylamino group selected from tert-butoxycarbonylamino, allyloxycarbonylamino, methoxycarbonylamino, ethoxycarbonylamino or propoxycarbonylamino;

and when R═R4′(CH2)nSO2 and n=0, R4′ is selected from amino; monosubstituted amino selected from as straight or branched (C1-C6)alkylamino, cyclopropylamino, cyclobutylamino, benzylamino or phenylamino; disubstituted amino selected from dimethylamino, diethylamino, ethyl(1-methylethyl)amino, monomethylbenzylamino, piperidinyl, morpholinyl, 1-imidazolyl, 1-pyrrolyl, 1-(1,2,3-triazolyl) or 4-(1,2,4-triazolyl); straight or branched (C1-C2)alkyl group selected from methyl or ethyl; (C6-C10)aryl group selected from phenyl, α-naphthyl or β-naphthyl; substituted (C6-C10)aryl group (substitution selected from halo, (C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); a heterocycle group selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:


such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl, or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:
such as imidazolyl, pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, indazolyl, thiazolyl, benzothiazolyl, 3-alkyl-3H-imidazo[4,5-b]pyridyl or pyridylimidazolyl, or a five membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom:
(A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo,(C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl) such as γ-butyrolactam, γ-butyrolactone, imidazolidinone or N-aminoimidazolidinone, or a six membered aromatic ring with one to three N, O, S or Se heteroatoms such as pyridyl, pyridazinyl, pyrazinyl, sym-triazinyl, unsym-triazinyl, pyrimidinyl or (C1-C3)alkylthiopyridazinyl, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom such as 2,3-dioxo-1-piperazinyl, 4-ethyl-2,3-dioxo-1-piperazinyl, 4-methyl-2,3-dioxo-1-piperazinyl, 4-cyclopropyl-2-dioxo-1-piperazinyl, 2-dioxomorpholinyl or 2-dioxothiomorpholinyl; and when R═R4′ (CH2)nSO2 and n=1-4, R4′ is selected from hydrogen; straight or branched (C1-C2)alkyl group selected from methyl or ethyl; R5 is selected from hydrogen; straight or branched (C1-C3)alkyl group selected from methyl, ethyl, n-propyl or 1-methylethyl; (C6-C10)aryl group selected from phenyl, α-naphthyl or β-naphthyl; (C7-C9)aralkyl group such as benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl; a heterocycle group selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:
such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl, or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:
such as imidazolyl, pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, indazolyl, thiazolyl, benzothiazolyl, 3-alkyl-3H-imidazo[4,5-b]pyridyl or pyridylimidazolyl, or a five membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom:
(A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo,(C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)

such as γ-butyrolactam, γ-butyrolactone, imidazolidinone or N-aminoimidazolidinone, or a six membered aromatic ring with one to three N, O, S or Se heteroatoms such as pyridyl, pyridazinyl, pyrazinyl, sym-triazinyl, unsym-triazinyl, pyrimidinyl or (C1-C3)alkylthiopyridazinyl, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom such as 2,3-dioxo-1-piperazinyl, 4-ethyl-2,3-dioxo-1-piperazinyl, 4-methyl-2,3-dioxo-1-piperazinyl, 4-cyclopropyl-2-dioxo-1-piperazinyl, 2-dioxomorpholinyl, 2-dioxothiomorpholinyl; or (CH2)nCOOR7 where n=0-4 and R7 is selected from hydrogen; straight or branched (C1-C3)alkyl group selected from methyl, ethyl, n-propyl or 1-methylethyl; or (C6-C10)aryl group selected from phenyl, α-naphthyl, β-naphthyl;

R6 is selected from hydrogen; straight or branched (C1-C3)alkyl group selected from methyl, ethyl, n-propyl or 1-methylethyl; (C6-C10)aryl group selected from phenyl, α-naphthyl or β-naphthyl; (C7-C9)aralkyl group such as benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl; a heterocycle group selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:


such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl, or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:
such as imidazolyl, pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, indazolyl, thiazolyl, benzothiazolyl, 3-alkyl-3H-imidazo[4,5-b]pyridyl or pyridylimidazolyl, or a five membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom:
(A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo,(C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)

such as γ-butyrolactam, γ-butyrolactone, imidazolidinone or N-aminoimidazolidinone, or a six membered aromatic ring with one to three N, O, S or Se heteroatoms such as pyridyl, pyridazinyl, pyrazinyl, sym-triazinyl, unsym-triazinyl, pyrimidinyl or (C1-C3)alkylthiopyridazinyl, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom such as 2,3-dioxo-1-piperazinyl, 4-ethyl-2,3-dioxo-1-piperazinyl, 4-methyl-2,3-dioxo-1-piperazinyl, 4-cyclopropyl-2-dioxo-1-piperazinyl, 2-dioxomorpholinyl, 2-dioxothiomorpholinyl; or (CH2)nCOOR7′ where n=0-4 and R7′ is selected from hydrogen; straight or branched (C1-C3)alkyl selected from methyl, ethyl, n-propyl or 1-methylethyl; or (C6-C10)aryl selected from phenyl, α-naphthyl or β-naphthyl; with the proviso that R5 and R6 cannot both be hydrogen; or R5 and R6 taken together are (CH2)2W(CH2)2, wherein W is selected from (CH2)n and n=0-1, NH, N(C1-C3)alkyl [straight or branched], N(C1-C4)alkoxy, oxygen, sulfur or substituted congeners selected from (L or D)proline, ethyl(L or D)prolinate, morpholine, pyrrolidine or piperidine; and the pharmacologically acceptable organic and inorganic salts or metal complexes.

Compounds of special interest are compounds according to the above formula III and IV in which Y is NO2;

R is selected from R4(CH2)nCO or R4′(CH2)nSO2; and when R═R4(CH2)nCO and n=0, R4 is selected from hydrogen; straight or branched (C1-C2)alkyl group selected from methyl or ethyl; a heterocycle group selected from a five membered aromatic or saturated ring with one N, O, or S heteroatom optionally having a benzo or pyrido ring fused thereto:


such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl, or a five membered aromatic ring with two N, O, or S heteroatoms optionally having a benzo or pyrido ring fused thereto:
such as imidazolyl, pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, indazolyl, thiazolyl, benzothiazolyl, 3-alkyl-3H-imidazo[4,5-b]pyridyl or pyridylimidazolyl, or a five membered saturated ring with one or two N, O or S heteroatoms and an adjacent appended O heteroatom:
(A is selected from hydrogen; straight or branched (C1-C2)alkyl; C6-aryl)

such as γ-butyrolactam, γ-butyrolactone, imidazolidinone or N-aminoimidazolidinone; (C1-C4)alkoxycarbonyl group selected from methoxycarbonyl, ethoxycarbonyl, straight or branched propoxylcarbonyl, straight or branched butoxycarbonyl or allyloxycarbonyl; vinyl or substituted vinyl group [substitution selected from (C1-C2)alkyl group, (C6-C10)aryl group selected from phenyl, α-naphthyl, β-naphthyl, substituted (C6-C10)aryl group (substitution selected from halo, (C1-C4)alkoxy, (C1-C4)alkoxycarbonyl), halo(C1-C3)alkyl group such as bromomethyl, fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, 2-fluoroethyl, 2,2-difluoroethyl, 2,2,2-trifluoroethyl, 2-bromoethyl or 2-iodoethyl, (C1-C4)alkoxy group such as allyloxy, methoxy, ethoxy, n-propoxy, n-butoxy or tert-butoxy; C6-aryloxy group selected from phenoxy or substituted phenoxy (substitution selected from halo, (C1-C4)alkyl); (C7-C10)aralkyloxy group such as benzyloxy, 1-phenylethyloxy or 2-phenylethyloxy; vinyloxy or substituted vinyloxy group (substitution selected from (C1-C2)alkyl); RaRbamino (C1-C4)alkoxy group, wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl; or RaRbaminoxy group, wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl; and when R═R4(CH2)nCO and n=1-4, R4 is selected from hydrogen; (C1-C2)alkyl group selected from methyl or ethyl; amino; monosubstituted amino selected from straight or branched (C1-C6)alkylamino, cyclopropylamino, cyclobutylamino, benzylamino or phenylamino; disubstituted amino selected from dimethylamino, diethylamino, ethyl(1-methylethyl)amino, monomethylbenzylamino, piperidinyl, morpholinyl, 1-imidazolyl, 1-pyrrolyl, or 1-(1,2,3-triazolyl); (C6-C10)aryl group selected from phenyl, α-naphthyl or β-naphthyl; substituted(C6-C10)aryl group (substitution selected from halo, (C1-C4)alkoxy, nitro, amino, (C1-C4)alkoxycarbonyl); acyloxy or haloacyloxy group selected from acetyl, propionyl or chloroacetyl; (C1-C4)alkoxy group such as allyloxy, methoxy, ethoxy, n-propoxy, n-butoxy or tert-butoxy; RaRbamino(C1-C4)alkoxy group, wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or RaRb is (CH2)n, n=2-6, or (CH2)2W(CH2)2 wherein W is selected from N(C1-C3)alkyl [straight or branched], NH, NOB [B is selected from hydrogen or (C1-C3)alkyl], O or S; or RaRbaminoxy group, wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or RaRb is (CH2)n, n=2-6, or (CH2)2W(CH2)2 wherein W is selected from N(C1-C3)alkyl [straight or branched], NH, NOB [B is selected from hydrogen or (C1-C3)alkyl], O or S; halo(C1-C3)alkyl group such as bromomethyl, fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, 2-fluoroethyl, 2,2-difluoroethyl, 2,2,2-trifluoromethyl, 2-bromoethyl or 2-iodoethyl; (C1-C4)alkoxycarbonylamino group selected from tert-butoxycarbonylamino, allyloxycarbonylamino, methoxycarbonylamino, ethoxycarbonylamino or propoxycarbonylamino;

and when R═R4′(CH2)nSO2 and n=0, R4′ is selected from straight or branched (C1-C2)alkyl group selected from methyl or ethyl; (C6-C10)aryl group selected from phenyl, α-naphthyl or β-naphthyl; subsituted (C6-C10)aryl group (substitution selected from halo, (C1-C4)alkoxy, nitro, (C1-C4)alkoxycarbonyl); a heterocycle group selected from a five membered aromatic or saturated ring with one N, O or S heteroatom optionally having a benzo or pyrido ring fused thereto:


such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl, or a five membered aromatic ring with two N, O or S heteroatoms optionally having a benzo or pyrido ring fused thereto:
such as imidazolyl, pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, indazolyl, thiazolyl, benzothiazolyl, 3-alkyl-3H-imidazo[4,5-b]pyridyl or pyridylimidazolyl; and when R═R4′(CH2)nSO2 and n=1-4, R4′ is selected from hydrogen; straight or branched (C1-C2)alkyl group selected from methyl or ethyl; R5 is selected from hydrogen; straight or branched (C1-C3)alkyl group selected from methyl, ethyl, n-propyl or 1-methylethyl;

R6 is selected from hydrogen; straight or branched (C1-C3)alkyl group selected from methyl, ethyl, n-propyl or 1-methylethyl; with the proviso that R5 and R6 cannot both be hydrogen; or R5 and R6 taken together are (CH2)2W(CH2)2, wherein W is selected from (CH2)n and n=0-1, NH, N(C1-C3)alkyl [straight or branched], N(C1-C4)alkoxy, oxygen, sulfur or substituted congeners selected from (L or D)proline, ethyl(L or D)prolinate, morpholine, pyrrolidine or piperidine; and the pharmacologically acceptable organic and inorganic salts or metal complexes.

DESCRIPTION OF THE PREFERRED EMBODIMENTS

The novel compounds of the present invention may be readily prepared in accordance with the following schemes.

The starting 7-(substituted amino)-6-demethyl-6-deoxytetracyclines described in formula 1, wherein X═NR1R2 and R1═R2 (1a) and X=NHR1 (1b) or the salts thereof are prepared by procedures known to those skilled in the art including those described in U.S. Pat. Nos. 3,226,436 and 3,518,306.

The starting 7-(substituted amino)-6-demethyl-6-deoxytetracyclines described in formula 1 wherein X═NR1R2 and R1═R2 (1c) are prepared according to Scheme 1.


In accordance with Scheme 1, a 7-(monoalkylamino)-6-demethyl-6-deoxytetracycline, 1b, in which X═NHR1 is reductively alkylated with an aldehyde to give an unsymmetrical dialkylamino, 1c.

In accordance with Scheme II, a 7-(substituted amino)-6-demethyl-6-deoxytetracycline or its salts, 1a or 1c, is treated with

a) a metal nitrate salt; such as calcium, potassium or sodium; and a strong acid; such as sulfuric acid, trifluoroacetic acid, methanesulfonic acid or perchloric acid or

b) nitric acid and a strong acid; such as sulfuric acid, trifluoroacetic acid, methanesulfonic acid or perchloric acid; to form the corresponding 7-(substituted amino)-9-nitro-6-demethyl-6-deoxytetracycline 2.

To produce the 9-(amino)-7-(substituted amino)-6-demethyl-6-deoxytetracyclines, 3, compound 2 or its salts is treated with hydrogen in an acidic alcohol solvent, in the presence of a suitable catalyst such as, for example:

a) any supported catalyst; such as 0.5-23% palladium-on-carbon, 0.5-25% palladium-on-barium, 0.5-25% platinum-on-carbon or 0.5-25% rhodium-on-carbon;

b) any reducible supported catalyst; such as Raney nickle or platinum oxide; or

c) a homogeneous hydrogenation catalyst; such as tris(triphenylphosphine)rhodium (I) chloride; to obtain the 9-amino-7-(substituted amino)-6-demethyl-6-deoxytetracycline, 3.

Alternatively, the 9-(amino)-7-(substituted amino)-6-demethyl-6-deoxytetracyclines, 3, are obtained by treating with:

a) stannous chloride dihydrate as described by R. B. Woodward, Org. Syn., Coll. Vol. 3,453 (1955);

b) a soluble metal sulfide, preferably sodium sulfide, in alcoholic solvents as described by G. R. Robertson, Org. Syn., Coll. Vol. 1, 52 (1941);

c) an active metal in mineral acid; such as iron, tin or zinc in dilute hydrochloric acid;

d) active metal couples; such as copper-zinc, tin-mercury or aluminum amalgam in dilute acid; or

e) transfer hydrogenation using triethylammonium formate and a supported catalyst as described by I. D. Entwistle et al., J. Chem. Soc., Perkin 1, 443 (1977).

Preferably, the 9-(amino)-7-(substituted amino)-6-demethyl-6-deoxytetracyclines, 3, are obtained as inorganic salts such as hydrochloric, hydrobromic, hydroiodic, phosphoric, nitric or sulfate.

SCHEME III

In accordance with Scheme III, a 9-(amino)-7-(substituted amino)-6-demethyl-6-deoxytetracycline or its salts, 3, is treated with an acyl chloride, acyl anhydride, mixed acyl anhydride, sulfonyl chloride or sulfonyl anhydride in the presence of a suitable acid scavenger in a variety of solvents to form the corresponding 9-(acyl or sulfonyl amino)-7-(substituted amino)-6-demethyl-6-deoxytetracycline, 4. The acid scavenger is selected from sodium bicarbonate, sodium acetate, pyridine, triethylamine, N,O-bis(trimethylsilyl)acetamide, N,O-bis(trimethylsilyl)trifluoroacetamide or a basic ion-exchange resin. The solvents are selected from water-tetrahydrofuran, N-methylpyrrolidone, 1,3-dimethyl-2-imidazolidione, hexamethylphosphoramide, 1,3-dimethyl-3,4,5,6-tetrahydro- 2(1H)-pyrimidinone or 1,2-dimethoxyethane.

Alternatively, in accordance with Scheme III, a 9-acylamino)-6-demethyl-6-deoxytetracycline, 5a, prepared by the procedures described in U.S. Pat. No. 3,239,499, or a 9-(sulfonylamino)-6-demethyl-6-deoxytetracycline, 5b, prepared by the procedures described in this invention, is treated with a halogenation agent such as bromine, N-bromoacetamide, N-bromosuccinimide, iodine monochloride, benzyltrimethylammonium chloride iodine monochloride complex or N-iodosuccinimide to give the corresponding 9-(acyl or sulfonylamino)-7-halo-6-demethyl-6-deoxytetracycline, 6.

Similarly, compound 5a or 5b can be treated with:

    • a) a metal nitrate such as calcium, potassium or sodium; and a strong acid such as sulfuric, trifluoroacetic, methanesulfonic acid or trifluoromethanesulfonic; or
    • b) nitric acid and a strong acid such as sulfuric, trifluoroacetic, methanesulfonic, trifluoromethanesulfonic or perchloric acid to give the corresponding 9-(acyl or sulfonyl amino)-7-nitro-6-demethyl-6-deoxytetracycline, 7.

In accordance with Scheme IV, a 9-(acyl or sulfonyl amino)-7-nitro-6-demethyl-6-deoxytetracycline, 7, is selectively N-alkylated with aldehydes or ketones in the presence of acid and hydrogen to the corresponding 7,9-di(substituted amino)-6-demethyl- 6-deoxytetracycline, 8, by methodology known to those skilled in the art (U.S. Pat. Nos. 3,226,436 and 3,518,306).

In accordance with Scheme V, Compounds 4,6,7, or 8 are selectively N-alkylated in the presence of formaldehyde and either a primary amine such as methylamine, ethylamine, benzylamine, methyl glycinate, (L or D)lysine, (L or D)alanine or their substituted congeners; or a secondary amine such morpholine, pyrrolidine, piperidine or their substituted congeners to give the corresponding Mannich base adduct, 9,10,11 or 12, or the desired intermediate or of the biologically active 7-(substituted)-9-(substituted amino)-6-demethyl- 6-deoxytetracyclines. Contempleted equivalents include those substituted morpholine, pyrrolidine or piperidine moieties wherein the substituents are chosen to provide the requisite increase in solubility without adversely affecting antibacterial activity.

The 7-(substituted)-9-(substituted amino)-6-demethyl-6-deoxytetracyclines may be obtained as metal complexes such as aluminum, calcium, iron, magnesium, mamganese and complex salts; inorganic and organic salts and corresponding Mannich base adducts using methods known to those skilled in the art (Richard C. Larock, Comprehensive Organic Transformations, VCH Publishers, 411-415, 1989). Preferably, the 7-(substituted)- 9-(substituted amino)-6-demethyl-6-deoxytetracyclines are obtained as inorganic salts such as hydrochloric, hydrobromic, hydroiodic, phosphoric, nitric or sulfate; or organic salts such as acetate, benzoate, citrate, cysteine or other amino acids, fumarate, glycolate, maleate, succinate, tartrate alkylsulfonate or aryl-sulfonate. In all cases, the salt formation occurs with the C(4)-dimethylamino group. The salts are preferred for oral and parenteral administration.

BIOLOGICAL ACTIVITY Methods for in Vitro antibacterial evaluation (Tables I-V)

The minimum inhibitory concentration (MIC), the lowest concentration of the antibiotic which inhibits growth of the test organism, is determined by the agar dilution method using 0.1 ml Muller-Hinton II agar (Baltimore Biological Laboratories) per well. An inoculum level of 1−5105 CFU/ml, and a range of anitbiotic concentrations (32-0,004 μg/ml) is used. MIC is determined after the plates are incubated for 18 hours at 35 C. in a forced air incubator. The test organisms comprise genetically defined strains that are sensitive to tetracycline and resistant strains that are insensitive to tetracycline, either by preventing the antibiotic from interacting with bacterial ribosomes (tetM) or by a tetK encoded membrane protein which confers tetracycline resistance by energy-dependent efflux of the antibiotic from the cell. E. coli in Vitro Protein translation System (Table VI)

An in vitro, cell free, protein translation system using extracts from E. coli strain MRE 600 (tetracycline-sensitive) and a derivative of MRE 600 containing the tetM determinant has been developed based on literature methods. [J. M. Pratt, Coupled TranScription-translation in Prokaryotic Cell-free Systems, Transcription and Translation, a Practical Approach, (B. D. Hames and S. J, Higgins, eds.) p. 179-209, IRL Press, Oxford-Washington, 1984]

The antibiotics are added to exponentially growing cultures of tetracycline-susceptible E. coli at growth inhibitory concentrations. After 30 minutes, excess antibiotic is removed from the bacteria by centrifugation and the organism is resuspended in fresh growth medium. The ability of bacteria to resume growth is monitored. Washing of inhibited cells alleviates growth inhibition due to chlortetracycline, but not that caused by polymyxin. This reflects the different binding characteristics of the drugs. Chlortetracycline binds reversibly to bacterial ribosomes, while polymyxin remains tightly associated with its target, the cytoplasmic membrane, and continues to prevent bacterial growth even when excess antibiotic is removed.

In Vivo Antibacterial Evaluation (Table VII)

The therapeutic effects of tetracyclines are determined against acute lethal infections with various staphylococcal and E. coli strains. Female mice, strain CD-1 (Charles River Laboratories), 202 grams, are challenged by an intraperitoneal injection of sufficient bacteria (suspended in broth or hog mucin) to kill non-treated controls within 24-48 hours. Antibacterial agents, contained in 0.5 ml of 0.2% aqueous agar, are administered subcutaneously or orally 30 minutes after infection. When an oral dosing schedule is used, animals are deprived of food for 5 hours before and 2 hours after infection. Five mice are treated at each does level. The 7 day survival ratios from 3 separate tests are pooled for calculation of median effective dose (ED50).

E. coli in vitro Protein Translation System(Table VIII)

An in vitro, cell free, protein translation system using extracts from E. coli stain MRE600 (tetracycline sensitive) and a derivative of MRE600 containing the tetM determinant has been developed based on literature methods [J. M. Pratt, Coupled Transcription-translation in Prokaryotic Cell-free Systems, Transcription and Translation, a Practical Approach, (B. D. Hames and S. J. Higgins, eds) p. 179-209, IRL Press, Oxford-Washington, 1984].

Using the systems described above, the novel tetracycline compounds of the present invention are tested for their ability to inhibit protein synthesis in vitro. Briefly, each 10μl reaction contains S30 extract (a whole extract) made from either tetracycline sensitive cells or an isogenic tetracycline resistant (tetM) strain, low molecular weight components necessary for transcription and translation (i.e. ATP and GTP), a mix of 19 amino acids (no methionine), 35S labeled methionine, DNA template (either pBR322 or pUC119), and either DMSO (control) or the novel tetracycline compound to be tested (Novel Tc) dissolved in DMSO.

The reactions are incubated for 20 minutes at 37 C. Timing is initiated with the addition of the S30 extract, the lase component to be added. After 30 minutes, 2.5 μl of the reaction is remobed and mixed with 0.5 ml of 1N NaOH to destroy RNA and tRNA. Two ml of 25% trichloroacetic acid is added and the mixture incubated at room temperature for 15 minutes. The trichloracetic acid precipitated material is collected on Whatman GF/C filters and washed with a solution of 10% trichloracetic acid. The filters are dried and the retained radioactivity, representing incorporation of 35S-methionine into polypeptides, is counted using standard liquid scintillation methods.

The percent inhibition (P.I.) of protein synthesis is determined to be: P . I . = 100 - [ Retained radioactivity of Novel TC containing sample Retained radioactivity of the DMSO control reaction ] 100

Testing Results

The claimed compounds exhibit antibacterial activity against a spectrum of tetracycline sensitive and resistant Gram-positive and Gram-negative bacteria, especially, strains of E. coli, S. aureus and E. faecalis, containing the tetM resistance determinants (Table I). Notable is 7-(dimethylamino)-9-(formylamino)- 6-demethyl-6-deoxytetracycline, as shown in Tables I and IV, which has good in vitro activity against tetracycline resistant strains containing the tetM resistance determinant (such as S. aureus UBMS 88-5, S. aureus UBMS 90-1 and 90-2, E. coli UBMS 89-1 and 90-4) and is equally as effective as minocycline against susceptible strains.

7-(Dimethylamino)-9-(formylamino)-6-demethyl- 6-deoxytetracycline demonstrates effective activity against minocycline susceptible stains including a variety of recently isolated bacteria from clinical sources (Table V). With the exception of some Protens spp., 7-(dimethylamino)-9-(formylamino)-6-demethyl-6-deoxytetracycline's activity is superior to that of minocycline against other isolates.

Protein synthesis, directed by cell-free extracts from the tetracycline susceptible strain MRE-600, are inhibited by tetracycline, minocycline and the 7-(dimethylamino)-9-(formylamino)-6-demethyl-6-deoxytetracycline of this invention (Table 6). Protein synthesis, directed by cell-free extracts from strain MRE 600 (tetM), is resistant to tetracycline and minocycline, since 50% inhibition of protein synthesis required addition of approximately 5-fold more antibiotic than in extracts prepared from stain MRE 600 (Table VI). However, in contrast, 7-(dimethylamino)-9-(formylamino)-6-demethyl-6-deoxytetracycline effectively inhibited protein synthesis in extracts prepared from either MRE 600 or MRE 600 (tetM) (Table VI). The evidence presented indicates that 7-(dimethylamino)-9-(formylamino)- 6-demethyl-6-deoxy-tetracycline is an inhibitor of protein synthesis at the ribosome level. The ability of 7-(dimethylamino)-9-(formylamino)-6-demethyl-6-deoxytetracycline to inhibit bacterial growth almost certainly reflects directed inhibition of bacterial synthesis. If so, then it is expected, like other tetracyclines, to exhibit a bacteriostatic effect against susceptible bacteria.

7-(Dimethylamino)-9-(formylamino)-6-demethyl- 6-deoxytetracycline binds reversibly to its target (the fibosome) since bacterial growth resumed when the compound was removed from the cultures by washing of the organism. Therefore, the ability of 7-(dimethylamino)- 9-(formylamino)-6-demethyl-6-deoxytetracycline to inhibit bacterial growth appears to be a direct consequence of its ability to inhibit protein synthesis at the ribosome level.

The enhanced activity (Table VII) of 7-(dimethylamino)-9-(formylamino)-6-demethyl-6-deoxytetracycline against tetracycline susceptible and resistant organisms (tetM) is also demonstrated in vivo in animals infected with S. aureus UBMS 90-1 and 90-2. The ED50's (Table VII) obtained for 7-(dimethylamino)- 9-(formylamino)-6-demethyl-6-deoxytetracycline are lower than those of minocycline.

The improved efficacy of 7-(dimethylamino)- 9-(formylamino)-6-demethyl-6-deoxytetracycline is demonstrated by the in vitro activity against isogenic strains into which the resistance determinants, such as tetM, were cloned (Tables I-IV); the inhibition of protein synthesis by tetM ribosomes (Table VI); and the in vivo activity against experimental infections caused by strains resistant to the tetracylcines, due to the presence of resistance determinants, such as tetM (Table VII).

As can be seen from Tables I-V, compounds of the invention may be used to prevent or control important veterinary diseases such as mastitis, diarrhea, urinary tract infections, skin infections, ear infections, wound infections and the like.

LEGEND FOR COMPOUNDS
LETTER NAME
A 7-(Dimethylamino)-9-(formylamino)-6-demethyl-6-de-
oxytetracyline
B 9-(Acetylamino)-7-(dimethylamino)-6-demethyl-6-de-
oxytetracylcine
C 7-(Diethylamino)-9-(formylamino)-6-demethyl-6-de-
oxytetracyline
D 7-(Diethylamino)-9-(formylamino)-6-demethyl-6-de-
oxytetracycline disulfate
E 9-(Acetylamino)-7-(diethylamino)-6-demethyl-6-de-
oxytetracycline disulfate
F 9-(Acetylamino)-7-(diethylamino)-6-demethyl-6-de-
oxytetracycline
G 9-(Formylamino)-7-iodo-6-demethyl-6-deoxytetracyc-
line sulfate
H 9-(Acetylamino)-7-iodo-6-demethyl-6-deoxytetracyc-
line sulfate
I 7-(Dimethylamino)-9[(trifluoroacetyl)amino]-6-de-
methyl-6-deoxytetracycline sulfate
J 7-(Dimethylamino)-9-[[(phenylmethoxy)acetyl]-
amino]-6-demethyl-6-deoxytetracycline
K 9-[[(Acetyloxy)acetyl]amino]-7-(dimethylamino)-6-
demethyl-6-deoxytetracycline
L 7-(Dimethylamino)-9-[(hydroxyacetyl)amino]-6-de-
methyl-6-deoxytetracycline
M 9-[(Aminoacetyl)amino]-7-(dimethylamino)-6-demeth-
yl-6-deoxytetracycline mono(trifluoroacetate)
N (7S-(7α,10aα)]-[[9-(aminocarbonyl)-7-(dimethyl-
amino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-
tetrahydroxy-10,12-dioxo-2-naphthacenyl]amino]-
oxoacetic acid ethyl ester
O 7-(Dimethylamino)-6-demethyl-6-deoxytetracycline
hydrochloride (minocycline hydrochloride)
P 9-(Benzoylamino)-7-(dimethylamino)-6-demethyl-6-
deoxytetracycline
Q 7-(Dimethylamino)-9-[(4-methoxybenzoyl)amino]-6-
demethyl-6-deoxytetracycline
R 7-(Dimethylamino)-9-[(2-methylbenzoyl)amino]-6-de-
methyl-6-deoxytetracycline
S 7-(Dimethylamino)-9-[(2-fluorobenzoyl)amino]-6-de-
methyl-6-deoxytetracycline
T 7-(Dimethylamino)-9-[(pentafluorobenzoyl)amino]-6-
demethyl-6-deoxytetracycline
U 7-(Dimethylamino)-9-[[3-(trifluoromethyl)benzoyl]-
amino]-6-demethyl-6-deoxytetracycline
V 7-(Dimethylamino)-9-[(4-nitrobenzoyl)amino]-6-de-
methyl-6-deoxytetracycline
W 7-(Dimethylamino)-9-[[(4-dimethylamino)benzoyl]-
amino]-6-demethyl-6-deoxytetracycline
X 9-[(4-Aminobenzoyl)amino]-7-(dimethylamino)-6-de-
methyl-6-deoxytetracycline sulfate
Y 7-(Dimethylamino)-9-[(2-furanylcarbonyl)amino]-6-
demethyl-6-deoxytetracycline
Z 7-(Dimethylamino)-9-[(2-thienylcarbonyl)amino]-6-
demethyl-6-deoxytetracycline
AA 7-(Dimethylamino)-9-[[(4-nitrophenyl)sulfonyl)-
amino]-6-demethyl-6-deoxytetracycline
BB 7-(Dimethyl)-9-[(3-nitrophenyl)sulfonyl]-
amino]-6-demethyl-6-deoxytetracycline
CC 7-(Dimethylamino)-9-[(phenylsulfonyl)amino]-6-de-
methyl-6-deoxytetracycline
DD 7-(Dimethylamino)-9-[(2-thienylsulfonyl)amino]-6-
demethyl-6-deoxytetracycline
EE 9-[[(4-Chlorophenyl)sulfonyl]amino]-7-(dimethyl-
amino)-6-demethyl-6-deoxytetracycline
FF 7-(Dimethylamino)-9-[(methylsulfonyl)amino)-6-de-
methyl-6-deoxytetracycline
GG 9-[[[(2-Acetylamino)-4-methyl-5-thiazolyl]sulfon-
yl]amino]-7-(dimethylamino)-6-demethyl-6-deoxyte-
tracycline
HH [7S-(7α,10aα)]-[9-(Aminocarbonyl)-4,7-bis(dimeth-
ylamino)-5,5a,6,6a,8,10,10a,12-octahydro-1,8,10a-
11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]car-
bamic acid methyl ester
II 7-(Dimethylamino)-9-([(dimethylamino)acetyl]-
amino)-6-demethyl-6-deoxytetracycline sulfate
TC Tetracycline hydrochloride
JJ (4S-(4alpha,12aalpha)]-4,7-Bis(dimethylamino)-9-
[[(dimethylamino)acetyl)amino)-1,4,4a,5,5a,6,11-
12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-
2-naphthacenecarboxamide disulfate
KK [4S-(4alpha,12aalpha)]-4,7-Bis(dimethylamino)-9-
[[(dimethylamino)acetyl)amino]-1,4,4a,5,5a,6,11-
12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-di-
oxo-2-naphthacenecarboxamide dihydrochloride
LL [4S-(4alpha,12aalpha)]-4,7-Bis(dimethylamino)-9-
[[dimethylamino)acetyl]amino]-1,4,4a,5,5a,6,11,-
12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-
2-naphthacenecarboxamide
MM [4S-(4alpha,12aalpha)]-4,7-Bis(dimethylamino)-1,
4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahy-
droxy-9-[[(methylamino)acetyl]amino]-1,11-dioxo-
2-naphthacenecarboxamide dihydrochloride
NN [7S-(7alpha,10aalpha)]-N-[9-(Aminocarbonyl)-4,
7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octa-
hydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naph-
thacenyl]-4-morpholineacetamide dihydrochloride
OO [4S-(4alpha,12aalpha)]-4,7-Bis(dimethylamino)-9-
[[(ethylamino)acetyl]amino)-1,4,4a,5,5a,6,11,12a-
octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-
2-naphthacenecarboxamide dihydrochloride
PP [4S-(4alpha,12aalpha)]-4,7-Bis(dimethylamino)-9-
[[(butylamino)actyl]amino]-1,4,4a,5,5a,6,11,12a-
octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-
naphthacenecarboxamide dihydrochloride
QQ [(4S-(4alpha,12aalpha)]-9[[(Cyclopropylamino)acetyl)-
amino]-4,7-Bis(dimethylamino)-1,4,4a,5,5a,6,11,-
12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-
2-naphthacenecarboxamide dihydrochloride
RR [4S-(4alpha,12aalpha)]-9-[[(Diethylamino)acetyl)-
amino]-4,7-Bis(dimethylamino)-1,4,4a,5,5a,6,11-
12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-
2-naphthacenecarboxamide dihydrochloride
SS (7S-(7alpha,10aalpha)]-N-[9-(Aminocarbonyl)-4,7-
bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro
1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacen-
yl]-1-pyrrolidineacetamide dihydrochloride
TT [4S-(alpha,12aalpha)]-4,7-Bis(dimethylamino)-1,4,
4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-
9-[[[(2-methylpropyl)amino]acetyl]amino]-1,11-
dioxo-2-naphthacenecarboxamide dihydrochloride
UU (7S-(7alpha,10aalpha)]-N-[9-(Aminocarbonyl)-4,-
7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahy-
dro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphtha-
cenyl)-1-piperidineacetamide dihydrochloride
VV [7S-(7alpha,10aalpha)]-N-[9-(Aminocarbonyl)-4,-
7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahy-
dro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naph-
thacenyl]-1H-imidazole-1-acetamide dihydrochloride
WW [4S-(4alpha,12aalpha)]-4,7-bis(dimethylamino)-1,4,
4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-
1,11-dioxo-9-[[(propylamino)acetyl]amino]-2-
naphthacenecarboxamide dihydrochloride
XX [4S-(4alpha,12aalpha)]-4,7-Bis(dimethylamino)-9-
([2-(dimethylamino)-1-oxopropyl]amino)-1,4,4a,5,
5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,
11-dioxo-2-naphthacenecarboxamide dihydrochloride
YY [4S-(4alpha,12aalpha)]-4,7-Bis(dimethylamino)-1,4,
4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-
9-[[2-(methylamino)-1-oxopropyl]amino]-1,11-
dioxo-2-naphthacenecarboxamide dihydrochloride
ZZ [4S-(4alpha,12aalpha)]-4,7-Bis(dimethylamino)-9-
[[4-(dimethylamino)-1-oxobutyl]amino]-1,4,4a,5,
5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,
11-dioxo-2-naphthacenecarboxamide dihydrochloride
AAA [7S-(7alpha,10aalpha)]-N-[9-(Aminocarbonyl)-4,7-
bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahy-
dro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naph-
thacenyl)-alpha-methyl-1-pyrrolidineacetamide di-
hydrochloride
BBB [4S-(4alpha,12aalpha)]-4,7-Bis(dimethylamino)-9-
[[(hexylamino)acetyl]amino]-1,4,4a,5,5a,6,11,12a-
octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-
naphthacenecarboxamide dihydrochloride
CCC [4S-(4alpha,12aalpha)]-9-[[(Butylmethylamino)-
acetyl]amino]-4,7-Bis(dimethylamino)-1,4,4a,5,5a,
6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-
dioxo-2-naphthacenecarboxamide dihydrochloride
DDD [4S-(4alpha,12aalpha)]-4,7-Bis(dimethylamino)-1,4,
4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-
1,11-dioxo-9-[[(pentylamino)acetyl]amino]-2-
naphthacenecarboxamide dihydrochloride
EEE [4S-(4alpha,12aalpha)]-4,7-Bis(dimethylamino)-1,4,
4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahy-
droxy-1,11-dioxo-9-[[[(phentylmethyl)amino]acetyl]-
amino]-2-naphthacenecarboxamide dihydrochloride
FFF [4S-(4alpha,12aalpha)]-4,7-Bis(dimethylamino)-9-
[[(dimethylamino)acetyl]amino]-1,4,4a,5,5a,6,11,
12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-
N-(1-pyrrolidinylmethyl)-2-naphthacenecarboxamide
GGG [4S-(4alpha,12aalpha)]-4,7-Bis(dimethylamino)-9-
[[[(dimethylamino)acetyl]amino]-1,4,4a,5,5a,6,11,
12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-
N-(4-morpholinylmethyl)-2-naphthacenecarboxamide
HHH [4S-(4alpha,12aalpha)]-4,7-Bis(dimethylamino)-9-
[[(dimethylamino)acetyl]amino]-1,4,4a,5,5a,6,11,
12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-
N-(1-piperidinylmethyl)-2-naphthacenecarboxamide
III [4S-(4alpha,12aalpha)]-9-[(Bromoacetyl]amino]-4,-
7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahy-
dro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naph-
thacenecarboxamide dihydrochloride
JJJ [4S-(4alpha,12aalpha)]-9-[(2-Bromo-1-oxopropyl)-
amino]-4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,
12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-
2-naphthacenecarboxamide hydrobromide
KKK [7S-(7alpha,10aalpha)-N-[2-[[9-(Aminocarbonyl)-4,-
7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahy-
dro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphtha-
cenyl]amino]-2-oxoethyl]glycine
LLL [7S-(7alpha,10aalpha)]-N-[9-(Aminocarbonyl)-4,7-
bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahy-
dro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphtha-
cenyl)-1-azetidenacetamide
MMM (4S-(4alpha-12aalpha)]-9-[[(Cyclobutylamino)ace-
tyl]amino]-4,7-Bis(dimethylamino)-1,4,4a,5,5a,6,11,
12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-
2-naphthacenecarboxamide

TABLE I
ANTIBACTERIAL ACTIVITY OF
9-(ACYLAMINO)-7-(SUBSTITUTED)-6-DEMETHYL-6-DEOXYTETRACYCLINES
MIC (μg/ml)
COMPOUND
ORGANISM A B C D E F G H I
S. aureus UBMS 88-5 (tetM) 0.06 0.12 0.12 0.25 4 0.5 1 1 16
S. aureus UBMS 88-4 (Sensitive) 0.015 ≦0.06 0.03 0.12 0.5 0.25 <0.015 0.25 8
S. aureus UBMS 90-1 (tetM) 0.06 ND 0.5 0.5 8 2 4 1 16
S. aureus UBMS 90-2 (tetM) 0.03 ND 0.12 0.12 2 0.5 0.5 0.5 16
S. aureus UBMS 90-3 (Sensitive) ≦0.015 ND 0.03 0.06 0.5 0.12 0.03 0.12 4
S. aureus UBMS 88-7 (tetK) 2 4 0.25 2 4 2 16 16 16
S. aureus IVES 2943 (meth. 4 64 1 4 8 2 32 32 ND
resistant)
S. aureus IVES 1983 (meth. 8 ND 1 4 16 4 32 32 32
resistant)
S. aureus ATCC 19213 (Sensitive) ≦0.015 0.12 ≦0.015  0.015 ≦0.015 ≦0.015 ND 0.12 1
S. aureus Smith (Sensitive) ≦0.015 0.12 0.03 0.03 0.5 0.12 0.03 0.12 8
S. haemolyticus AVAH 88-3 0.03 ND 0.12 ND 8 2 0.06 2 0.5
E. faecalis 12201 0.12 0.5 0.5 1 16 4 16 2 16
E. faecalis ATCC 29212 ≦0.015 0.12 0.06 0.12 2.0 0.25 0.25 0.25 8
E. coli UBMS 88-1 (tetB) 32 >128 16 >32 >32 >32 >32 >128 >32
E. coli UBMS 88-2 (Sensitive) 0.12 2 0.25 0.5 >32 32 1 >128 32
E. coli UBMS 89-1 (tetM) 0.12 ND 1 ND 32 4 1 128 32
E. coli UBMS 89-2 (Sensitive) 0.12 ND 0.5 0.5 >32 32 1 16 32
E. coli ATCC 25922 0.06 2 0.25 0.5 32 4 0.5 16 32
MIC (μg/ml)
COMPOUND
ORGANISM J K L M N O HH II
S. aureus UBMS 88-5 (tetM) 4 0.25 4 1 32 2 0.25 0.12
S. aureus UBMS 88-4 (Sensitive) 2 0.12 4 1 2 ≦0.015 0.03 0.06
S. aureus UBMS 90-1 (tetM) 4 0.25 8 2 >32 4 1 0.25
S. aureus UBMS 90-2 (tetM) 2 0.06 2 0.5 32 2 0.25 0.06
S. aureus UBMS 90-3 (Sensitive) 0.5 0.03 1 0.5 1 ≦0.015 0.03 0.06
S. aureus UBMS 88-7 (tetK) 2 32 >32 >32 8 0.06 0.5 1
S. aureus IVES 2943 (meth. 4 32 >32 >32 32 1 2 1
resistant)
S. aureus IVES 1983 (meth. 4 32 >32 >32 >32 1 2 1
resistant)
S. aureus ATCC 29213 (Sensitive) 0.06 ≦0.015 0.5 0.5 0.25 ≦0.015 ≦0.015 0.03
S. aureus Smith (Sensitive) 0.5 ≦0.015 0.5 1 2 ≦0.015 0.03 0.12
S. haemolyticus AVAH 88-3 4 0.5 16 1 4 0.03 0.25 0.25
E. faecalis 12201 2 0.25 4 0.25 32 4 2 0.12
E. faecalis ATCC 29212 4 0.06 2 0.25 32 0.5 0.25 0.03
E. coli UBMS 88-1 (tetB) >32 16 >32 2 >32 8 16 0.25
E. coli UBMS 88-2 (Sensitive) >32 4 >32 2 >32 0.5 ND ND
E. coli UBMS 89-1 (tetM) >32 1 >32 2 >32 16 4 0.12
E. coli UBMS 89-2 (Sensitive) >32 8 >32 2 >32 0.5 4 0.25
E. coli ATCC 25922 32 4 32 2 32 0.25 2 0.12

TABLE II
ANTIBACTERIAL ACTIVITY OF
9-(AROYLAMINO) AND 9-(HETEROYLAMINO)-7-(SUBSTITUTED)-6-DEMETHYL-6-DEOXYTETRACYCLINES
MIC (μm/gl)
COMPOUND
ORGANISM P O R S T U V W X Y Z Q
S. aureus UBMS 88-5 (tetM) 4 8 4 2 4 1 2 32 8 16 8 2
S. aureus UBMS 88-4 (Sensitive) 4 8 2 2 4 0.5 2 8 1 4 8 ≧0.015
S. aureus UBMS 90-1 (tetM) 4 8 8 4 4 1 2 16 16 32 4 4
S. aureus UBMS 90-2 (tetM) 4 8 2 1 2 1 1 8 8 8 4 2
S. aureus UBMS 90-3 (Sensitive) 1 4 1 1 2 0.5 0.5 8 1 2 2 ≦0.015
S. aureus UBMS 88-7 (tetK) 8 16 4 8 4 1 4 16 8 >32 32 0.06
S. aureus IVES 2943 (meth. 16 8 4 8 4 1 4 8 >32 >32 32 4
resistant)
S. aureus IVES 1983 (meth. 8 16 8 4 4 1 8 8 >32 >32 32 4
resistant)
S. aureus ATCC 29213 (Sensitive) 0.25 1 0.12 0.5 1 0.5 0.5 2 0.5 0.5 0.5 ≦0.015
S. aureus Smith (Sensitive) 1 4 1 1 4 1 0.5 4 1 2 2 ≦0.015
S. haemolyticus AVAH 88-3 4 8 8 4 4 1 4 16 8 >32 8 0.03
E. faecalis 12201 8 8 8 4 4 1 4 16 32 32 8 4
E. faecalis ATCC 29212 4 8 2 4 4 1 4 8 8 8 8 0.5
E. coli UBMS 88-1 (tetB) >32 >32 2 >32 >32 >32 >32 >32 >32 >32 >32 8
E. coli UBMS 88-2 (Sensitive) >32 >32 >32 >32 >32 >32 >32 >32 >32 >32 >32 8
E. coli UBMS 89-1 (tetM) ND ND ND ND ND >32 >32 >32 >32 >32 >32 16
E. coli UBMS 89-2 (Sensitive) >32 >32 >32 >32 >32 ≧32 >32 >32 >32 >32 >32 0.5
E. coli ATCC 25922 >32 >32 >32 >32 >32 ≧32 >32 >32 >32 >32 >32 0.25

TABLE III
ANTIBACTERIAL ACTIVITY OF 9-(SULFONYLAMINO)-
7-(SUBSTITUTED)-6-DEMETHYL-6-DEOXYTETRACYCLINES
MIC (μm/gl)
COMPOUND
ORGANISM AA BB CC DD EE FF GG Q
S. aureus UBMS 88-5 (tetM) 0.12 ND 4 0.5 0.12 0.25 16 4
S. aureus UBMS 88-4 (Sensitive) 0.12 1 0.03 0.5 0.12 0.25 4 0.03
S. aureus UBMS 90-1 (tetM) 0.5 2 4 1 0.25 0.25 32 2
S. aureus UBMS 90-2 (tetM) 0.12 0.5 0.05 0.25 0.12 0.06 4 2
S. aureus UBMS 90-3 (Sensitive) 0.06 0.12 4 0.25 0.12 0.12 2 ≦0.015
S. aureus UBMS 88-7 (tetK) 2 4 4 2 1 8 32 0.0.6
S. aureus IVES 2943 (meth. 4 4 4 4 0.5 16 >32 2
resistant)
S. aureus IVES 1983 (meth. 8 8 4 4 1 16 32 1
resistant)
S. aureus ATCC 29213 (Sensitive) 0.12 0.06 ≦0.015 0.03 0.03 0.03 0.5 ≦0.015
S. aureus Smith (Sensitive) 0.12 0.25 4 0.03 0.12 0.12 2 >0.015
S. haemolyticus AVAH 88-3 2 4 4 2 ND ND ND 0.06
E. faecalis 12201 ND ND ND ND ND ND ND 8
E. faecalis ATCC 29212 0.12 0.12 0.06 0.25 0.06 0.06 1 0.5
E. coli UBMS 88-1 (tetB) 16 >32 16 32 >32 8 >32 16
E. coli UBMS 88-2 (Sensitive) 8 4 8 8 >32 2 >32 0.5
E. coli UBMS 89-1 (tetM) 4 ND ND ND ND ND 32 16
E. coli UBMS 89-2 (Sensitive) 16 16 16 16 >32 2 >32 0.5
E. coli ATCC 25922 4 2 2 4 >32 2 >32 0.5

TABLE IA
ANTIBACTERIAL ACTIVITY OF 9-(ACYLAMINO)-7-(SUBSTITUTED)-
6-DEMETHYL-6-DEOXYTTRACYCLINES
JJ KK LL MM NN OO PP
E. coli UBMS 88-1 TetB 0.25 0.25 0.25 1 >32 1 0.5
E. coli J3272 Tet sens. 0.25 0.12 0.12 1 >32 1 0.5
E. coli MC4100 Tet sens. NT NT NT NT NT NT NT
E. coli MC4100 TetB 0.25 0.25 0.25 1 >32 1 0.5
E. coli PRP1 TetA 2 1 1 16 >32 2 1
E. coli J3272 TetC 1 1 0.5 8 >32 2 0.5
E. coli UBMS 89-1 TetM 0.25 0.12 0.12 1 32 1 0.25
E. coli UBMS 89-2 Tet Sens. 0.25 0.25 0.12 1 >32 1 0.5
E. coli J2175 0.25 0.25 0.12 1 >32 1 0.25
E. coli BAJ9003 0.03 0.03 NG 0.25 0.5 0.12 0.12
E. coli UBMS 90-4 TetM 0.25 0.25 0.25 CONT CONT 0.5 0.25
E. coli UBMS 90-5 0.25 0.25 0.12 1 >32 1 0.5
E. coli #311 (MP) 0.25 0.25 0.12 1 >32 1 0.25
E. coli ATCC 25922 0.25 0.25 0.12 1 >32 1 0.25
E. coli J3272 TetD 0.12 0.12 0.06 0.05 32 0.5 0.25
S. marcescens FPOR 8733 4 2 2 16 >32 8 2
X. maltophilia NEMC 87210 0.5 0.25 0.25 8 32 2 0.5
Ps. aeruginosa ATCC 27853 8 4 4 16 >32 16 16
S. aureus NEMC 8769/89-4 0.06 0.06 ≦0.015 0.5 0.5 0.5 0.12
S. aureus UBMS 88-4 0.25 0.12 0.06 0.5 2 1 0.25
S. aureus UBMS 88-5 TetH 0.25 0.25 0.12 0.5 4 1 0.5
S. aureus UBMS 88-7 TetK 1 0.25 0.5 16 32 8 2
S. aureus UBMS 90-1 TetM 0.25 0.25 0.12 1 4 1 0.5
S. aureus UBMS 90-3 0.12 0.03 0.06 0.5 2 0.5 0.25
S. aureus UBMS 90-2 TetM 0.25 0.12 0.12 0.5 2 0.5 0.5
S. aureus IVES 2943 2 1 1 32 >32 8 2
S. aureus ROSE (MP) 2 1 1 32 >32 8 2
S. aureus SMITH (MP) 0.12 0.06 0.06 0.5 2 0.5 0.12
S. aureus IVES 1983 2 1 1 16 >32 8 2
S. aureus ATCC 29213 0.03 ≦0.015 0.06 1 2 1 0.25
S. hemolyticus AVHAH 88-3 0.25 0.12 0.12 1 32 1 0.25
Enterococcus 12201 0.12 0.12 0.06 0.25 2 0.25 0.12
E. faecalis ATCC 29212 0.12 0.06 0.06 0.25 2 0.25 0.12
QQ RR SS TT UU VV WW
E. coli UBMS 88-1 TetB 4 1 0.25 0.5 0.5 >32 0.25
E. coli J3272 Tet sens. 2 1 0.25 0.5 0.5 >32 0.25
E. coli MC4100 Tet sens. NT NT NT NT NT NT NT
E. coli MC4100 TetB 2 1 0.25 0.5 0.5 >32 0.25
E. coli PRP1 TetA 32 2 0.5 2 1 >32 1
E. coli J3272 TetC 8 1 0.25 0.5 0.5 >32 0.25
E. coli UBMS 89-1 TetM 1 0.25 0.12 0.25 0.12 >32 0.25
E. coli UBMS 89-2 Tet Sens. 2 1 0.25 0.5 0.5 >32 0.25
E. coli J2175 2 1 0.25 0.5 0.5 >32 0.25
E. coli BAJ9003 0.25 0.06 ≦0.015 0.06 0.06 1 0.06
E. coli UBMS 90-4 TetM 2 0.5 0.25 0.5 0.5 >32 0.25
E. coli UBMS 90-5 2 1 0.25 0.5 0.5 >32 0.25
E. coli #311 (MP) 2 0.5 0.12 0.5 0.25 >32 0.25
E. coli ATCC 25922 2 0.5 0.25 0.5 0.25 >32 0.25
E. coli J3272 TetD 2 0.25 0.12 0.12 0.25 >32 0.12
S. marcescens FPOR 8733 >32 4 2 4 4 >32 2
X. maltophilia NEMC 87210 2 0.25 0.5 0.5 0.12 >32 0.5
Ps. aeruginosa ATCC 27853 >32 32 16 16 32 >32 8
S. aureus NEMC 8769/89-4 0.12 0.06 0.03 0.03 0.06 4 0.06
S. aureus UBMS 88-4 0.5 0.25 0.25 0.25 0.25 8 0.25
S. aureus UBMS 88-5 TetH 0.5 0.25 0.25 0.25 0.25 32 0.25
S. aureus UBMS 88-7 TetK 4 0.5 0.5 2 0.25 32 1
S. aureus UBMS 90-1 TetM 0.5 0.25 0.25 0.25 0.25 32 0.12
S. aureus UBMS 90-3 0.5 0.25 0.12 0.12 0.12 4 0.12
S. aureus UBMS 90-2 TetM 0.5 0.25 0.25 0.25 0.12 16 0.25
S. aureus IVES 2943 16 1 1 2 0.25 >32 2
S. aureus ROSE (MP) 16 1 1 2 0.5 >32 2
S. aureus SMITH (MP) 0.25 0.25 0.12 0.12 0.12 4 0.12
S. aureus IVES 1983 8 0.25 0.5 2 0.5 >32 2
S. aureus ATCC 29213 0.5 0.12 0.12 0.25 0.12 8 0.25
S. hemolyticus AVHAH 88-3 2 0.5 0.25 0.25 0.12 >32 0.25
Enterococcus 12201 0.5 0.12 0.12 0.25 0.12 4 0.12
E. faecalis ATCC 29212 0.25 0.12 0.12 0.25 0.06 4 0.25
XX YY ZZ AAA BBB CCC DDD
E. coli UBMS 88-1 TetB 0.5 0.5 >32 0.5 0.5 1 0.5
E. coli J3272 Tet sens. 0.5 0.5 NT NT NT NT NT
E. coli MC4100 Tet sens. NT NT 2 0.12 0.25 0.25 0.12
E. coli MC4100 TetB 1 0.5 >32 0.5 0.5 2 1
E. coli PRP1 TetA 1 1 32 0.5 0.5 1 0.5
E. coli J3272 TetC 1 2 32 0.5 0.5 1 0.5
E. coli UBMS 89-1 TetM 0.12 0.5 32 0.12 0.25 0.25 0.25
E. coli UBMS 89-2 Tet Sens. 0.5 0.5 16 0.5 0.25 2 0.5
E. coli J2175 0.5 0.5 16 0.5 0.25 2 0.5
E. coli BAJ9003 0.06 0.06 1 0.06 0.06 0.12 0.12
E. coli UBMS 90-4 TetM 0.5 0.5 16 0.5 0.25 1 0.5
E. coli UBMS 90-5 0.5 0.5 16 0.5 0.25 2 0.5
E. coli #311 (MP) 0.5 0.5 16 0.25 0.5 1 0.5
E. coli ATCC 25922 0.5 0.5 8 0.25 0.12 1 0.5
E. coli J3272 TetD 0.25 0.25 4 0.12 0.12 0.5 0.25
S. marcescens FPOR 8733 4 8 >32 4 4 16 8
X. maltophilia NEMC 87210 0.5 4 32 0.5 4 0.25 0.5
Ps. aeruginosa ATCC 27853 32 16 >32 >32 16 >32 32
S. aureus NEMC 8769/89-4 0.12 0.12 1 0.12 0.06 0.12 0.25
S. aureus UBMS 88-4 0.25 0.5 2 0.25 0.25 0.5 0.5
S. aureus UBMS 88-5 TetH 0.25 0.5 8 0.25 0.5 0.5 0.5
S. aureus UBMS 88-7 TetK 1 4 16 0.5 2 1 2
S. aureus UBMS 90-1 TetM 0.25 0.25 8 0.5 0.25 1 1
S. aureus UBMS 90-3 0.25 0.12 2 0.25 0.06 0.25 0.5
S. aureus UBMS 90-2 TetM 0.25 0.25 4 0.25 0.25 0.25 0.5
S. aureus IVES 2943 1 8 >32 0.5 4 1 4
S. aureus ROSE (MP) 1 8 >32 2 16 2 4
S. aureus SMITH (MP) 0.25 0.25 2 0.25 0.12 0.5 0.25
S. aureus IVES 1983 1 4 >32 0.5 4 1 4
S. aureus ATCC 29213 0.25 0.5 2 0.25 0.25 0.5 1
S. hemolyticus AVHAH 88-3 0.5 0.5 8 0.5 0.5 0.5 0.5
Enterococcus 12201 0.12 0.25 8 0.12 0.25 0.25 0.25
E. faecalis ATCC 29212 0.12 0.12 4 0.12 0.12 0.12 0.25
EEE FFF GGG HHH III
E. coli UBMS 88-1 TetB 2 0.25 0.25 0.25 >32
E. coli J3272 Tet sens. NT NT NT NT 16
E. coli MC4100 Tet sens. 0.5 0.06 0.06 0.12 NT
E. coli MC4100 TetB 4 0.25 0.25 0.25 >32
E. coli PRP1 TetA 4 2 1 2 >32
E. coli J3272 TetC 2 1 1 0.5 >32
E. coli UBMS 89-1 TetM 0.5 0.12 0.12 0.25 4
E. coli UBMS 89-2 Tet Sens. 4 0.25 0.25 0.25 32
E. coli J2175 4 0.25 0.25 0.25 32
E. coli BAJ9003 0.25 ≦0.015 0.03 0.03 0.25
E. coli UBMS 90-4 TetM 0.5 0.12 0.25 0.25
E. coli UBMS 90-5 0.5 0.25 0.25 0.25 16
E. coli #311 (MP) 0.5 0.25 0.25 0.25 8
E. coli ATCC 25922 0.5 0.12 0.12 0.25 16
E. coli J3272 TetD 0.5 0.12 0.12 0.12 32
S. marcescens FPOR 8733 4 4 4 4 >32
X. maltophilia NEMC 87210 1 0.25 0.5 0.5 4
Ps. aeruginosa ATCC 27853 32 8 8 8 >32
S. aureus NEMC 8769/89-4 0.12 0.25 0.25 0.25 0.12
S. aureus UBMS 88-4 0.25 0.12 0.12 0.25 0.5
S. aureus UBMS 88-5 TetH 0.5 0.12 0.12 0.25 1
S. aureus UBMS 88-7 TetK 2 1 1 0.5 2
S. aureus UBMS 90-1 TetM 0.5 0.12 0.25 0.25 1
S. aureus UBMS 90-3 0.25 0.12 0.12 0.12 0.5
S. aureus UBMS 90-2 TetM 0.25 0.12 0.12 0.12 0.5
S. aureus IVES 2943 2 2 2 2 4
S. aureus ROSE (MP) 8 2 2 2 8
S. aureus SMITH (MP) 0.25 0.12 0.12 0.12 0.5
S. aureus IVES 1983 2 2 2 2 4
S. aureus ATCC 29213 0.5 0.12 0.25 0.25 0.5
S. hemolyticus AVHAH 88-3 2 0.25 0.5 0.5 2
Enterococcus 12201 0.25 0.12 0.12 0.12 1
E. faecalis ATCC 29212 0.25 0.06 0.06 0.06 0.5
JJJ KKK LLL MMM
E. coli UBMS 88-1 TetB >32 >32 0.5 0.5
E. coli J3272 Tet sens. >32 >32 0.25 0.06
E. coli MC4100 Tet sens. NT 32 NT NT
E. coli MC4100 TetB >32 >32 0.5 0.25
E. coli PRP1 TetA >32 >32 1 4
E. coli J3272 TetC >32 >32 0.5 0.5
E. coli UBMS 89-1 TetM 32 >32 0.25 0.25
E. coli UBMS 89-2 Tet Sens. >32 >32 0.5 0.5
E. coli J2175 >32 >32 0.25 0.25
E. coli BAJ9003 4 16 0.06 0.03
E. coli UBMS 90-4 TetM >32 >32 0.25 0.25
E. coli UBMS 90-5 >32 >32 0.25 0.5
E. coli #311 (MP) >32 >32 0.25 0.25
E. coli ATCC 25922 >32 >32 0.25 0.25
E. coli J3272 TetD >32 >32 0.12 0.12
S. marcescens FPOR 8733 >32 >32 2 8
X. maltophilia NEMC 87210 16 >32 1 0.5
Ps. aeruginosa ATCC 27853 >32 >32 8 32
S. aureus NEMC 8769/89-4 4 32 0.12 0.5
S. aureus UBMS 88-4 8 32 0.25 0.25
S. aureus UBMS 88-5 TetH 8 >32 0.25 0.25
S. aureus UBMS 88-7 TetK 16 >32 2 4
S. aureus UBMS 90-1 TetM 16 >32 0.25 0.5
S. aureus UBMS 90-3 2 16 0.12 0.12
S. aureus UBMS 90-2 TetM 8 32 0.25 0.25
S. aureus IVES 2943 32 >32 2 4
S. aureus ROSE (MP) >32 >32 2 8
S. aureus SMITH (MP) 4 16 0.25 0.25
S. aureus IVES 1983 32 >32 2 4
S. aureus ATCC 29213 4 32 2 0.25
S. hemolyticus AVHAH 88-3 16 >32 0.25 0.24
Enterococcus 12201 16 >32 0.25 0.24
E. faecalis ATCC 29212 16 16 0.25 0.25
NG = No Growth
CONT = Contaminated
NT = Not Tested

TABLE IV
Susceptibility of Sensitive and Resistant (tetM)
Organisms to Tetracyclines
MIC (μg/ml)
Organisms A O TC
E. coli UBMS 88-2 (Sensitive) 0.12 0.5 ND
E. coli UBMS 90-4 (tetM) 1 64 64
S. aureus UBMS 88-4 (Sensitive) <0.015 0.03 0.12
S. aureus UBMS 88-5 (tetM) 0.03 2 32
S. aureus UBMS 90-3 (Sensitive) <0.015 0.03 0.12
S. aureus UBMS 90-1 (tetM) 0.12 4 32
N. gonorrhoeae IL 611 (Sensitive) 0.06 0.5 ND
N. gonorrhoeae 6418 (tetM) 1 >32 >32
E. faecalis UBMS 90-6 (tetM) 0.12 8 32
E. faecalis UBMS 90-7 (tetM) 0.5 8 32

TABLE V
In vitro Activity of Compounds A and O Against Clinical Isolates
MIC (μg/ml)+
Organism No. Tested Antibiotic Range MIC50 MIC90
Neisseria  (9) A 0.015-1.00 0.03 1.00
gonorrhoeae O 0.03->32.00 0.25 >32.00
Haemophilus (18) A <0.008-0.06 0.06 0.06
influenzae O 0.06-0.25 0.12 0.25
Enterococcus (14) A <0.015-2.00 0.12 1.00
faecalis O <0.015-16.00 4.00 16.00
Enterococcus (11) A <0.015-2.00 0.06 2.00
faecium O <0.015-16.00 8.00 16.00
Escherichia coli (10) A 0.06->32.00 0.25 >32.00
O 0.12-32.00 0.25 16.00
Klebsiella (10) A 0.25->32.00 0.50 0.50
pneumoniae O 1.00->32.00 1.00 4.00
Proteus spp.  (9) A 0.50->32.00 2.00 >32.00
indole + O 1.00->32.00 16.00 >32.00
Bacteroides spp. (15) A <0.15-4.00 0.25 2.00
O <0.15-16.00 1.00 4.00
In Vitro Activity of KK and Comparative
Antibiotics vs Recent Clinical and Agricultural Isolates
MIC (μg/ml)
Organism [No. Tested] KK O TC
Staphylococcus aureus, [15] 0.12-2 0.06-4 0.25->64
methicillin-resistant
Staphylococcus aureus, [15] 0.12-0.25 0.03-0.12 0.12-1
methicillin-susceptible
Staphylococcus [16] 0.12-8 0.03-1 0.12->64
Coagulase-negative,
methicillin-susceptible
Enterococcus faecalis [10] 0.015-0.12 0.03-16 0.12-64
Enterococcus faecium [10] 0.03-0.12 0.03-16 0.12-64
Enterococcus spp.  [8] 0.015-0.06 0.03-16 0.12->64
Vancomycin-resistant
Streptococcus pyogenes [10] 0.06-0.12 0.03-2 0.12-16
Streptococcus agalactiae [10] 0.06-0.25 0.12-16 0.25-64
Streptococcus pneumoniae [10] 0.03-0.25 0.06-0.5 0.12-2
Listeria monocytogenes  [8] 0.06-0.12 0.015-0.03 0.12-0.5
Escherichia coli [30] 0.12-4 0.25-32 0.5->64
(Clinical)
Escherichia coli [15] 0.12-4 1-16 2->64
(Agricultural)
Shigella spp. [14] 0.06-0.5 0.25-8 0.25->64
Klebsiella pneumoniae [10] 0.25-8 0.5-8 0.5->64
Klebsiella oxytoca [10] 0.5-1 0.5-4 0.5-1
Citrobacter freundii [10] 0.25-8 0.03-32 0.5-16
Citrobacter diversus [10] 0.25-1 0.25-4 0.5-4
Salmonella spp. [11] 0.25-0.5 0.5-16 0.5->64
(Clinical)
Salmonella cholerasuis [15] 0.5-16 2->64 1->64
(Agricultural)
Serratia mercescens [10] 2-8 1-8 8->64
Enterobacter cloacae [10] 0.5-1 0.25-4 0.5-2
Enterobacter aerogenes [10] 0.5-1 0.5-1 0.5-1
Providencia spp. [13] 2-8 4->64 1->64
Proteus mirabilis [26] 1-32 1-32 0.5-64
Proteus vulgaris [18] 0.5-4 0.5-16 0.25-64
Morganella morganii [16] 0.5-4 0.25-32 0.25->64
Pseudomonas aeruginosa [10] 1-16 1-16 2-32
Xanthomonas maltophilia [10] 0.5-2 0.12-1 8-16
Moraxeila catarrhalis [18] 0.06-0.12 0.03-0.12 0.06-0.5
Neisseria gonorrhoeae [14] 0.25-1 0.5-64 1->64
Haemophilus influenzae [15] 0.5-2 0.5-2 1-32
Pasturella multocida [17] 0.03-0.25 0.015-4 0.06-16
(Agricultural & Clinical)
Bordetella bronchiseptica [10] 0.12 0.06-0.12 0.12-0.25
(Agricultural)
Bacteroides fragilis [11] 0.06-0.2 <0.008-16 0.25->64
Bacteroides fragilis group [10] 0.06-2 <0.008-4 0.25-32
Bacteroides spp.  [9] 0.03-1 0.03-16 0.25->64
Clostridium difficile [12] 0.03 0.015-16 0.12-32
Clostridium perfringens [16] 0.03-1 <0.008-16 0.015-16
Clostridium spp.  [9] 0.015-0.12 <0.008-16 0.015-64
Anaerobic Gram [15] 0.015-0.06 0.05-8 4->64
(+) Cocci
+MIC50 = minimum concentration required to inhibit 50% of strains tested.
MIC90 = minimum concentration required to inhibit 90% of strains tested

TABLE VI
Inhibition of Protein Synthesis Directed by E. coli
Cell-free Ribosomes with Tetracyclines
IC50 (μg/ml)+
Antibiotic TC Sensitive Host Tet M Host
Tetracycline 0.6 2.0
Compound O 0.4 2.0
Compound A <0.3 0.4
+Concentration of antibiotic required to inhibit protein synthesis by 50% compared to a drug-free control

TABLE VII
In vivo Protective Activity of Compounds A and O in Mice
Infected with Staphylococci Containing the tetM Determinant
Organism Compound ED50 (mg/kg)+
S. aureus UBMS 90-1 A 0.22
O 1.7
S. aureus UBMS 90-2 A 0.49
O 3.0
In Vitro Protective Activity in Mice
Compounds (ED50 (mg/kg)
Route of
Antibiotic
Organism Administration JJ KK LL PP RR SS TT
S. aureus SMITH (sens) Oral 9.6  8-16  4-8 >16 8-16 8-16 8-16
S. aureus SMITH (sens) Intraveneous 0.61 0.68 0.25-0.5 1-2 1-2  1-2 
S. aureus SMITH (sens) Subcutaneous 0.66
Escherichia coli Intraveneous 2.49
UBMS 90-4 (Tet-M)
Route of
Antibiotic
Organism Administration BBB WW XX YY AAA DDD EEE O
S. aureus SMITH (sens) Oral 4-8 >16 8-16 >16 >16 8-16 8-16 0.74
S. aureus SMITH (sens) Intraveneous 1.8 0.82 0.5-1 0.5-1 0.37
S. aureus SMITH (sens) Subcutaneous
Escherichia coli Intraveneous >32
UBMS 90-4 (Tet-M)
+Median effective dose protecting 50% of the infected mice, single subcutaneous dosing.

TABLE VIII
In Vitro Transcription and Protein Translation
Sensitivity to Tetracycline Compounds
COMPOUND % INHIBITION
Organism Concentration Wild Type S30 TetM S30
KK 1.0 mg/ml 92 95
0.5 mg/ml 90 96
0.25 mg/ml 89 93
0.12 mg/ml 84 93
0.06 mg/ml 82 89
0.03 mg/ml 81 75
MM 1.0 mg/ml 99 99
0.2 mg/ml 98 97
0.06 mg/ml 95 92
OO 1.0 mg/ml 99 99
0.2 mg/ml 97 95
0.06 mg/ml 94 87
QQ 1.0 mg/ml 99 99
0.2 mg/ml 97 95
0.06 mg/ml 92 85
RR 1.0 mg/ml 99 99
0.2 mg/ml 97 97
0.06 mg/ml 93 90
VV 1.0 mg/ml 99 98
0.2 mg/ml 93 92
0.06 mg/ml 91 79
WW 1.0 mg/ml 99 98
0.2 mg/ml 99 97
0.06 mg/ml 93 88
XX 1.0 mg/ml 98 97
0.2 mg/ml 96 89
0.06 mg/ml 85 78
Minocycline 1.0 mg/ml 98 68
0.2 mg/ml 89 43
0.06 mg/ml 78  0

When the compounds are employed as antibacterials, they can be combined with one or more pharmaceutically acceptable carriers, for example, solvents, diluents and the like, and may be administered orally in such forms as tablets, capsules, dispersible powders, granules, or suspensions containing, for example, from about 0.05 to 5% of suspending agent, syrups containing, for example, from about 10 to 50% of sugar, and elixirs containing, for example, from about 20 to 50% ethanol, and the like, or parenterally in the form of sterile injectable solutions or suspensions containing from about 0.05 to 5% suspending agent in an isotonic medium. Such pharmaceutical preparations may contain, for example, from about 25 to about 90% of the active ingredient in combination with the carrier, more usually between about 5% and 60% by weight.

An effective amount of compound from 2.0 mg/kg of body weight to 100.0 mg/kg of body weight should be administered one to five times per day via any typical route of administration including but not limited to oral, parenteral (including subcutaneous, intravenous, intramuscular, intrasternal injection or infusion techniques), topical or rectal, in dosage unit formulations containing conventional non-toxic pharmaceutically acceptable carriers, adjuvants and vehicles. It will be understood, however, that the specific dose level and frequency of dosage for any particular patient may be varied and will depend upon a variety of factors including the activity of the specific compound employed, the metabolic stability and length of action of that compound, the age, body weight, general health, sex, diet, mode and time of administration, rate of excretion, drug combination, the severity of the particular condition, and the host undergoing therapy.

These active compounds may be administered orally as well as by intravenous, intramuscular, or subcutaneous routes. Solid carriers include starch, lactose, dicalcium phosphate, microcrystalline cellulose, sucrose and kaolin, while liquid carriers include sterile water, polyethylene glycols, non-ionic surfactants and edible oils such as corn, peanut and sesame oils, as are appropriate to the nature of the active ingredient and the particular form of administration desired. Adjuvants customarily employed in the preparation of pharmaceutical compositions may be advantageously included, such as flavoring agents, coloring agents, preserving agents, and antioxidants, for example, vitamin E, ascorbic acid, BHT and BHA.

The preferred pharmaceutical compositions from the standpoint of ease of preparation and administration are solid compositions, particularly tablets and hard-filled or liquid-filled capsules. Oral administration of the compounds is preferred.

These active compounds may also be administered parenterally or intraperitoneally. Solutions or suspensions of these active compounds as a free base or pharmacologically acceptable salt can be prepared in water suitably mixed with a surfactant such as hydroxy-propylcellulose. Dispersions can also be prepared in glycerol, liquid, polyethylene glycols and mixtures thereof in oils. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms.

The pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. In all cases, the form must be sterile and must be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacterial and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (e.g., glycerol, propylene glycol and liquid polyethylene glycol), suitable mixtures thereof, and vegetable oil.

The invention will be more fully described in conjunction with the following specific examples which are not to be construed as limiting the scope of the invention.

EXAMPLE 1 [4S-(4α,12aα)]-4,7-Bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-9-nitro-1,11-dioxo-2-naphthacenecarboxamide sulfate (1:1)

To a stirred ice bath cooled solution of 0.444 g of [4S-(4α,12aα)]-4,7-bis(dimethylamino)-1,4,4a,5,5a,- 6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide hydrochloride, prepared by the procedure described in U.S. Pat. No. 3,226,436, dissolved in 15 ml of sulfuric acid is added 0.101 g of sodium nitrate. The mixture is stirred in the cold for 45 minutes followed by the dropwise addition to 500 ml of diethyl ether. The resulting solid is collected, washed with diethyl ether and dried to give 0.6 g of the desired product as a solid.

MS(FAB): m/z 503(M+H) and 601(M+H2SO4+H).

EXAMPLE 2 [4S-(4α,12aα)]-9-Amino-4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide sulfate (1:1)

A mixture of 2.0 g of product from Example 1 in 20 ml of 2-methoxyethanol is stirred for 10 minutes and filtered. The filtrate is shaken, in a pressure bottle, with 1.0 g of 10% palladium-on-carbon and 5 ml of 2N sulfuric acid, under 30 lbs. of hydrogen pressure, for 1 hour. The reaction mixture is filtered and the filtrate concentrated in vacuo to half volume. The solution is poured into 100 ml of diethyl ether, the solid collected, washed with diethyl ether and dried to give 1.6 g of the desired product as a solid.

MS(FAB): m/z 473(M+H).

EXAMPLE 3 [4S-(4α,12aα)]-4,7-Bis(dimethylamino)-9-(formylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide

To a stirring 0 C. solution of 3.0 g of product from Example 2, 0.451 g of anhydrous sodium acetate and 50 ml of 98% formic acid is added, dropwise, 7.4 ml of acetic anhydride. The reaction is stirred at 0 C. for 10 minutes followed by stirring at room temperature for 1 hour. The mixture is poured into 500 ml of diethyl ether and the precipitate collected. The solid is washed with diethyl ether and dried to give 2.9 g of the desired product.

MS (FAB): m/z 501 (M+H).

EXAMPLE 4 [4S-(4α,12aα)]-4,7-Bis(dimethylamino)]-9-(formylamino)- 1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a,tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide sulfate

To a solution of 3.5 g of product from Example 3 in 150 ml of distilled water is added sufficient 0.75N sulfuric acid to bring the reaction solution of pH 3.6. The solution is lyophilized to give 3.6 g of the desired salt.

MS (FAB): m/z 501 (M+H).

EXAMPLE 5 [4S-(4α,12aα)]-4,7-Bis(dimethylamino)]-9-forylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide monohydrochloride

To a solution of 3.5 g of product from Example 3 in 150 ml of distilled water is added sufficient 0.75N hydrochloric acid to bring the reaction solution of pH 3.6. The solution is lyophilized to give 3.6 g of the desired salt.

MS (FAB): m/z 501 (M+H).

EXAMPLE 6 [4S-(4α,12aα)]-9-(Acetylamino)]-4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide

To a stirring solution of 0.468 g of product from Example 2 in 5 ml of water is added 0.50 g of sodium acetate and 0.2 ml of acetic anhydride. The reaction is stirred at room temperature for 10 minutes followed by the addition of 0.2 ml of concentrated ammonium hydroxide. After stirring 5 hours at room temperature, the reaction is treated with 0.5 ml of concentrated sulfuric acid. The reaction solution is extracted with 4 portions of n-butyl alcohol and the aqueous layer is concentrated in vacuo to dryness. The residue is triturated with 20 ml of methyl alcohol, filtered and the organic layer is concentrated in vacuo to give 0.35 g of the desired product.

MS(FAB): m/z 515 (M+H).

EXAMPLE 7 [4S-(4α,12aα)]-4,7-Bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-9-[(trifluoroacetyl)amino]-2-naphthacenecarboxamide sulfate

A mixture of 0.20 g of product from Example 2 and 3.0 ml of trifluoroacetic anhydride is stirred at room temperature for 6 hours. The reaction liquid is decanted from the solid residue. The solid is dried, dissolved in 10 ml of methyl alcohol, stirred for 20 minutes and the mixture is poured into 100 ml of diethyl ether. The solid is collected and dried to give 0.16 g of the desired product.

MS (FAB): m/z 569 (M+H).

EXAMPLE 8 [4S-(4α,12aα)]-7-(Diethylamino)-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-9-nitro-1,11-dioxo-2-naphthacenecarboxamide sulfate (1:2).

To a stirred ice cooled solution of 0.660 g of [4S-(4α,12aα)]-7-(diethylamino)-4-(dimethylamino)-1,4,4a, 5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide hydrochloride, prepared by the procedure described in U.S. Pat. No. 3,226,436, dissolved in 15 ml of sulfuric acid is added 0.151 g of sodium nitrate. The mixture is stirred in the cold followed by dropwise addition to 500 ml of diethyl ether. The resulting solid is collected, washed with diethyl ether and dried to give 0.8 g of the desired product as a solid.

MS(FAB): m/z 531(M+H) and 629(M+H2SO4+H).

EXAMPLE 9 [4S-(4α,12aα)]-9-Amino-7-(diethylamino)-4-(dimethylamin)-1,4,4a,5,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide sulfate (1:2)

The title compound is prepared by the procedure of Example 2, using 0.82 g of product from Example 8, to give 0.65 g of the desired product as a solid. 1H NMR (CD3SOCD3): δ4.25(s,1H,4-H) and 7.27(s,1H,8-H).

MS(FAB): m/z 501(M+H) and 599(M+H2SO4+H).

EXAMPLE 10 [4S-(4α,12aα)]-7-(Diethylamino)-4-(dimethylamino)-9-(formylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,1212a -tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide sulfate (1:2)

To a solution of 0.238 g of product from Example 9 in 6 ml of formic acid is added 0.035 g of sodium acetate and 0.75 ml of acetic anhydride. The reaction mixture is stirred at room temperature for 1.5 hours then poured into 200 ml of diethyl ether. The solid is collected and dried at 50 C. to give 0.125 g of the desired product.

MS(FAB): m/z 529 (M+H) and 627 (M+H2SO4+H).

EXAMPLE 11 [4S-(4α,12aα)]-9-(Acetylamino)-7-(diethylamino)-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide sulfate (1:2)

To a solution of 0.16 g of product from Example 9 in 0.6 ml of water is added 0.125 g of sodium acetate. After stirring for 5 minutes, 0.05 ml of acetic anhydride is added. The reaction is stirred for 15 minutes, 0.025 ml of ammonium hydroxide is added and the stirring continued for an additional 5 minutes. The mixture is acidified with 0.125 ml of sulfuric acid, extracted with n-butyl alcohol and concentrated in vacuo. The residue is dissolved in methyl alcohol and added to diethyl ether. The solid is collected and dried to give 0.10 g of the desired product.

MS(FAB): m/z 543 (M+H) and 641 (M+H2SO4+H).

EXAMPLE 12 [4S-(4α,12aα)]-7-(Diethylamino)-4-(dimethylamino)-9-(formylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,1212a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide

A solution of 0.2 g of product from Example 10 in 10 ml of water is treated with sodium acetate to achieve pH 5-6. The mixture is extracted with chloroform. The organic extracts are dried with sodium acetate, concentrated in vacuo and the solid triturated with diethyl ether/hexane to give 0.11 g of the desired product.

MS (FAB): m/z 529 (M+H).

EXAMPLE 13 [4S-(4α,12aα)]-9-(Acetylamino)-7-(diethylamino)-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide

A solution of 0.25 g of product from Example 11 in 10 ml of water is treated with sodium acetate to achieve pH 6. The mixture is extracted with chloroform. The organic extracts are dried with sodium acetate, concentrated in vacuo and the solid triturated with diethyl ether/hexane to give 0.090 g of the desired product.

MS(FAB): m/z 543 (M+H).

EXAMPLE 14 [4S-(4α,12aα)]-4-(Dimethylamino)-7-(ethylmethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide hydrochloride

A solution of 0.460 g of [4S-(4α,12aα)]-4-(dimethylamino)- 7-(ethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide hydrochloride, prepared by the procedure described in U.S. Pat. No. 3,226,436, in 0.5 ml of 97% formic acid and 0.75 ml of 40% aqueous formaldehyde is heated at reflux temperature for 2 hours, concentrated to volume and poured into diethyl ether. The resulting solid is collected, washed with diethyl ether and dried to give 0.30 g of the desired product.

EXAMPLE 15 [4S-(4α,12aα)]-4-(Dimethylamino)-7-(ethylmethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3.10.12,12a-tetrahydroxy-9-nitro-1,11-dioxo-2-naphthacenecarboxamide sulfate

The title compound is prepared by the procedure of Example 8, using 0.460 g of product from Example 14, 15 ml of sulfuric acid and 0.101 g of sodium nitrate to give 0.5 g of the desired product.

EXAMPLE 16 [4S-(4α,12aα)-9-Amino-4-(dimethylamino)-7-(ethylmethylamino)- 1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide sulfate

The title compound is prepared by the procedure of Example 2, using 1.0 g of product from Example 15, 20 ml of 2-methoxyethanol, 1.0 g of 10% palladium-on-carbon and 5 ml of 2N sulfuric acid to give 0.8 g of the desired product.

EXAMPLE 17 [4S-(4α,12aα)]-4-(Dimethylamino)-7-(ethylmethylamino)-9-(formylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide sulfate

The title compound is prepared by the procedure of Example 3, using 1.5 g of product from Example 16, 0.235 g of anhydrous sodium acetate, 25 ml of 98% formic acid and 3.7 ml of acetic anhydride to give 1.35 g of the desired product.

EXAMPLE 18 [4S-(4α,12aα)]-9-(Acetylamino)-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide sulfate

To a solution of 3.2 g of [4S-(4α,12aα)]-9-amino- 4-dimethylamino-1,2,3,4,4a,5,5a,6,11,11a,12, 12a-dodecahydro-10,12aα-dihydroxy-1,3,11,12-tetraoxo-2-naphthacenecarboxamide, prepared by the procedure described in U.S. Pat. No. 3,239,499, in 50 ml of water is added a solution of 2.5 g of sodium acetate in 12 ml of water. The mixture is cooled to 0 C. and 1 ml of acetic anhydride is added with stirring. The reaction is stirred for 20 minutes, 0.5 ml of ammonium hydroxide is added and stirred for 5 minutes. Two and one half ml of sulfuric acid is added, the reaction is extracted twice with n-butyl alcohol, the combined organic layers are washed with water and concentrated in vacuo. The residue is dissolved in methyl alcohol and added dropwise to 500 ml of diethyl ether. The solid is collected and dried to give 2.3 g of the desired product.

MS(FAB): m/z 472 (M+H) and 570 (M+H2SO4+H).

EXAMPLE 19 [4S-(4α,12aα)]-4-(Dimethylamino)-9-(formylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide monohydrochloride

To a 0 C. solution of 1.06 g of [4S-(4α,12aα)]-9-amino-4-dimethylamino-1,2,3,4,5a, 6,11,11a,12,12a-dodecahydro-10,12aα-dihydroxy-1,3,11, 12-tetraoxo-2-naphthacenecarboxamide, prepared by the procedures described in U.S. Pat. No. 3,239,499, in 50 ml of formic acid is added 2.4 ml of acetic anhydride. After stirring for 5 minutes, the cooling bath is removed and the reaction is stirred for 55 minutes. The mixture is added to 400 ml of diethyl ether. The resulting solid is collected, washed with diethyl ether and dried to give 1.1 g of the desired product.

MS (FAB): m/z 458 (M+H).

This procedure is a modification of U.S. Pat. No. 3,239,499.

EXAMPLE 20 [4S-(4α,12aα)]-4-(Dimethylamino)-9-(formylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-7-iodo-1,11-dioxo-2-naphthacenecarboxamide sulfate

To a well stirred 0 C. solution of 0.278 g of product from Example 19 in 10 ml of sulfuric acid is added, in portions, 0.1344 g of N-iodosuccinimide. The reaction is stirred at 0 C. for 20 minutes then poured into 500 ml of diethyl ether. The resulting solid is collected, washed with diethyl ether and dried to give 0.251 g of the desired product.

MS (FAB): m/z 584 (M+H).

EXAMPLE 21 [4S-(4α,12aα)]-4-(Dimethylamino)-9-(formylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-7-nitro-1,11-dioxo-2-naphthacenecarboxamide sulfate

To a well stirred 0 C. solution of 0.278 g of product from Example 19 in 10 ml of sulfuric acid is added 0.3 ml of 10% nitric acid in sulfuric acid. The reaction is stirred at 0 C. for 20 minutes then poured into 500 ml of diethyl ether. The resulting solid is collected, washed with diethyl ether and dried to give 0.26 g of the desired product.

MS (FAB): m/z 503 (M+H).

EXAMPLE 22 [4S-(4α,12aα)]-4-(Dimethylamino)-9-(formylamino)-7-[(1-methylethyl)amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide sulfate

A solution of 0.2 g of product from Example 21 (1:2 salt), 0.5 ml of acetone, 0.5 ml of 0.5N sulfuric acid and 10 ml of 2-methoxyethanol is shaken under 35 lbs. of hydrogen, in the presence of platinum oxide, for 2 hours. The catalyst is removed by filtration, the filtrate concentrated in vacuo to volume and poured into diethyl ether. The resulting solid is collected and dried to give 0.135 g of the desired product.

EXAMPLE 23 [4S-(4α,12aα)]-4,7-Bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-9-[(methoxyacetyl)amino]-1,11-dioxo-2-naphthacenecarboxamide

To a well stirred solution of 0.055 g of product from Example 2, 0.200 g of sodium bicarbonate and 1 ml of N-methylpyrrolidone is added a solution of 0.011 g of methoxyacetyl chloride in 0.5 ml of acetonitrile. After 5 minutes, the suspension is filtered and the filtrate diluted with 50 ml of tert-butyl methyl ether. The resulting solid is collected and dried to give 0.040 g of the desired product.

MS(FAB): m/z 545 (M+H).

EXAMPLE 24 [4S-(4α,12aα)]-4,7-Bis(dimethylamino)-9-(cyclopropylcarbonylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide

The title compound is prepared by the procedure of Example 23, using 0.055 g of product from Example 2, 0.20 g of sodium bicarbonate, 1.0 ml N-methylpyrrolidone, 0.010 g of cyclopropanecarbonyl chloride and 0.5 ml of acetonitrile to give 0.030 g of the desired product.

EXAMPLE 25 [4S-(4α,12aα)]-4,7-Bis(dimethylamino)-9-(chloroacetylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide

The title compound is prepared by the procedure of Example 23, using 0.055 g of product from Example 2, 0.20 g of sodium bicarbonate, 1 ml of N-methylpyrrolidone, 0.013 g of chloroacetyl chloride and 0.5 ml of acetonitrile to give 0.035 g of the desired product.

EXAMPLE 26 [4S-(4α,12aα)]-9-[(4-Bromo-1-oxobutyl)amino]-4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro- 3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide

The title compound is prepared by the procedure of Example 23, using 0.055 g of product from Example 2, 0.20 g of sodium bicarbonate, 1 ml of N-methylpyrrolidone, 0.025 g of 4-bromobutyryl chloride and 0.5 ml of acetonitrile to give 0.050 g of the desired product.

MS(FAB): m/z 622 (M+H).

EXAMPLE 27 [4S-(4α,12aα)]-4,7-Bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-9-[(1-oxo-2-propenyl)amino]-2-naphthacenecarboxamide

The title compound is prepared by the procedure of Example 23, using 0.055 g of product from Example 2, 0.20 g of sodium bicarbonate, 1.0 ml N-methylpyrrolidone, 0.011 g of acryloyl chloride and 0.5 ml of acetonitrile to give 0.040 g of the desired product.

MS (FAB): 513 (M+H).

EXAMPLE 28 [4S-(4α,12aα)]-9-[[(Acetyloxy)acetyl]amino]-4,7-Bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide

The title compound is prepared by the procedure of Example 23, using 0.055 g of product from Example 2, 0.20 g of sodium bicarbonate, 1.0 ml of N-methylpyrrolidone, 0.013 g of acetoxyacetyl chloride and 0.5 ml of acetonitrile to give 0.040 g of the desired product.

MS (FAB): m/z 573 (M+H).

EXAMPLE 29 [4S-(4α,12aα)]-4,7-Bis(dimethylamino)-9-(phenylthioacetylamino)-1,4,4a,5,5a,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide

The title compound is prepared by the procedure of Example 23, using 0.110 g of product from Example 2, 0.40 g of sodium bicarbonate, 4.0 ml of N-methylpyrrolidone, 0.035 g of phenylthioacetyl chloride and 0.5 ml of acetonitrile to give 0.075 g of the desired product.

EXAMPLE 30 [4S-(4α,12aα)]-4,7-Bis(dimethylamino)-9-(pyruvylamino)1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide

The title compound is prepared by the procedure of Example 23, using 0.110 g of product from Example 2, 0.40 g of sodium bicarbonate, 1.0 ml of N-methylpyrrolidone, 0.018 g of pyruvyl chloride and 0.5 ml of acetonitrile to give 0.060 g of the desired product.

EXAMPLE 31 [4S-(4α,12aα)]-4,7-Bis(dimethylamino)-9-(ethoxycarbonylacetylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide

The title compound is prepared by the procedure of Example 23, using 0.055 g of product from Example 2, 0.20 g of sodium bicarbonate, 1.0 ml of N-methylpyrrolidone, 0.013 g of ethyl malonyl chloride and 0.5 ml of acetonitrile to give 0.035 g of the desired product.

EXAMPLE 32 [4S-(4α,12aα)]-4,7-Bis(dimethylamino)-9-(4-bromophenylacetylamino)-1,4,4a,5,5a,6,11,12-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide

The title compound is prepared by the procedure of Example 23, using 0.055 g of product from Example 2, 0.20 g of sodium bicarbonate, 1.0 ml of N-methylpyrrolidone, 0.018 g of 4-bromophenylacetyl chloride and 0.5 ml of acetonitrile to give 0.040 g of the desired product.

EXAMPLE 33 [4S-(4α,12aα)]-9-(Benzoylamino)4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide

To a vigorously stirring solution of 0.066 g of product from Example 2, 0.085 g of sodium acetate and 3 ml of tetrahydrofuran is added 0.015 ml of benzoyl chloride and 0.25 ml of water. The reaction is stirred for 1 hour. The organic layer is decanted, washed with saturated sodium chloride, dried and concentrated in vacuo. The residue is chromatographed on acid-washed diatomaceous earth using a two phase system of hexane:ethyl acetate:2-methyoxyethanol:water (50:50:17:6) to give in the second void volume 0.030 g of the desired product as an orange solid.

MS(FAB): m/z 577 (M+H).

1H NMR (d6-DMSO): δ2.45 (s,6H,C(4)N(CH3)2), 2.57(s, 6-H,C(7)N(CH3)2), 7.5-7.6(m,3H, benzoyl), 7.86(s,1H, H-8), 7.96(d,J=7 Hz,2H, benzoyl).

EXAMPLES 34-41 (Table I)

Substantially following the method described in detail hereinabove in Example 33 using [4S-(4α,12aα)]- 9-amino-4,7-bis(dimethylamino)-1,4,4a, 5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide sulfate (product from Example 2), the compounds of this invention listed below in Examples 34-41 are prepared.

TABLE I
Ex. Acid Chloride Product Spectra
34 4-Methoxybenzoyl [4S-(4alpha,12aalpha)]-4,7- MS(FAB): m/z 607(M+H); 1H NMR
chloride Bis(dimethylamino)-1,4,4a,5 (d6-DMSO): delta 2.45(s, 6H,
5a,6,11,12a-octahydro-3,10, C(4)NMe2), 2.57(s, 6H, C(7)
12,12a-tetrahydroxy-9-[(4- NMe2), 7.06(d, J=9Hz, 2H of 4-
methoxybenzoyl)amino]-1,11- methoxybenzoyl), 7.84(s, 1H,
dioxo-2-naphthacenecarbox- H-8), 7.97(d, J=9Hz, 2H of 4-
amide methoxybenzoyl)
35 2-Methylbenzoyl [4S-(4alpha,12aalpha)]-4,7- MS(FAB): m/z 591(M+H); 1H NMR
chloride Bis(dimethylamino)-1,4,4a,5 (d6-DMSO): delta 2.52(m, 12H,
5a,6,11,12a-octahydro-3,10, C(4)NMe2 & C(7)NMe2), 7.25-
12,12a-tetrahydroxy-9-[(2- 7.56(m, 4H from 2-methylben-
methylbenzoyl)amino]-1,11- zoyl), 7.98(s, 1H, H-8)
dioxo-2-naphthacenecarbox-
amide
36 2-Fluorobenzoyl [4S-(4alpha,12aalpha)]-4,7- MS(FAB): m/z 595(M+H); 1H NMR
chloride Bis(dimethylamino)-9-[(2- (d6-DMSO): delta 2.47-2.51
fluorobenzoyl)amino]-1,4,4a, (m, 6H, C(4)NMe2), 2.57(bs, 6H,
5,5a,6,11,12a-octahydro-3,10, C(7)NMe2), 7.39(m, 2H from
12,12a-tetrahydroxy-1,11- 2-fluorobenzoyl), 7.63(m, 1H
dioxo-2-naphthacenecarbox- from 2-fluorobenzoyl), (m,
amide 1H from 2-fluorobenzoyl),
8.24(s, 1H, H-8)
37 Pentafluoro- [4S-(4alpha,12aalpha)]-4,7- MS(FAB): m/z 667(M+H); 1H NMR
benzoyl chloride Bis(dimethylamino)-1,4,4a, (d6-DMSO): delta 2.5(m, 12H,
5,5a,6,11,12a-octahydro-3,10, C(4)NMe2 & C(7)NMe2), 8.08
12,12a-tetrahydroxy-9- (s, 1H, H-8)
[(pentafluorobenzoyl)amino]-
1,11-dioxo-2-naphthacenecar-
boxamide
38 3-Trifluoro- [4S-(4alpha,12aalpha)-4,7- MS(FAB): m/z 645(M+H); 1H NMR
methylbenzoyl Bis(dimethylamino)-1,4,4a,5, (d6-DMSO): delta 2.50(m, 6H,
chloride 5a,6,11,12a-octahydro-3,10, C(4)NMe2), 2.57(m, 6H, C(7)
12,12a-tetrahydroxy-1,11- NMe2), 7.85(m, 2H of 3-tri-
dioxo-9-[[3-(trifluoro- fluoromethylbenzoyl), 7.99
methyl)benzoyl]amino)-2- (m, 1H of 3-trifluoromethyl-
naphthacenecarboxamide benzoyl), 8.28(1H of 3-tri-
fluoromethylbenzoyl), 8.33
(s, 1H, H-8), 8.31-8.42(m, 2H)
39 2-Furoyl [4S-(4alpha,12aalpha)]-4,7- MS(FAB): m/z 567(M+H); 1H NMR
chloride Bis(dimethylamino)-9-[(2- (d6-DMSO): delta 2.47(m, 6H,
furanylcarbonyl)amino]-1,4, C(4)NMe2), 2.56(s, 6H, C(7)
4a,5,5a,6,11,12a-octahydro- NMe2), 6.73(s, 1H of furanyl)
3,10,12,12a-tetrahydroxy- 7.31(s, 1H of furanyl), 7.95
1,11-dioxo-2-naphthacene- (s, 1H of furanyl), 8.00(s,
carboxamide 1H, H-8)
40 2-Thiophene- [4S-(4alpha,12aalpha)]-4,7- MS(FAB): m/z 583(M+H); 1H NMR
carbonyl Bis(dimethylamino)-1,4,4a, (d6-DMSO): delta 2.49(m, 6H,
chloride 5,5a,6,11,12a-octahydro- C(4)NMe2), 2.56(s, 6H, C(7)
3,10,12,12a-tetrahydroxy- NMe2), 7.21(m, 1H of
1,11-dioxo-9-[(2-thienyl- thienyl), 7.70(s, 1H, H-8),
carbonyl)amino]-2-naphtha- 7.85(m, 1H of thienyl), 8.01
cenecarboxamide (m, 1H of thienyl)
41 4-Nitro- [4S-(4alpha,12aalpha)]-4,7- MS(FAB): m/z 622(M+H); 1H NMR
benzoyl Bis(dimethylamino)-1,4,4a, (d6-DMSO): delta 2.50(m, 6H,
chloride 5,5a,6,11,12a-octahydro- C(4)NMe2), 2.57(s, 6H, C(7)
3,10,12,12a-tetrahydroxy-9- NMe2), 7.76(s, 1H, H-8), 8.20
[(4-nitrobenzoyl)amino]- (d, J=9Hz, 2H of 4-nitrobenzoyl),
1,11-dioxo-2-naphthacene- 8.36(d, J=9Hz, 2H of 4-
carboxamide nitrobenzoyl)

EXAMPLE 42 [4S-(4α,12aα)]-9-[(4-Aminobenzoyl)amino]-4,7-Bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide sulfate

A mixture of 0.030 g of product from Example 41, 0.010 g of 10% palladium-on-carbon, 1.5 ml of 2-methoxyethanol and 0.175 ml of 2N sulfuric acid, in a pressure bottle, is shaken under 30 lbs. of hydrogen pressure for 40 minutes. The catalyst is removed by filtration and the filtrate is concentrated in vacuo and codistilled with benzene. The oily residue is dissolved in 0.5 ml of 2-methoxyethanol, precipitated with diethyl ether and the solid collected to give 0.018 g of the desired product.

MS (FAB): m/z 592 (M+H).

EXAMPLE 43 [4S-(4α,12aα)]-4,7-Bis(dimethylamino)-9-[[(4-dimethylamino)benzoyl]amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide

A mixture of 0.065 g of product from Example 41, 2.0 ml of 2-methoxyethanol, 0.025 g of 10% palladium-on-carbon, 0.4 ml of 2N sulfuric acid and 0.3 ml of 37% aqueous formaldehyde, in a pressure bottle, is shaken under 30 lbs. of hydrogen pressure for 50 minutes. The catalyst is removed by filtration and the filtrate is concentrated in vacuo and codistilled with heptane. The oily residue is dissolved in 1.0 ml of 2-methoxyethanol, precipitated with diethyl ether to give 0.085 g of the desired product as the sulfate salt. The sulfate salt is dissolved in 0.5 ml of water and 6 ml of tetrahydrofuran followed by the addition of 0.10 g of sodium acetate. The organic layer is washed with saturated sodium chloride, dried and concentrated in vacuo. The residue is triturated with ethyl acetate/heptane to give 0.035 g of the desired product as the free base.

MS(FAB): m/z 620 (M+H)

1H NMR (d6-DMSO): δ2.50(m,6H,C(4)NMe2), 2.57(s, 6H, C(7)NMe2), 3.33(s,6H, NMe2 of 4-dimethylaminobenzoyl), 7.76(s,1H,H-8), 8.20(d,J=9 Hz,2H of 4-dimethylaminobenzoyl), 8.37(d,J=9 Hz,2H of 4-dimethylaminobenzoyl).

EXAMPLE 44 [7S-(7α,10aα)]-[2-[[9-(Aminocarbonyl)-4,7-Bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]amino]-2-oxoethyl]carbamic acid 1,1-dimethylethyl ester

A mixture of 0.850 g of product from Example 2 (as the disulfate), 0.680 g of sodium acetate in 25 ml of tetrahydrofuran and 5 ml of water is stirred at 25 C. for 5 minutes. The solution is treated with 0.359 g of (succinimyloxycarbonyl)methyl carbamic acid tert-butyl ester, stirred for 2 hours and extracted with chloroform. The organic layer is concentrated in vacuo to give 0.50 g of the desired product.

MS (FAB): m/z 630 (M+H).

EXAMPLE 45 [4S-(4α,12aα)]-9-[(Aminoacetyl)amino]-4,7-Bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide mono(trifluoroacetate)

A solution of 0.030 g of product from Example 44 and 1.0 ml of trifluoroacetic acid is maintained at 24 C. for 24 hours followed by concentrating in vacuo. The residue is triturated with methyl alcohol and the solid collected to give 0.024 g of the desired product.

MS (FAB): m/z 530 (M+H).

EXAMPLE 46 [4S-(4α,12aα)]-4,7-Bis(dimethylamino)-9-[[(dimethylamino)acetyl]amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide sulfate

A mixture of 0.030 g of product from Example 45, 0.020 g of 10% palladium-on-carbon, 0.5 ml of 37% formaldehyde, 1.5 ml of 2-methoxyethanol and 0.175 ml of 2N sulfuric acid, in a pressure bottle, is shaken under 30 lbs. of hydrogen pressure for 40 minutes. The catalyst is removed by filtration and the filtrate is concentrated in vacuo and codistilled with benzene. The oily residue is dissolved in 0.5 ml of 2-methoxyethanol, precipitated with diethyl ether and the precipitate collected to give 0.025 g of the desired product.

EXAMPLE 47 [4S-(4α,12aα)]-4,7-Bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-9-[(phenylsulfonyl)amino]-2-naphthacenecarboxamide

A mixture of 0.30 g of product from Example 2, 0.40 g of sodium acetate in 10 ml of tetrahydrofuran and 1.5 ml of water is stirred for 10 minutes under argon. The organic layer is separated, dried over anhydrous sodium sulfate and treated with 0.125 ml of benzenesulfonyl chloride and 0.60 g of sodium bicarbonate. The reaction is stirred vigorously for 1.5 hours. The organic layer is decanted and codistilled with heptane. The residue is dissolved in ethyl acetate, dried and concentrated in vacuo. The residue is chromatographed on diatomaceous earth using hexane:ethyl acetate:2-methoxyethanol:water (35:65:15:5) to give 0.036 g of the desired product as a yellow solid.

MS(FAB): m/z 613 (M+H).

1H NMR (CDCl3): δ2.44(bs,6H,C(4)NMe2), 2.55(s,6H, C(7)-NMe2, 7.38-7.45(m,2H,m-H's from benzenesulfonyl), 7.52-7.56(m,1H,p-H from benzenesulfonyl), 7.58(s,1H,H-8), 7.78(d,J=7 Hz,2H,o-H's from benzenesulfonyl).

EXAMPLES 48-53 (Table II)

Substantially following the method described in detail hereinabove in Example 47 using [4S-(4α,12aα)]- 9-amino-4,7-bis(dimethylamino)-1,4,4a, 5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide sulfate (product from Example 2) and the appropriate alkyl, aryl or heteroarylsulfonyl chloride, the compounds of this invention listed below in Examples 48-53 are prepared.

TABLE II
Ex. Sulfonyl Chloride Product Spectra
48 4-Chlorobenzene- [4S-(4alpha,12aalpha)]-9- MS(FAB): m/z 622(M+H); 1H NMR
sulfonyl chloride [[(4-chlorophenyl)sulfonyl]- (d6-DMSO): delta 2.48(m, 12H,
amino]-4,7-bis(dimethyl- C(4)NMe2 & C(7)NMe2), 7.16
amino)-1,4,4a,5,5a,6,11,12a (s, 1H, H-8), 7.62 d, J=9Hz, 2H
tetrahydroxy-1,11-dioxo-2- of 4-chlorobenzenesulfonyl),
naphthacenecarboxamide 7.75(d, J=9Hz, 2H of 4-chloro-
benzenesulfonyl)
49 3-Nitrobenzene- [4S-(4alpha,12aalpha)]-4,7- MS(FAB): m/z 658(M+H); 1H NMR
sulfonyl chloride Bis(dimethylamino)-1,4,4a,5 (d6-DMSO): delta 2.44-2.45
5a,6,11,12a-octahydro-3,10, (m, 12H, C(4)NMe2) & C(7)NMe2
12,12a-tetrahydroxy-9-[(3- 7.51-7.62(m, 3H of 3-nitro-
nitrophenyl)sulfonyl]amino]- benzenesulfonyl), 7.74-7.78
1,11-dioxo-2-naphthacenecar- (m, 1H of 3-nitrobenzenesul-
boxamide fonyl), 7.75(s, 1H, H-8)
50 4-Nitrobenzene- [4S-(4alpha,12aalpha)]-4,7- MS(FAB): m/z 658(M+H); 1H NMR
sulfonyl chloride Bis(dimethylamino)-1,4,4a,5, (CDCl3): delta 2.46(s, 6H, C(4)
5a,6,11,12a-octahydro-3,10, NMe2), 2.58(s, 6H C(7)NMe2)
12,12a-tetrahydroxy-9- 7.59(s, 1H, H-8), 7.96(d, J=
[[(4-nitrophenyl)sulfonyl) 9Hz, 2H of 4-nitrobenzene-
amino]-1,11-dioxo-2- sulfonyl), 8.25(d, J=9Hz,
naphthacenecarboxamide 2H of 4-nitrobenezene-
sulfonyl).
51 2-Thiophene [4S-(4alpha,12aalpha)]-4,7- MS(FAB): m/z 619(M+H); 1H NMR
sulfonyl Bis(dimethylamino)-1,4,4a,5, (d6-DMSO): delta 2.50(m, 6H,
chloride 5a,6,11,12a-octahydro-3,10, C(4)NMe2), 2.54(s, 6H, C(7)
12,12a-tetrahydroxy-1,11- NMe2), 7.14(m, 1H of thienyl),
dioxo-9-[(2-thienylsulfonyl) 7.20(m, 1H of thienyl), 7.51
amino]-2-naphthacenecarbox- (s, 1H of thienyl), 7.91(s,
amide 1H, H-8)
52 2-Acetamido-4- [4S-(4alpha,12aalpha)]-4- MS(FAB): m/z 691(M+H); 1H NMR
methyl-5-thiazole [[)2-(Acetylamino)-4-methyl- (CDCl3) delta 2.21(s, 3H, thia-
sulfonyl 5-thiazolyl]sulfonyl]amino]- zoyl H CCONH), 2.40(s, 3H,
chloride 4,7-bis(dimethylamino)-1,4, thiazoyl H3C), 2.54(s, 6H, C(4)
4a,5,5a,6,11,12a-octahydro- NMe2), 2.51(s, 6H, C(7)NMe2),
3,10,12,12a-tetrahydroxy-1, 7.68(s, 6H, C(7)NMe2, 7.65(s,
11-dioxo-2-naphthacenecar- 1H, H-8)
boxamide
53 Ethane sulfonyl [4S-(4alpha,12aalpha)]-4,7- MS(FAB): m/z 565(M+H); 1H NMR
chloride Bis(dimethylamino)-9- (CDCl3): delta 0.88(t, 3H, CH 3
[(ethylsulfonyl)amino]-1,4, CH2SO2), 2.4-2.6(m, 12H, C(4)
4a,5,5a,6,11,12a-octahydro- NMe2 & C(7)NMe2), 3.34(q, 2H,
3,10,12,12a-tetrahydroxy- CH3CH 2SO2) 7.61(s, 1H, H-8)
1,11-dioxo-2-naphthacene-
carboxamide

EXAMPLE 54 [4S-(4α,12aα)]-4,7-Bis(dimethylamino)-9-(formylamino)-1,4,4a,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-N-(1-pyrrolidinylmethyl)-2-naphthacenecarboxamide

A solution of 0.30 g of product from Example 3 and 1.2 equivalents of 30% aqueous formaldehyde in 6.0 ml of 2-methoxyethanol is treated with 5.0 equivalents of pyrrolidine. The reaction is stirred vigorously at room temperature for 1.5 hours. The crystalline solid is collected and dried to give 0.25 g of the desired product.

MS(FAB): m/z 584 (M+H).

EXAMPLE 55 [4S-(4α,12aα)]-4,7-Bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-9-[(methanesulfonyl)amino]-1,11-dioxo-2-naphthacenecarboxamide

A mixture of 0.30 g of product from Example 2, 0.40 g of sodium acetate in 10 ml of tetrahydrofuran and 1.5 ml of water is stirred for 10 minutes at room temperature under argon. The organic layer is separated, dried over sodium sulfate, filtered and treated with 0.10 ml of methanesulfonyl chloride and 0.60 g of sodium bicarbonate. The reaction is stirred vigorously for 1.5 hours. The organic layer is decanted and codistilled with heptane. The residue is dissolved in ethyl acetate, dried and concentrated in vacuo. The crude product is chromatographed on diatomaceous earth using hexane:ethyl acetate:2-methoxyethanol:water (35:65:15:5) to give 0.016 g of the desired product as a yellow solid.

MS (FAB): m/z 551 (M+H).

EXAMPLE 56 [4S-(4α,12aα)]-4,7-Bis(dimethylamino)-9-[(methanesulfonyl)amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-N-(pyrrolidinylmethyl)-2-naphthacenecarboxamide

A solution of 0.30 g of product from Example 55 and 1.2 equivalents of 30% aqueous formaldehyde in 6.0 ml of 2-methoxyethanol is treated with 5.0 equivalents of pyrrolidine. The reaction is stirred vigorously at room temperature for 1.5 hours. The crystalline solid is collected and dried to give 0.250 g of the desired product.

MS(FAB): m/z 634 (M+H).

EXAMPLE 57 4S-(4α,12aα)]-4,7-Bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-9-[[(phenylmethoxy)acetyl]amino]-2-naphthacenecarboxamide

The title compound is prepared by the procedure of Example 23, using 0.055 g of product from Example 2, 0.20 g of sodium bicarbonate, 1.0 ml of N-methylpyrrolidine, 0.018 g of benzyloxyacetyl chloride and 0.5 ml of acetonitrile to give 0.060 g of the desired product.

MS (FAB): m/z 622 (M+H).

EXAMPLE 58 [7S-(7α,10aα)]-[[9-(Aminocarbonyl)-4,7-Bis(dimethylamino)-5,5a,6,6a,7,10,10a12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]amino] oxo-acetic acid ethyl ester

The title compound is prepared by the procedure of Example 23, using 0.055 g of product from Example 2, 0.20 g of sodium bicarbonate, 1.0 ml of N-methylpyrrolidone, 0.015 g of ethyl oxalyl chloride and 0.5 ml of acetonitrile to give 0.030 g of the desired product.

MS(FAB): m/z 574 (M+H).

EXAMPLE 59 [4S-(4α,12aα)]-4,7-Bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-9-[(hydroxyacetyl)amino]-1,11-dioxo-2-naphthacenecarboxamide

A mixture of 0.048 g of product from Example 28 and 0.6 ml of concentrated sulfuric acid is stirred at room temperature for 2 hours, poured into diethyl ether and the precipitated salt collected. The salt is dissolved in 10 ml of tetrahydrofuran, 0.250 g of sodium acetate is added and the mixture stirred for 1 hour. The reaction is filtered and the filtrate is concentrated in vacuo. The residue is chromatographed on a poly(styrene-vinyl benzene)copolymer column with water:acetonitrile (1:1) to give 0.018 g of the desired product as a light yellow solid.

MS (FAB): m/z 532 (M+H).

EXAMPLE 60 [4S-(4α,12aα)]-9-(Acetylamino)-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetra-hydroxy-1,11-dioxo-2-naphthacenecarboxamide sulfate

To a 0 C. solution of 1.06 g of [4S-(4α,12aα)]- 9-amino-4-(dimethylamino)-1,2,3,4,4a,5,5a,6,11,11a,12, 12a-dodecahydro-10,12aα-dihydroxy-1, 3,11,12-tetraoxo-2-naphthacenecarboxamide, prepared by the procedures described in U.S. Pat. No. 3,239,499, in 50 ml of acetic acid is added 2.4 ml of acetic anhydride. After 5 minutes, the reaction is allowed to warm to room temperature. The reaction mixture is poured into 500 ml of diethyl ether and the resulting precipitate is collected. The precipitate is washed with diethyl ether and dried to give 1.1 g of the desired product.

MS(FAB): m/z 472 (M+H).

EXAMPLE 61 [4S-(4α,12aα)]-4-(Dimethylamino)-9-(acetylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-7-iodo-1,11-dioxo-2-naphthacenecarboxamide sulfate

To a stirring 0 C. solution of 0.278 g of product from Example 60 in 10 ml of sulfuric acid is added, portionwise, 0.1344 g of N-iodosuccinimide. After stirring at 0 C. for 20 minutes, the reaction mixture is poured into 400 ml of diethyl ether. The resultant precipitate is collected, washed with diethyl ether and dried to give 1.1 g of the desired product as a solid.

MS(FAB): m/z 598 (M+H) and 696 (M+H2SO4+H).

EXAMPLE 62 [7S-(7α,10aα)]-[9-(Aminocarbonyl)-4,7-Bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]carbamic acid methyl ester

To a room temperature mixture of 0.60 g of product from Example 2 in 2 ml of 1-methyl-2-pyrrolidinone is added 0.60 g of sodium bicarbonate. The mixture is stirred for 5 minutes followed by the addition of 0.12 ml of methyl chloroformate. The reaction is stirred at room temperature for 30 minutes and filtered into 200 ml of t-butyl methyl ether. The resulting solid is collected and dried to give 0.370 g of the desired product.

MS(FAB): m/z 531 (M+H).

1H NMR (d6DMSO): δ2.6(s,12H,C(4)NMe2 and C(7)NMe2), 3.7(m,3H,o-CH 3), 7.8(s,1H,H-3), 8.7(s,1H,aromatic NH), 9.1(d,2H,CONH2).

EXAMPLE 63 [7S-(7α,10aα)]-[9-(Aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]carbamic acid (2-diethylamino) ethyl ester

The title compound is prepared by the procedure of Example 62, using 0.443 g of product from Example 2, 2 ml of 1-methyl-2-pyrrolidone, 0.165 g of β-diethylaminoethyl chlorocarbonate hydrochloride and 0.443 g of sodium bicarbonate to give 0.350 g of the desired product.

1H NMR (d6DMSO): δ1.2(m,6H,-N(CH2CH 3)2), 2.5(s, 6H, C(7)NMe2), 2.7(s,6H,C(4)NMe2), 3.4(m,2H, OCH2CH 2N), 3.51(m,4H,-N(CH 2CH3)2), 4.0(m,2H,OCH 2CH2N), 6.8(s,1H,H-3), 9.0(d,2H,CONH2).

EXAMPLE 64 [7S-(7α,10aα)]-[9-(Aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl] carbamic acid ethenyl ester

The title compound is prepared by the procedure of Example 62, using 0.189 g of product from Example 2, 1 ml of 1-methyl-2-pyrrolidone, 0.75 ml of acetonitrile, 0.20 g of sodium bicarbonate and 0.037 g of vinyl chloroformate to give 0.133 g of the desired product.

MS (FAB): m/z 548 (M+H).

1H NMR (d6DMSO+TFA): δ4.35(s,1H,H-7), 4.6(d,1H, CH═CH2cis), 4.9 (d, 1H, CH═CH2,trans), 7.2(m, 2H, OCH═CH2), 8.1(s,1H,H-3), 9.6 & 9.1(s,2H,CONH2), 9.61(s,H,aromatic NH)

EXAMPLE 65 [7S-(7α,10aα)]-[9-(Aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]carbamic acid 2-propenyl ester

The title compound is prepared by the procedure of Example 62, using 0.213 g of product from Example 2, 1 ml of 1-methyl-2-pyrrolidone, 0.75 ml of acetonitrile, 0.20 g of sodium bicarbonate and 0.054 g of allyl chloroformate to give 0.143 g of the desired product.

1H NMR (d6DMSO+TFA): δ4.65(d,2H,═CHCH 2), 5.25(d,1H, CH═CH 2cis), 5.4(d,1H,CH═CH 2trans), 6.0 (m,1H,CH2═CH 2), 8.1(s,1H,H-3), 9.1(s,1H,aromatic NH), 9.6 & 9.0 (s,2H, CONH2).

Substantially following the methods described in detail hereinabove in Example 23, the compounds of this invention listed below in Examples 66-82 are prepared. Example 72 uses the appropriate anhydride rather than the acid chloride.

EXAMPLE 66 [4S-(4α,12aα)]-4-(Dimethylamino)-9-[[(4-fluorophenoxy)acetyl]amino]-1,4,4,a,5,5,a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-7-iodo-1,11-dioxo-2-naphthacenecarboxamide. EXAMPLE 67 [7S-(7α,10aα)]-N-[9-(Aminocarbonyl)-4,7-Bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-2-thiopheneacetamide. EXAMPLE 68 [4S-(4α,12aα)]-9-[[(Dimethylamino)acetyl]amino]-4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide. EXAMPLE 69 [4S-(4α,12aα)]-4-(Dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro- 3,10,12,12a-tetrahydroxy-7-iodo-9-[[(methylthio)acetyl]amino]-1,11-dioxo-2-naphthacenecarboxamide. EXAMPLE 70 [4S-(4α,12aα)]-4-(Dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-7-[(1-methylethyl)amino]-1,11-dioxo-9-[(3,3,3-trichloro-1-oxopropyl)amino]- 2-naphthacenecarboxamide. EXAMPLE 71 [4S-(4α,12aα)]-4,7-Bis(dimethylamino)-9-[(1,3-dioxo-3-phenylpropyl)amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,12-dioxo-2-naphthacenecarboxamide. EXAMPLE 72 [4S-(4α,12aα)]-4,7-Bis(dimethylamino)-9-[4-(dimethylamino)-1-oxobutyl]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide. EXAMPLE 73 [4S-(4α,12aα)]-4-(Dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-9-[[(phenylsulfonyl)acetyl]amino]-2-naphthacenecarboxamide. EXAMPLE 74 [7S-(7α,10aα)]-N-[9-(Aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a-octahydro-1,8,10a,11-tetrahydroxy-4-iodo-10,12-dioxo-2-naphthacenyl]-5-methyl-2-furanacetamide. EXAMPLE 75 [7S-(7α,10aα)]-N-[9-(Aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-2-thiazoleacetamide. EXAMPLE 76 [7S-(7α,10aα)]-2-[[[9-(Aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]amino]carbonyl]benzoic acid. EXAMPLE 77 [7S-(7α,10aα)]-N-[9-(Aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-3-methyl-2-oxo-1-imidazolidineacetamide. EXAMPLE 78 [7S-(7α,10aα)]-N-[9-(Aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-5,6-dimethylpyrazinecarboxamide. EXAMPLE 79 [7S-(7α,10aα)]-N-[9-(Aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-3-methyl-3H-imidazo[4,5-b]pyridine-2-acetamide. EXAMPLE 80 [4S-(4α,12aα)]-4,7-Bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-9-[[(pentafluorophenyl)acetyl]amino]-2-naphthacenecarboxamide. EXAMPLE 81 [7S-(7α,10aα)]-N-[9-(Aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-4-iodo-10,12-dioxo-2-naphthacenyl]-4-ethyl-2,3-dioxo-1-piperazinecarboxamide. EXAMPLE 82 [7S-(7α,10aα)]-N-[9-(Aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-4-ethyl-2,3-dioxo-1-piperazinecarboxamide. EXAMPLES 83-86

Substantially following the methods described in detail hereinabove in Example 44, the compounds of this invention listed below in Examples 83-86 are prepared.

EXAMPLE 83 [7S-(7α,10aα)]-[2-[[9-Aminocarbonyl-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy1,1210,12-dioxo-2-napthacenyl]amino]-2-oxoethyl]carbamic acid 1,1-dimethyl ester. EXAMPLE 84 [7S-[2(S*),(7α,10aα)]]-[2-[[9-(Aminocarbonyl)-4-(diethylamino)- 7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro- 1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl] amino]-1-methyl-2-oxoethyl]carbamic acid 1,1-dimethylethyl ester. EXAMPLE 85 [7S-[2(S*),(7α,10aα)]]-[2-[[9-(Aminocarbonyl)-4,7-bis (dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8, 10a,11-tetrahydroxy-10,12-dioxo-2- naphthacenyl]amino]- 2-oxo-1-phenylethyl]carbamic acid 1,1-dimethylethyl ester. EXAMPLE 86 [7S-[2(S*),(7α,10aα)]]-[4-[[9-(Aminocarbonyl)-4,7-bis (dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8, 10a,11-tetrahydroxy-10,12-dioxo-2- naphthacenyl]amino]- 3-[[(1,1-dimethylethoxy)carbonyl]amino]-4-oxobutanoic acid 1,1-dimethylethyl ester. EXAMPLES 87-91

Substantially following the methods described in detail hereinabove in Examples 45, the compounds of this invention listed below in Examples 87-91 are prepared.

EXAMPLE 87 [4S-(4α,12aα)]-9-[(Aminoacetyl)amino]-7-(diethylamino)-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide. EXAMPLE 88 [4S-(4α,9(S*),12aα)]-9-[(2-Amino-1-oxopropyl)amino]-7-(dimethylamino)-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide. EXAMPLE 89 [4S-(4α,9(S*),12aα)]-9-[(Aminophenylacetyl)amino]-4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide. EXAMPLE 90 [7S-[2(S*),7α,10aα)]]-3-Amino-4-[[9-(aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro- 1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]amino]-4-oxobutanoic acid. EXAMPLE 91 [7S-[2(S*),7α,10aα)]]-4-[[9-(Aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10,10a-tetrahydroxy-10,12-dioxo-2-naphthacenyl]amino]-3-(dimethylamino)-4-oxobutanoic acid. EXAMPLES 92-94

Substantially following the methods described in detail hereinabove in Example 47, the compounds of this invention listed below in Examples 92-94 are prepared.

EXAMPLE 92 [4S-(4α,12aα)]-4-(Dimethylamino)-9-[[(2,2-dimethylpropyl)sulfonyl]amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-7-[(1-methylethyl)amino]-1,11-dioxo-2-naphthacenecarboxamide. EXAMPLE 93 [7S-(7α,10aα)]-4-[[[9-(Aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]amino] sulfonyl]butanoic acid. EXAMPLE 94 [4S-(4α,12aα)]-4-(Dimethylamino)-9-[[(1,1-dimethylethyl)sulfonyl]amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-7-iodo-1,11-dioxo-2-naphthacenecarboxamide. EXAMPLE 95 [4S-(4α,12aα)]-4,7-Bis(dimethylamino]-9-[[(diethylamino)acetyl]amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide sulfate

The title compound is prepared by the procedure of Example 46, using 0.030 g of product from Example 45, 0.020 g of 10% palladium-on-carbon, 2.5 equivalents of acetaldehyde, 1.5 ml of 2-methoxyethanol and 0.175 ml of 2N sulfuric acid to give the desired product as a solid.

EXAMPLE 96

Dimethylaminoacetyl chloride hydrochloride

A mixture of 15 g of N,N-dimethylglycine hydrochloride (pulverized and dried in a vacuum oven at 45-50 C. for 24 hours) and 13.85 ml of thionyl chloride is heated, very slowly, in a sand bath to 78 C. and kept at this temperature for 1 hours. Toluene is added to the mixture and the excess liquid is removed by pipette. This step is repeated several times. The solid is then transferred to a Buchner funnel, washed with methylene chloride and dried under vacuum at 50 C. for 24 hours to yield 14.2 g of the desired intermediate.

EXAMPLE 97 [4S-(4alpha,12aalpha)]-4,7-Bis(dimethylamino)-9-[[(dimethylamino)acetyl]amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide dihydrochloride

To a mixture of 6.68 g of 9-amino-4,7-bis(dimethylamino)- 6-demethyl-6-deoxytetracycline in 120 ml of DMPU and acetonitrile is added 6.57 g of sodium carbonate. The mixture is stirred for 5 minutes, followed by the addition of 2.83 g of product from Example 96. The reaction is stirred for 1 hour, filtered and the filtrate is added slowly to a mixture of methylene chloride/diethyl ether (1200 ml/400 ml). The solid is collected, dissolved in 250 ml methyl alcohol and added slowly to 1600 ml of methylene chloride. The precipitate is collected, washed with diethyl ether and dried to give 5.75 g of the desired product.

MS(FAB): m/z 558 (M+H).

EXAMPLE 98 [4S-4alpha,12aalpha)]-9-[(Chloroacetyl)amino]-4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide dihydrochloride

To a room temperature solution of 0.334 g of 9-amino-4,7-bis(dimethyamino)-6-dimethyl-6-deoxytetracycline sulfate, 6 ml of 1,3-dimethyl-3,4,5,6-tetrahydro- 2(1H)pyrimidinone, hereinafter called DMPU, and 2 ml of acetonitrile is added 0.318 g of sodium carbonate. The mixture is stirred for 5 minutes followed by the addition of 0.068 g of chloroacetyl chloride. The reaction is stirred for 30 minutes, filtered, and the filtrate added dropwise to 100 ml of diethyl ether, containing 1 ml of 1M hydrochloric acid in diethyl ether. The resulting solid is collected and dried to give 0.340 g of the desired product.

MS (FAB): m/z 549 (M+H).

EXAMPLE 99 [4S-(4alpha,12aalpha)]-9-[(Bromoacetyl)amino]-4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide dihydrochloride

The title compound is prepared by the procedure of Example 98, using 0.668 g of 9-amino-4,7-bis(dimethylamino)- 6-dimethyl-6-deoxytetracycline sulfate, 6 ml of DMPU, 2 ml of acetonitrile, 0.636 g of sodium carbonate and 0.215 g of bromoacetyl chloride. Seven tenths of a gram of the desired product is obtained.

MS(FAB): m/z 593 (M+H).

EXAMPLE 100 [4S-(4alpha,12aalpha)]-9-[(Bromoacetyl)amino]-4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide (free base)

To 0.20 g of product from Example 99 in 3 ml of 1,3-dimethyl-2-imidazolidenone is added 0.30 g of sodium bicarbonate. The reaction is stirred at room temperature for 15 minutes and filtered. The filtrate is added to 15 ml of diethyl ether and the resulting precipitate is collected to give 0.150 g of the desired product as the free base.

EXAMPLE 101 [4S-(4alpha,12aalpha)]-9-[(Bromoacetyl)amino]-4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide monohydrobromide

To a solution of 5.01 g of 9-amino-4,7-bis(dimethylamino)- 6-dimethyl-6-deoxytetracycline, 100 ml of DMPU and 25 ml of acetonitrile is added 5.0 g of sodium carbonate. The reaction is stirred, under argon, at room temperature for 5 minutes, followed by the addition of 3.03 g of bromoacetyl bromide. The stirring is continued for an additional hour. The solid is collected and the filtrate is added slowly to isopropyl alcohol/diethyl ether (200 ml/750 ml). The yellow solid is collected, washed with isopropanol and diethyl ether to give 5.77 g of the desired intermediate.

MS(FAB): m/z 593 (M+H).

EXAMPLE 102 [4S-(4alpha,12aalpha)]-9-[(2-Bromo-1-oxopropyl)amino]-4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide hydrobromide

The title compound is prepared by the procedure of Example 98, using 1.00 g of 9-amino-4,7-bis(dimethylamino)- 6-demethyl-6-deoxytetracycline, 1.0 g of sodium carbonate and 0.648 g of 2-bromopropionyl bromide to give 0.981 g of the desired product.

MS(FAB): m/z 607 (M+H).

EXAMPLE 103 [4S-(4alpha,12aalpha)]-9-[(4-Bromo-1-oxobutyl)amino]-7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide dihydrochloride

The title compound is prepared by the procedure of Example 98, using 1.34 g of 9-amino-4,7-bis(dimethylamino)- 6-demethyl-6-deoxytetracycline sulfate, 1.3 g of sodium carbonate, 24 ml of DMPU, 8 ml of acetonitrile and 0.389 g of 4-bromobutyryl chloride to give 1.45 g of the desired product.

EXAMPLE 104 [4S-(4alpha,12aalpha)]-4,7-Bis(dimethylamino)-9-[[(dimethylamino)acetyl]amino]-1,4,4a,5,5a,6,11,12a-octa-hydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide dihydrochloride

To a solution of 0.15 g of product from Example 99 in 4 ml of DMPU is added 0.85 g of dimethylamine (40% in water). The reaction is stirred for 20 minutes followed by concentration in vacuo to remove any excess dimethylamine. The mixture is filtered and the filtrate added, dropwise, to 70 ml of isopropyl alcohol/diethyl ether (1:1). To this solution is added 1 ml of 1M hydrochloric acid/diethyl ether. The resulting precipitate is collected, washed with isopropyl alcohol and diethyl ether, and dried to give 0.11 g of the desired product.

MS(FAB): m/z 558 (M+H).

EXAMPLE 105 [4S-(4alpha,12aalpha)]-4,7-Bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-9-[[(methylamino)acetyl]amino]-1,11-dioxo-2-naphthacenecarboxamide dihydrochloride (331,256)

A mixture of 0.1258 g of product from Example 99, 5 ml of 40% methylamine in water and 5 ml of methyl alcohol, under Argon, is stirred at room temperature for 30 minutes. The excess methylamine is removed in vacuo and the residue diluted with a small volume of methyl alcohol. The diluted reaction solution is added dropwise to 100 ml of diethyl ether containing 1 ml of 1M hydrochloric acid in diethyl ether and 10 ml of isopropyl alcohol. The resulting solid is collected and dried to give 0.106 g of the desired product.

MS(FAB): m/z 544 (M+H).

Substantially following the methods described in detail herein above in Example 105, the compounds of this invention listed below in Examples 106-125 are prepared.

Starting
Material
Example Prod. of NS(FAB):
# Name Exp. Reactant Rx Time m/z
106 [7S-(7alpha,10aalpha)]-N-[9-Aminocarbonyl)-4,7-bis(di- 99 Morpholine 0.5 hr. 600(M+H)
methylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-
tetrahydroxy-10,12-dioxo-2-naphthacenyl]-4-morpholineacet-
amide dihydrochloride
107 [4S-(4alpha,12aalpha,)]-4,7-Bis(dimethylamino)-9-[[(ethyl- 99 Ethylamine 2 hr 558(M+H)
amino)acetyl]amino]-1,4,4a,5,5a,6,11,12,-octahydro-3,10,- (70% in water)
12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide
dihydrochloride.
108 [4S-(4alpha,12aalpha)]-9-[[(Cyclopropylamino)acetyl]amino]- 99 Cyclopropylamine 2 hr. 570(M+H)
4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,-
12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide di-
hydrochloride.
109 [4S-(4alpha,12aalpha)]-4,7-Bis(dimethylamino)-9-[[(butyl- 99 Butylamine 2 hr. 586(M+H)
amino)acetyl]amino]-1,4,4.,5,5a,6,11,12a-octahydro-3,10,12,-
12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide dihy-
drochloride.
110 [4S-(4alpha,12aalpha)]-9-[[(Diethylamino)acetyl]amino]-4,7- 99 Diethylamine 2 hr. 586(M+H)
bis(dimethylamino)-1,4,4a,5,5a,6,11,12,-octahydro-3,12,12,-
12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboximide dihy-
drochloride.
111 [7S-(7alpha,10aalpha)-N-]9-(Aminocarbonyl)-4,7-bis(dimethyl- 99 Pyrrolidine 0.5 hr. 584(M+H)
amino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10,,11-tetrahydr-
oxy-10,12-dioxo-2-naphthacenyl]-1-pyrrolidineacetamide dihy-
drochloride.
112 [4S-(4alpha,12aalpha)]-4,7-Bis(dimethylamino)-1,4,4a,5,5a- 99 Isobutylamine 2 hr. 586(M+H)
6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-9-[[[2-methyl-
propyl)amino]acetyl]amino]-1,11-dioxo-2-naphthacenecarbox-
aide dihydrochloride.
113 [7S-(7alpha,10aalpha)]-N-[9-(Aminocarbonyl)-4,7-bis(di- 99 Piperidine 1 hr. 598(M+H)
methylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-
tetrahydroxy-10,12-dioxo-2-naphthacenyl]-1-piperidineacet-
amide dihydrochloride.
114 [7S-(7alpha,10aalpha)]-N-]-(Aminocarbonyl)-4,7-bis(di- 99 Imidazole 1 hr. 579(M+H)
methylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-
tetrahydroxy-10,12-dioxo-2-naphthacenyl]-1H-imidazole-1-
-acetemide dihydrochloride.
115 [4S-(4alpha,12aalpha)]-4,7-Bis(dimethylamino)-1,4,4a,5,5a- 99 Propylamine 0.75 hr. 570(M+H)
6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-9-
[[(propylamino)acetyl]amino)-2-naphthacenecarboxamide
dihydrochloride.
116 [4S-(4alpha,12aalpha)]-4,7-Bis(dimethylamino)-9-[[dimethyl- 99 Dimethylamine 0.5 hr. 558(M+H)
amino)acetyl]amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,
12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide disulfate.
117 [4S-(4alpha,12aalpha)]-4,7-Bis(dimethylamino)-9-[[dimethyl- 99 Dimethylamine 0.5 hr. 558(M+H)
amino)acetyl]amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,
12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide.
118 [4S-(4alpha,12aalpha)]-4,7-Bis(dimethylamino)-9-[[hexyl- 99 n-Hexylamine 2 hr. 614(M+H)
amino)acetyl]amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,-
12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide dihydro-
chloride.
119 [4S-(4alpha,12aalpha)]-4,7-Bis(dimethylamino)-9-[[2-(dimethyl- 102 Dimethylamine 2.5 hr. 572(M+H)
amino)-1-oxopropyl]amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,10, (40% in water)
12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide dihydro-
chloride.
120 [4S-(4alpha,12aalpha)]-4,7-Bis(dimethylamino)-1,4,4a,5,5a,6,11, 102 Methylamine 2 hr. 558(M+H)
12a-octahydro-3,10,12,12a-tetrahydroxy-9-[[2-(methylamino)-1- (40% in water)
oxopropyl]amino]-1,11-dioxo-2-naphthacenecarboxamide dihydro-
chloride.
121 [7S-(7alpha,10aalpha)]-N-[9-(Aminocarbonyl)-4,7-bis(dimethyl- 102 Pyrrolidine 1 hr. 598(M+H)
amino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-
10,12-dioxo-2-naphthacenyl]-alpha-methyl-1-pyrrolidine-
acetamide dihydrochloride.
122 [4S-(4alpha,12aalpha)]-4,7-Bis(dimethylamino)-9-[[(4-(dimethyl- 103 Dimethylamine 2 hr. 586(M+H)
amino)-1-oxobutyl]amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,10, (40% in water)
12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide dihydro-
chloride.
123 [4S-(4alpha,12aalpha)]-9-[[(Butylmethylamino)acetyl]amino]- 99 N-methylbutylamine 2 hr. 600(M+H)
4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,
12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide dihydro-
chloride.
124 [4S-(4alpha,12aalpha)]-4,7-Bis(dimethylamino)-1,4,4a,5,5a- 99 Amylamine 2 hr. 600(M+H)
6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-9-
[[[(pentylamino)acetyl]amino]-2-naphthacenecarboxamide
dihydrochloride.
125 [4S-(4alpha,12aalpha)]-4,7-Bis(dimethylamino)-1,4,4a,5,5a- 99 Benzylamine 1 hr. 620(M+H)
6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-9-
[[[(phenylmethyl)amino]acetyl]amino]-2-naphthacenecarboxamide
dihydrochloride.

EXAMPLE 126 [7S-(7alpha,10aalpha)]-N-[2-[[9-(Aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]amino]- 2-oxoethyl]glycine phenylmethyl ester

To 0.30 g of benzylglycine hydrochloride in 3 ml of 1,3-dimethyl-2-imidazolidinone is added 0.60 g of sodium bicarbonate. The mixture is stirred at room temperature for 15 minutes and filtered. To the filtrate is added 0.20 g of product from Example 100. The reaction mixture is sirred at room temperature for 1 hour and then added to diethyl ether. The resulting solid is collected.

EXAMPLE 127 [7S-(7alpha,10aalpha)]-N-[2-[[9-(Aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]amino]- 2-oxoethyl]glycine

One-tenth of a gram of product from Example 126 in 10 ml of monomethyl ethylene glycol is reduced catalytically, in a Parr shaker, with 0.10 g of 10% palladium on carbon, at 30 psi of hydrogen, for 2 hours. The reaction mixture is filtered and the filtrate concentrated to give 0.050 g of the desired product.

CI-MS: m/z 588 (M+H).

General Procedure for the Preparation of Mannich Bases

A mixture of 0.5 g of product from Example 117, 3 ml of t-butyl alcohol, 0.55 ml of 37% formaldehyde, and 0.55 ml of pyrrolidine, morpholine or piperidine is stirred at room temperature for 30 minutes followed by heating at 100 C. for 15 minutes. The reaction mixture is cooled to room temperature and triturated with diethyl ether and hexane. The solid is collected, washed with diethyl ether and hexane, and dried to give the desired product.

In this manner the following compounds are made:

EXAMPLE 128 [4S-(4alpha, 12aalpha)]-4,7-Bis(dimethylamino)-9-[[(dimethylamino)acetyl]amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-N-(1-pyrrolidinyl-methyl)-2-naphthacenecarboxamide EXAMPLE 129 [4S-(4alpha, 12aalpha)]-4,7-Bis(dimethylamino)-9-[[ (dimethylamino)acetyl]amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-N-(4-morpholinyl-methyl)-2-naphthacenecarboxamide EXAMPLE 130 [4S-(4alpha, 12aalpha)]-4,7-Bis(dimethylamino)-9-[[(dimethylamino)acetyl]amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-N-(1-piperdinylmethyl)-2-naphthacenecarbonoxide EXAMPLE 131 [7S-7alpha,10aalpha)]-N-[9-(Aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12,octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-napthacenyl]-1-azetidineacetamide

The title compound is prepared by the procedure of Example 105 using 0.20 g of product form Example 99, 0.50 g of azetidine and 5 ml of DMPU to give 0.126 g of the desired product.

MS(FAB): m/z 570 (M+H).

EXAMPLE 132 [4S-(4alpha,12aalpha)]-9-[[(Cyclobutylamino)acetyl]amino]-4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide hydrochloride

To a solution of 0.200 g of 9-(bromoacetylamino)- 7-dimethylamino-6-demethyl-6-deoxytetracycline in 2 ml of 1,3-demethyl-2-imidazolidinone is added 0.1 ml of cyclobutylamine. The resulting solution is stirred at room temperature for 45 minutes and then added to 50 ml of diethyl ether. An oil layer is formed and the diethyl ether layer is decanted and the oil is dissolved in 5 ml of 0.1N methanolic hydrogen chloride. The resulting solution is added to 50 ml of diethyl ether, yielding 0.050 g of solid.

MS(FAB): m/z 584 (M+H).

Patent Citations
Cited PatentFiling datePublication dateApplicantTitle
US2482055Feb 11, 1948Sep 13, 1949American Cyanamid CoAureomycin and preparation of same
US2619420Sep 17, 1949Nov 25, 1952American Cyanamid CoAnimal and poultry feed containing aureomycin mash
US2731497May 14, 1954Jan 17, 1956American Cyanamid CoProduction of tetracycline
US2734018Sep 28, 1953Feb 7, 1956by niesne assignIrcso
US2878289May 28, 1956Mar 17, 1959American Cyanamid Co6-demethyltetracyclines and methods for preparing the same
US2911339Nov 27, 1957Nov 3, 1959American Cyanamid CoStreptomyces aureofaciens fermentation process
US2997471Aug 18, 1958Aug 22, 1961Bristol Myers CoTetracycline derivatives
US3007965Feb 13, 1959Nov 7, 1961American Cyanamid CoNew tetracyclines produced by streptomyces aureofaciens
US3023239Dec 9, 1959Feb 27, 1962American Cyanamid CoRecrystallization of demethylchlortetracycline
US3026248Sep 11, 1959Mar 20, 1962Pfizer & Co CThioglycerol and formaldehyde sulfoxylate stabilized tetracycline antibiotics in polyhydric alcohol solvents
US3043875Feb 8, 1960Jul 10, 1962Pfizer & Co CHalogenated tetracycline derivatives and processes for their preparation
US3050558Dec 9, 1959Aug 21, 1962American Cyanamid CoRefining of demethylchlortetracycline
US3092556Feb 12, 1962Jun 4, 1963American Cyanamid CoTetracycline fermentation
US3128227Jun 17, 1954Apr 7, 1964American Cyanamid CoAntibiotic intramuscular composition
US3145228Sep 6, 1962Aug 18, 1964Pfizer & Co C5-alkoxy-and 5-benzyloxy-tetracycline, derivatives and analogues thereof
US3148212Dec 22, 1961Sep 8, 1964American Cyanamid CoReductive alkylation process
US3200149May 5, 1961Aug 10, 1965Pfizer & Co Calpha-6-deoxytetracycline derivatives and process
US3219529Oct 4, 1962Nov 23, 1965American Cyanamid CoStable tetracycline solutions
US3226436May 17, 1963Dec 28, 1965American Cyanamid Co7-and 9-alkylamino-6-deoxytetracycline
US3239499May 19, 1961Mar 8, 1966Pfizer & Co CTetracycline derivative
US3250809Oct 9, 1964May 10, 1966Pfizer & Co C6-deoxy-6-demethyl-6-halomethylene tetracyclines and their 11a-chloro and fluoro derivatives
US3250810Oct 9, 1964May 10, 1966Pfizer & Co C6-hydroxy-6-halomethyl tetracyclines
US3338963Oct 28, 1960Aug 29, 1967American Cyanamid CoTetracycline compounds
US3341585Dec 1, 1966Sep 12, 1967American Cyanamid CoSubstituted 7-and/or 9-amino-6-deoxytetracyclines
US3345410Dec 1, 1966Oct 3, 1967American Cyanamid CoSubstituted 7- and/or 9-amino tetracyclines
US3360557May 10, 1963Dec 26, 1967American Cyanamid Co9-hydroxytetracyclines and a process of preparing same
US3360561Jun 19, 1967Dec 26, 1967American Cyanamid CoNitration of tetracyclines
US3373196Mar 21, 1967Mar 12, 1968American Cyanamid Co7-and/or 9-(lower alkyl) amino-5a, 6-anhydrotetracyclines
US3373197Apr 27, 1967Mar 12, 1968American Cyanamid CoSubstituted 6-epitetracyclines and 5a-epi-6-epitetracyclines
US3373198Apr 27, 1967Mar 12, 1968American Cyanamid CoSubstituted 5a, 11a-dehydro-6-epitetracyclines
US3397230Mar 14, 1966Aug 13, 1968American Cyanamid CoNitration of tetracyclines
US3403179Jan 10, 1967Sep 24, 1968American Cyanamid CoNovel 7-(1, 2-bis-substituted-hydrazino)-tetracyclines and methods of preparing same
US3433834Mar 14, 1966Mar 18, 1969American Cyanamid CoNitration of 11a-chloro tetracyclines
US3483251Mar 3, 1967Dec 9, 1969American Cyanamid CoReductive alkylation process
US3502696Jun 17, 1966Mar 24, 1970Pfizer & Co CAntibacterial agents
US3502698Apr 16, 1968Mar 24, 1970American Home ProdNovel 13alpha-lower alkylgona-1,3,5(10)-trienes
US3509184Aug 1, 1966Apr 28, 1970Pfizer & Co CAnthracyclidine-acetic acid derivatives
US3515731Apr 3, 1967Jun 2, 1970Pfizer & Co CAntibacterial agents
US3518306Feb 19, 1968Jun 30, 1970American Cyanamid Co7- and/or 9-(n-nitrosoalkylamino)-6-demethyl-6-deoxytetracyclines
US3526629Apr 2, 1968Sep 1, 1970American Cyanamid CoBeta-hydroxyethylpiperazinocarboxymethyl - 7 - dimethylamino - 6 - deoxy-6-demethyltetracycline
US3579579Apr 18, 1968May 18, 1971American Cyanamid CoSubstituted 7- and/or 9-amino-6-demethyl-6-deoxytetracyclines
US3586483Oct 14, 1968Jun 22, 1971American Cyanamid CoMethod for detecting the presence of tetracycline antibiotics
US3697552Oct 31, 1969Oct 10, 1972PfizerAnthracyclidine-acetic acid derivatives
US3772363Mar 7, 1972Nov 13, 1973Pfizer3,4,10-trioxo octahydroanthracene-2-aminoacetic acids and derivatives thereof
US3809751Sep 24, 1970May 7, 1974American Cyanamid CoAntibiotic-stable liquid protein supplements containing non-protein nitrogen,phosphorus and a tetracycline antibiotic
US3812188Aug 19, 1968May 21, 1974American Cyanamid CoPurification of 7-chlorotetracycline
US3829453Mar 8, 1972Aug 13, 1974PfizerOctahydroanthracene-2-aminoacetic acids and esters and mixed anhydrides thereof
US3849493Mar 7, 1972Nov 19, 1974PfizerD-ring substituted 6-deoxytetracyclines
US3862225Jan 7, 1971Jan 21, 1975PfizerD-ring substituted tetracyclines
US3901942Sep 17, 1973Aug 26, 1975Farmaceutici ItaliaTetracycline derivatives substituted in the 7 position and process for preparing the same
US3978000Mar 19, 1975Aug 31, 1976American Cyanamid CompanyReduction
US4029600May 20, 1976Jun 14, 1977American Cyanamid CompanyCarbon particulates with controlled density
US4031137Feb 11, 1976Jun 21, 1977American Cyanamid CompanyCatalysts based on carbon supports and use in catalytic deoxidation process
US4038315May 11, 1972Jul 26, 1977American Cyanamid CompanyIsolation and recovery of calcium chloride complex of 7-dimethylamino-6-dimethyl l-6-deoxytetracycline hydrochloride
US4081370Feb 22, 1977Mar 28, 1978American Cyanamid CompanyCarbon black
US4666897Dec 29, 1983May 19, 1987Research Foundation Of State UniversityInhibition of mammalian collagenolytic enzymes by tetracyclines
US4837030Oct 6, 1987Jun 6, 1989American Cyanamid CompanyNovel controlled release formulations of tetracycline compounds
US4911924Apr 17, 1987Mar 27, 1990University Of New MexicoInduction of antibiotic hypersensitivity in tetracycline-resistance microorganisms
US4918208Jul 22, 1988Apr 17, 1990Nippon Kayaku Kabushiki KaishaProcess for producing 7-dimethylamino-6-demethyl-6-deoxytetracycline
US4925833Dec 29, 1986May 15, 1990The Research Foundation Of State University Of New YorkUse of tetracycline to enhance bone protein synthesis and/or treatment of osteoporosis
US4975271Dec 19, 1988Dec 4, 1990Vipont Pharmaceutical, Inc.Muscosal delivery systems for treatment of periodontal disease
US5021407Apr 11, 1986Jun 4, 1991Trustees Of Tufts CollegeAdministering blocking agents which overcome antibiotic resistance
US5045538Jun 28, 1990Sep 3, 1991The Research Foundation Of State University Of New YorkPromoting protein synthesis in skeletal muscle systems
US5122519Jun 27, 1989Jun 16, 1992American Cyanamid CompanyTetracyclines in solvent, gelling vehicle
US5143661Oct 22, 1990Sep 1, 1992American Cyanamid CompanyA composition for microencapsulation of drugs for sustained release
US5280888Mar 24, 1992Jan 25, 1994Societe Jacques DuboisResilient buffer made of metal wire
US5281628Oct 4, 1991Jan 25, 1994American Cyanamid CompanyPharmaceuticals
US5284963Aug 13, 1992Feb 8, 1994American Cyanamid CompanyReacting 9-amino tetracycline derivative with haloacyl halide in mixture of polar aprotic solvent, inert solvent, base; reacting product under inert atmosphere with nucleophilic amine
US5326759Nov 1, 1993Jul 5, 1994American Cyanamid Company9-amino-7-(substituted)-6-demethyl-6-deoxytetracyclines
US5328902Aug 13, 1992Jul 12, 1994American Cyanamid Co.Antibiotics
US5384259Dec 6, 1991Jan 24, 1995American Cyanamid CompanyConstruct and method for expression of tetracycline resistance genes in E. Coli
US5386041Feb 8, 1994Jan 31, 1995American Cyanamid CompanyAntibiotic
US5401729Feb 24, 1994Mar 28, 1995American Cyanamid Company7-(substituted)-9-[(substituted glycyl)amido]-6-demethyl-6-deoxytetracyclines
US5401863Mar 29, 1994Mar 28, 1995American Cyanamid Company9-amino-7-(substituted)-6-demethyl-6-deoxytetracyclines
US5420272Aug 13, 1992May 30, 1995American Cyanamid Company7-(substituted)-8-(substituted)-9-](substituted glycyl)amido]-6-demethyl-6-deoxytetracyclines
US5430162Mar 21, 1994Jul 4, 1995American Cyanamid Company7-(substituted)-8-(substituted)-9-substituted amino)-6-demethyl-6-deoxytetracyclines
US5442059Aug 13, 1992Aug 15, 1995American Cyanamid CompanyAntibiotics for mammalian and veterninary diseases
US5457096Sep 26, 1994Oct 10, 1995American Cyanamid CompanyAntibiotic
US5466684Sep 12, 1994Nov 14, 1995American Cyanamid Company7-(substituted)-9-[(substituted glycyl)amido]-6-demethyl-6-deoxytetracyclines
US5495018Dec 8, 1994Feb 27, 1996American Cyanamid Company7-(substituted-9-(substituted amino)-6-demethyl-6-deoxytetracyclines
US5495030Sep 1, 1994Feb 27, 1996American Cyanamid Company9-[(substituted glycyl)amido)]-6-demethyl-6-deoxytetracyclines
US5495031Sep 13, 1994Feb 27, 1996American Cyanamid CompanyProcess for the production of 7-(substituted)-9-[(substituted glycyl)amido]-6-demethyl-6-deoxytetracyclines
US5495032Sep 27, 1994Feb 27, 1996American Cyanamid CompanyProcess for producing 7-(substituted)-8-(substituted-9-[(substituted glycyl)amido]-6-demethyl-6-deoxytetracyclines
US5512553May 31, 1995Apr 30, 1996American Cyanamid CompanyPreventing or treating bacterial infections
US5567692May 18, 1995Oct 22, 1996American Cyanamid Company9-[(substituted glycyl) amido)]-6-demethyl-6-deoxytetracyclines
US5675030Nov 16, 1994Oct 7, 1997American Cyanamid CompanyAdding methylene chloride
US5789188May 13, 1996Aug 4, 1998American Cyanamid CompanyControlled gene expression
US5886175Dec 8, 1994Mar 23, 1999American Cyanamid CompanyTetracycline antibiotics
USRE26253Oct 24, 1961Aug 15, 1967 And z-alkylamino-g-deoxytetracycline
USRE26271Oct 28, 1960Sep 26, 1967 Reductive alkylation process
EP0109850A2Nov 21, 1983May 30, 1984Unisys CorporationSpeed independent selector switch employing M-out-of-N codes
GB901107A Title not available
WO1984001895A1Nov 17, 1983May 24, 1984Univ TuftsTetracycline activity enhancement
WO1989002270A1Sep 16, 1988Mar 23, 1989Theodore KrupinMethod of lowering intraocular (eye) pressure
Non-Patent Citations
Reference
1Adamson et al., "Aplastic Anemia," Hematology 4<SUP>th </SUP>ed., Williams WJ et al, eds.; McGraw Hill, New York (1990) pp. 158-174.
2Allen, "Minocycline," Ann. Intern. Med. 85:482-487 (1976).
3Altemeier et al., "Intra-abdominal Abscesses, " American Journal of Surgery 125:70-79 (1973).
4Bell, "Oral Penicillins in the Treatment of Chronic Staphylococcal Osteomyelitis," Lancet 10:295-297 (1968).
5Benitz et al., "Morphologic Effects of Minocycline in Laboratory Animals, " Toxicol. Appl. Pharmacol. 11:150-170 (1967).
6Bennion et al., "Gangrenous and Perforated Appendicitis with Peritonitis: Treatment and Bacteriology," Clinical Therapeutics 12(Suppl C):31-44 (1990).
7Bocker et al., "Identification and Determination of the Principal Metabolites of Minocycline in Humans," J. Chromatogr. 568:363-374 (1991).
8Bohnen et al., "Prognosis in Generalized Peritonitis. Relation to Cause and Risk Factors," Archives of Surgery 118:285-290 (1983).
9Boothe et al., "6-Deoxytetracyclines, I. Chemical Modification by Electrophilic Substitution" J. Am. Chem. Soc., 82:1253-1254 (1960).
10Bryant et al., "Increased Frequency of Doxycycline Side Effects," Pharmacotherapy 7:125-129 (1987).
11Buyske et al., "Concentration and Persistence of Tetracycline and Chlortetractycline in Bone," J. Pharmacol. Exper. Ther. 130:150-156 (1960).
12 *Chopra, Handbook of Experimental Pharmacology, vol. 78, 317-392, Springer-Verlag (1985).
13Ciancio et al., "An Evaluation of Minocycline in patients with Periodontal Disease", Journal of Periodontology 51:530-534 (1980).
14Collins, "Cell-Free Synthesis of Proteins Coding for Mobilisation functions of colE1 and Transportation" Gene 6:28-42 (1979).
15Conte et al., "Steady-State Serum and Intrapulmonary Pharmacokinetics and Pharmacodynamics of Tigecycline," Int. J. Antimicrob. Agents 25(6):523-529 (2005).
16Degenkolb et al., "Structural Requirements of Tetracycline-tet Repressor Interaction: Dermination of Equilibrium Binding Constants for Tetracycline Analogs with the Tet Repressor", Antimicrob. Agents Chemother. 35:1591-1595 (1991).
17DeJonge et al., "Inhibition of Mitochondrial-Protein Synthesis in Rat Small-Intestinal Epithelium," Eur. J. Biochem. 32:356-364 (1973).
18Dietz et al., "Comparative Toxicity and Carcinogenicity Studies of Tetracycline and Oxytetracycline in Rats and Mice," Fund. Appl. Toxicol. 17:335-346 (1991).
19Entwistle et al., "Reduction of Nitro-compounds", J. Chem. Soc. 1:443 (1977).
20Fanning et al., "Distressing Side-effects of Minocycline Hydrochloride," Arc Intern Med. 136:761-762 (1976).
21Feigin, "Clindamycin Treatment of Osteomyelitis and Septic Arthritis in Children," Pediatr. 55:213-223 (1975).
22Fry et al., "Determinants of Death in Patients with Intraabdominal Abscess, " Surgery 88:517-523 (1980).
23Garrison, "Histamine, Bradykinin, 5-Hydroxytryptamine, and Their Antagonists," In: Gilman AG, Rall TW et al., eds. Goodman and Gilman's The Pharmacological Basis of Therapeutics 8<SUP>th </SUP>ed. Elmsford, NY: Pergamon Press pp. 575-582 (1990).
24Gilbaldi et al., Pharmacokinetics, 2<SUP>nd </SUP>ed., "One-Compartment", Marcel Dekker, Inc., NY, 1982, pp. 1-43.
25Gorbach, "Antimicrobial Prophylaxis for Appendectomy and Colorectal Surgery," Reviews of Infectious Diseases 13(Suppl 10):S815-S820 (1991).
26Gugler et al., "Effects of Antacids on the Clinical Pharmacokinetics of Drugs. An Update," Clin. Pharmacokinet. 18:210-219 (1990).
27Gump et al., "Side Effects of Minocycline: Different Dosage Regimen," Antimicrob Agents Chemother. 12:642-646 (1977).
28Hlavka et al., "The 6-Deoxytetracyclines. III Electrophilipic and Nucleophilic Substitution", J. Am. Chem. Soc., 84:1426-1430 (1962).
29Jonas et al., "Minocycline," Ther. Drug Monit. 4:137-145 (1982).
30Kantrowitz et al., "Histamine-Mediated Myocardial Damage in Rabbits," J. Mol. Cell. Cardiol. 14:551-555 (1982).
31King, "Animal Models in the Study of Vomiting, " Can. J. Physiol. Pharmacol. 68:260-268 (1990).
32Larock, Comprehensive Organic Transformations, VCH Publishers, 411-415, (1989).
33 *Levy, Antimicrobial Agents and Chemotheraphy, vol. 33 No. 8, 1373-1374 (Aug. 1989).
34Loeliger et al., "Reliability and Clinical Impact of the Normalization of the Prothrombin Times in Oral Anticoagulant Control", Thrombosis & Haemostasis 53:148-154 (1985).
35MacDonald et al., "Pharmacokinetic Studies on Minocycline in Man," Clinical Pharmacology and Therapeutics 14:852-861 (1973).
36Misgen, "Compatibilities and Incompatibilities of Some Intravenous Solution Admixtures", Am. J. Hosp. Pharm. 22:92-94 (1965).
37Mitscher; "The Chemistry of the Tetracyline Antibiotic", Marcel Dekker, Inc. Chapter 6.3, p. 172-173 and Chapter 2, p. 53-54, (1978).
38Monnier et al., "Visual Compatability of Heparin with Selected Intravenous Admixtures", ASHP Midyear Clinical Meeting, vol. 25, p. P-186E (Dec. 1990).
39Morrison et al., "Amines I. Preparation and Physical Properties", Organic Chemistry, 4<SUP>th </SUP>ed., pp. 894, 898-900, 902 (1983).
40Mosdell et al., "Antibiotic Treatment for Surgical Peritonitis," Annals of Surgery 214:543-549 (1991).
41Nelis et al., "Metabolism of Minocyclinein Humans, " Drug Metab Dispos. 10:142-146 (1982).
42Noble et al., "Short-term Toxicity and Observation on Certain Aspects of the Pharmacology of a Unique Tetracycline-Minocycline," Toxicol Appl. Pharmacol. 11:128-149 (1967).
43Norden et al., "Clindamycin Treatment of Experimental Chronic Osteomyelitis Due to Staphylococcus Aureus," J. Infect. Dis. 153:956-959 (1986).
44Norden et al., "Treatment of Experimental Chronic Osteomyelitis Due to Staphylococcus Aureus with Ampicillin/Sulbactam," J. Infect. Dis. 161:52-53 (1990).
45Norden et al., "Treatment of Experimental Chronic Osteomyelitis Due to Staphylococcus Aureus with Vancomycin and Rifampin," J. Infect. Dis. 147:352-357 (1983).
46Norden, "Experimental Chronic Staphylococcal Osteomyelitis in Rabbits: Treatment with Rifampin Alone and in Combination with Other Antimicrobial Agents," Rev. Infect. Dis. 5(Suppl 3):S491-S494 (1983).
47Norden, "Lessons Learned from Animal Models of Osteomyelitis," Rev. Infect. Dis. 10:103-110 (1988).
48Pawelczyk et al., "Kinetics of Drug Decomposition Part 74.Kinetics of Degradation of Minocycline in Aqueous Solution", Pharmacol. Pharm. 34:409-421 (1982).
49Pratt, Coupled TranScription-translation in Prokaryotic Cell-free Systems, Transcription and Translation, a Practical Approach, (B.D. Hames and S.J. Higgins, eds.) p. 179-209, IRL Press, Oxford-Washington, (1984).
50Raasch, "Interaction of Oral Antibiotics and Common Chronic Medications" Geriatrics 42:69-74 (1987).
51Remmers et al., "Some Observations on the Kinetics of the C.4 Epimerization of Tetracycline," J. Pharm. Sci., 52:752-756 (1963).
52Rissing, "Animal Models of Osteomyelitis: Knowledge, Hypothesis and Speculation," Infect. Dis. Clin. North Am. 4:377-390 (1990).
53Robertson, "p-Aminophenyllacetic Acid", Org. Syn. Coll. 1:52 (1941).
54 *Salyers, Molecular Microbiology 4(1), 151-156 (1990).
55Skillman et al., "Respiratory Failure, Hypotension, Sepsis, and Jaundice. A Clinical Syndrome Associated with Lethal Hemorrhage from Acute Stress Ulceration of the Stomach," American Journal of Surgery 117:523-530 (1969).
56Slama et al., "Oral Ciprofloxacin Therapy for Osteomyelitis Caused by Aerobic Gram Negative Bacilli," Am. J. Med. 82(Suppl 4A):259-261 (1987).
57Solomkin et al., "Results of a Multicenter Trial Comparing Imipenem/Cilastatin to Tobramycin/Clindamycin for Intra-abdominal Infections," Annals of Surgery 212:581-591 (1990).
58Spencer et al., "6-Deocytetracyclines,. V. 7,9-Disubstituted Products", J. Med. Chem. 6:405-407 (1963).
59Sum et al., "Synthesis of Novel Tetracycline Derivatives with Substitution at the C-8 Position," Tetrahedron Letters vol. 35, No. 12, pp. 1835-1836 (1994).
60Swenson et al. "The Bacteriology of Intra-abdominal Infections," Archives of Surgery 109:398-399 (1974).
61Tapp et al., "Tetracycline Toxicity," Experientia 22:530-531 (1966).
62The Merck Index, Entries #2111 and 5936 10<SUP>th </SUP>Ed. (1983) pp. 300,301, & 869.
63Tice, "Outpatient Parenteral Antimicrobial Therapy for Osteomyelitis," Infect. Dis. Clin. North Am. 12:903-919 (1998).
64Van Den Bogert et al., "Tissue distribution and Effects on Mitochondrial Protein Synthesis of Tetracyclines After Prolonged Continuous Intravenous Administration to Rats," Biochem. Pharmacol. 30:1706-1709 (1981).
65Waldvogel, "Osteomyelitis," In Gorbach SL et al., eds. Infectious Diseases, Saunders, Philadelphia 1339-1344 (1988).
66Watson, "Chloramphenicol Toxicity in Dogs," Research in Veterinary Science 23:66-69 (1977).
67Westfall et al., "Formulation of a Stable Trace Element Solution for TPN" Am. J. Hosp. Pharm. 37:1620 (1980).
68Williams et al., "Minocycline: Possible Vestibular Side-Effects," Lancet. 2:744-746 (1974).
69Woodward, "m-Hydroxybenzaldehyde", Org. Syn. Coll. 3:453 (1955.
70World Health Organization Technical Report Series 687-1-184 (1983).
71Yuen, et al., "Kinetics of Concomitatnt Degradation of Tetracycline to Epitetracycline to Epitetracycline, Anhydrotetracycline, and Epianhydrotetracycline in Acid Phospate Solution", J. Pharm, Sci. 66:1648-1650 (1977).
72Zubay, "In-vitro Synthesis of Protein in Microbial Systems", Ann. Rev. Genet. 7:267-287 (1973).
Referenced by
Citing PatentFiling datePublication dateApplicantTitle
US7858600 *Feb 24, 2004Dec 28, 2010Paratek Pharmaceuticals, Inc.Non-antibiotic resistant; Gram-positive and Gram-negative bacteria; Salmonella, Streptococcus, Escherichia
US8501716Aug 9, 2012Aug 6, 2013Tetraphase Pharmaceuticals, Inc.C7-fluoro substituted tetracycline compounds
US8796245Dec 18, 2012Aug 5, 2014Tetraphase Pharmaceuticals, Inc.C7-fluoro substituted tetracycline compounds
Classifications
U.S. Classification514/152, 548/300.4, 540/200, 548/263.2, 544/154, 548/356.5, 552/203, 552/205, 548/267.6, 546/195, 548/538, 549/487, 548/316.4
International ClassificationC07D333/24, C07D277/22, C07C237/26, A61K31/65, C07D333/38, C07D277/46, C07D307/68, C07C233/64, C07D333/34, C07D205/04
Cooperative ClassificationC07D307/68, C07C237/26, C07D333/38, C07D333/24, C07D277/46, C07C2103/46, C07D205/04, C07D333/34
European ClassificationC07D333/38, C07C237/26, C07D333/34, C07D333/24, C07D205/04, C07D307/68, C07D277/46
Legal Events
DateCodeEventDescription
Jul 15, 2014CCCertificate of correction
Nov 7, 2013ASAssignment
Owner name: WYETH HOLDINGS LLC, NEW JERSEY
Effective date: 20131024
Free format text: CHANGE OF NAME;ASSIGNOR:WYETH HOLDINGS CORPORATION;REEL/FRAME:031598/0537